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Abstract 
High blood pressure (BP), measured conventionally using clinic, ambulatory or home BP 
monitoring, is associated with target organ damage; however, the exact underlying mechanisms 
are not clear. A hypothesis which has gained wide acceptance during the last decade supports 
the notion that variability in BP (BPV) could provide important clinical information, over and 
above mean BP levels, and therefore could be relevant to the diagnosis and management of 
hypertension. Key gaps in the literature relating to BPV are that the prognostic significance of 
BPV as well as its impact on hypertension diagnosis and effect of treatment are unclear. The 
overall aims of this project were to investigate the effect of BPV on target organ damage in 
specific populations, to determine the impact of BPV on hypertension diagnosis, and to 
determine the effect of a novel intervention on BPV.  
Data supporting the notion that BPV may offer independent prognostic value are inconsistent, 
and this may be due to the wide variety of methodologies used for measuring BPV. BPV can 
be quantified from short-term BP monitoring (using 24-hour BP), mid-term BP (using home 
BP in the morning, evening or day-to-day) or long-term BP monitoring (using visit-to-visit 
clinic BP).  Study 1 (chapter 1), aimed to examine the effect of BPV methodologies on the 
magnitude of BPV itself, as well as the effect of participant characteristics on BPV. Key 
methodological factors assessed were 1) the number of BP readings or visits used to quantify 
BPV and 2) the duration of BP monitoring. Following a scoping review process, data were 
extracted from 102 studies. The novel findings of this study were that the methodology used to 
quantify BPV, as well as age and mean BP level, affects the magnitude of BPV itself. This 
underscores the need to standardize BPV protocols, particularly regarding the number of BP 
readings and visits. 
Study 2 (chapter 2), aimed to determine the prognostic value of short-term BPV on organ 
damage related to retinal microvascular abnormalities in a post-hoc, hypothesis generating 
analysis among 35 non-diabetic and 28 patients with type II diabetes mellitus (T2DM). The 
novel findings of this study were that the BPV–related mechanisms underlying microvascular 
complications may differ between people with and without T2DM. 
Study 3 (chapter 3) sought to determine the prognostic value of short-term, mid-term and long-
term BPV on organ damage related to heart structure and large artery stiffness in a follow-up 
study among 286 patients with uncomplicated hypertension and low to moderate 
cardiovascular risk. The important new findings were that changes in mean BP levels, but not 
x 
BPV, were most relevant to changes in organ damage in patients with uncomplicated 
hypertension. Therefore, BPV appears to offer limited clinical utility in this patient population. 
Studies 4 and 5 aimed to determine the impact of within-visit BPV on hypertension diagnosis 
among adults (chapter 4), and children and adolescents (chapter 5), participating in the 
Australian Health Survey 2011-2013. Due to highly age-dependent reading-to-reading changes 
in BP, hypertension classification in adults varied according to the number of readings used for 
BP assessment (study 4). Moreover, the findings in study 5 showed that within-visit BP was 
highly variable in children and adolescents, with the magnitude of change being highly affected 
by BP level and age. The key finding from both studies was the significant impact of BPV on 
hypertension diagnosis, and this highlights the need for out-of-clinic BP measures to confirm 
diagnosis. 
Study 6 (chapter 6), aimed to determine the effect of vitamin D supplementation on long-term 
BPV, aortic stiffness, peripheral and central BP indices, among 241 individuals with vitamin 
D deficiency and knee osteoarthritis. The results showed that vitamin D supplementation did 
not improve long-term BPV, aortic stiffness or any other BP indices, in this patient population. 
Following on from this work we were invited to write an expanded review on the evidence 
from published randomised controlled trials regarding the effect of vitamin D supplementation 
on cardiovascular surrogate and hard clinical endpoints, including BPV (Appendix 4; study 7). 
This review concluded that vitamin D supplementation was ineffective for improving 
cardiovascular health among various patient populations, including the presence or absence of 
vitamin D deficiency. 
In summary, this PhD research program has made several novel observations. The 
methodology to quantify BPV can affect the magnitude of BPV itself and therefore BPV 
methodologies need to be standardized. Furthermore, the research has showed that short-term 
BPV may play a role in the pathophysiology of microvasculature in patients with T2DM; 
however, BPV (short-term, mid-term or long-term) did not offer additional prognostic value 
regarding organ damage (heart structure and large artery stiffness), over and above mean BP 
levels, among patients with uncomplicated hypertension and low to moderate cardiovascular 
risk. Additionally, within-visit BP was highly variable in adults as well as children and 
adolescents, implying that assessment and diagnosis of elevated BP should be confirmed using 
out-of-clinic BP monitoring. Finally, vitamin D was not effective in improving long-term BPV, 
large artery stiffness or other BP measures. Taken all together, this research provides novel 
xi 
data that significantly adds to the current knowledge body around BPV, by addressing key 
literature gaps related to the measurement and clinical implications of BPV. 
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Preface 
High blood pressure (BP) is associated with cardiovascular morbidity and mortality; however, 
the exact underlying mechanisms are not clear. Whilst cardiovascular risk related to 
hypertension is traditionally assessed using the mean of clinic or out-of-clinic BP 
measurements, such as 24-hour or home BP, research has been exploring an alternative 
hypothesis which could offer important clinical information to the overall assessment of 
cardiovascular risk associated with high BP. This hypothesis suggests that assessing blood 
pressure by quantifying its fluctuations over time could add considerable clinically relevant 
information, over and above the mean BP level, and therefore could be a useful guide in the 
diagnosis and treatment treatment and diagnosis of hypertension.1 Blood pressure variability 
(BPV) can be assessed from very short-term BP monitoring (measurements over minutes), 
short-term (measurements over a period of 24 hours), mid-term (measurements over days) and 
long-term (measurement over visits). Although, there has been an increasing number of studies 
exploring BPV in the last decade, significant research gaps remain.  
Firstly, evidence from studies investigating BPV in relation to cardiovascular risk are equivocal 
and this may be due to the varying protocols and methodologies used to assess BPV. Although, 
there have been speculations that specific methodological factors could affect the magnitude 
of BPV itself (i.e. the number of BP readings used for assessment), no study has systematically 
explored the literature in order to identify specific methodological issues and provide 
recommendations for standardizing the protocols and methodology of measuring BPV. 
Moreover, different BPV measures (i.e. short-term or long-term) could be linked to different 
pathophysiological profiles2 as well as different outcomes in specific populations, therefore the 
prognostic significance of BPV is still unclear. At the same time, the effect of very short-term 
BP fluctuations (over minutes or over readings) on hypertension classification and diagnosis, 
2 
in adults as well as children and adolescents, is unclear. Lastly, there are limited data from 
clinical trials that aim to reduce BPV via novel arterial destiffening interventions.  
This research program comprises a series of analyses from convenience data samples, as well 
as systematic reviews, to address key deficits in the field of BPV. It was necessary to develop 
an understanding of the methodology used to quantify BPV and how this may affect the 
quantification of BPV. This was achieved using a systematic scoping review of the literature 
(chapter 1; study 1). Analyses conducted within chapters 2 and 3 were derived from two clinical 
studies completed within the Blood Pressure Research Group at Menzies, and enabled 
examination of key gaps related to the clinical implications of BPV, with end organ damage as 
the outcomes (retinal arteriolar markers, cardiac structure and large artery stiffness).  
Chapters 4 and 5 were made possible from data publicly available within the Australian Health 
Survey 2011-2013. From these data we determined the clinical importance of BPV in relation 
to hypertension diagnosis in adults as well as children and adolescents. Lastly, to address a key 
gap related to interventions to modify BPV, we employed a retrospective analysis from within 
a randomised controlled trial where we aimed to investigate the effect of artery destiffening 
(via vitamin D supplementation) on long-term BPV. Confirmation of this analysis was then 
determined using a literature review which investigated the effect of vitamin D 
supplementation on cardiovascular clinical endpoints, including BPV. 
The above aims were investigated in separate studies and have resulted in several published 
manuscripts, in addition to some manuscripts being prepared for publication or currently in 
submission, to peer-reviewed scientific journals. Published manuscripts or those which are 
being prepared for publication at the time of thesis submission are presented in their final 
submitted format as per the requirements of each journal; therefore, the presentation format 
and style of each individual chapter may be slight different between chapters. This thesis 
3 
contains 6 chapters and each chapter represents a separate study which directly contributes to 
the overall thesis aims. The individual contributions of each study to the thesis aims are 
presented at the end of each thesis chapter. 
4 
Chapter 1 
Methodological factors affecting quantification of blood pressure variability: a scoping 
review 
At the time of thesis submission, this chapter is under peer-review with the Journal of 
Hypertension. 
Veloudi P., Sharman JE. 
5 
1.1 Abstract 
Objectives. Blood pressure variability (BPV) may offer independent prognostic information. 
However, data supporting this notion are inconsistent, and this may be due to the wide variety 
of methodologies used for measuring BPV. A systematic analysis on the effect of BPV 
methodologies on BPV itself has never been undertaken and was the aim of this study. We also 
sought to determine the effect of participant characteristics on BPV. 
Methods. A scoping review process was used to identify the effect of BPV methodologies on 
BPV magnitude. Key methodological factors assessed were 1) the number of BP readings or 
visits used to quantify BPV and 2) the duration of BP monitoring. Additionally, the relationship 
between age and mean BP level on BPV was investigated. Analyses were performed across 
studies that measured BPV over the short-term (using 24-hour BP), mid-term (using home BP 
in the morning, evening or day-to-day) and long-term (using visit-to-visit clinic BP).  
Results. Data were extracted from 96 studies. The number of BP readings and visits used to 
quantify BPV were positively associated with mid- and long-term BPV. Duration was weakly 
associated with mid-term (morning) BPV. Age was positively associated with long- and mid-
term (day-to-day), but not short-term BPV. Mean BP level was positively associated with BPV, 
except mid-term BPV (morning and evening). 
 Conclusions. The methodology used to quantify BPV, as well as age and mean BP level, 
affects the magnitude of BPV itself. This highlights the need to standardize BPV protocols, 
particularly regarding the number of BP readings and visits. 
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1.2 Introduction 
A plethora of data suggest that blood pressure variability (BPV) may offer prognostic 
information, over and above mean BP levels.2-5 Blood pressure (BP) is characterised by a 
degree of variability which can be observed over readings from minute to minute, hours, days, 
months or years. Three distinctive types of BPV have emerged among clinical studies during 
the last decade: short-term (using 24-hour BP monitoring) which quantifies BP fluctuations 
over hours; mid-term (using home BP monitoring) which quantifies BP fluctuations over days 
and lastly, long-term BPV (using clinic BP monitoring) which quantifies BP fluctuations over 
visits spaced over months or years. However, various protocols and methodologies have been 
used to quantify BPV, which could impact the magnitude of BPV itself. Additionally, it is not 
clear whether participant characteristics, such as age or mean BP level, could affect the 
magnitude of BPV and, therefore, the identification of normative reference ranges and cut-off 
values for risk stratification. Altogether, the above issues have created an uncertainty as to how 
BPV may be used in clinical practice. 
Among the most important methodological issues that may affect the quantification of BPV is 
the number of readings used to quantify short- and mid-term BPV or the number of visits used 
to quantify long-term BPV, which vary greatly among studies. Another methodological issue 
is the duration of monitoring, in which various protocols have been used for mid-term and 
long-term quantification of BPV. For example, to quantify mid-term BPV, Fukui et al.6 used 3 
readings over 14 days, whereas Satoh et al.7 used 28 readings over 28 days. On the other hand, 
for the quantification of long-term BPV, Sohn et al.8 used 6 visits over 3.5 years, whereas Chia 
et al.9 used 3 to 4 visits per year, over 15 years of BP monitoring. Moreover, it has been 
suggested that BPV magnitude may be affected by participant characteristics such as age and 
mean BP level. Although, methodological discrepancies concerning the measurement of BPV 
have been noted by many,10,11 there has never been a systematic review of the literature to 
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quantify the effect of the number of BP readings or the duration of BP monitoring used to 
quantify BPV, nor the effect of participant characteristics, on BPV assessment. Therefore, this 
study aimed to identify how different BPV methodologies may affect the magnitude of BPV 
with the following foci: 1) the number of BP readings or visits used to quantify BPV and 2) the 
duration of BP monitoring. Additionally, this analysis sought to investigate the relationship 
between age and mean BP level on BPV magnitude.  
1.3 Methods 
Scoping review process   
A scoping review technique was chosen as the most appropriate method to address the aims.12 
This involved an iterative approach to examine and describe the literature, which was based on 
Arksey and O’Malley’s five-stage scoping review process:13 1) identify the research question, 
2) identify relevant studies, 3) select the studies, 4) chart the data and 5) report the results. 
Following the identification of the main research question (already described in the 
introduction as the study aims), the literature was examined to identify the most common metric 
used to quantify BPV, and the last step was identification of studies that had reported average 
BPV for the population under investigation.  
Publication of studies examining BPV date back to the late 1920s;14 since then, an abundance 
of studies examining mainly short-term BPV have been published. However, a series of key-
papers on BPV by Rothwell et al. published in 2010,1,15,16 was a turning point towards 
publication of studies that sought to examine BPV using a variety of BP monitoring techniques 
(long-term, mid-term BPV). In view of the changing nature of BPV research and clinical 
practice, this work was not intended to analyse all available data in the field of BPV, but 
moreover to restrict analysis to capture a representative sample of contemporary BPV studies 
in which short-, mid- and long-term BPV was measured, as per the intent of a scoping review.12 
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Therefore, the 2006-2016 timespan; a decade which depicts the range of contemporary 
methodological approaches in BPV research, was chosen to provide representative data. 
Studies were identified through an English language search of PubMed, google scholar and 
grey literature using the following keywords: short-term, ambulatory, mid-term, home, day-to-
day, long-term, visit-to-visit and blood pressure variability or blood pressure fluctuations or 
blood pressure variations. 
Study selection 
The criteria for inclusion were defined based on an iterative analysis of the literature, as 
described above. Our initial goal was to determine the most common type of metric used to 
quantify BPV (e.g. standard deviation, SD; coefficient of variation, CV; average real variation, 
ARV etc.) and then concentrate our final data synthesis on those studies that reported average 
BPV using this common metric. All study designs were eligible for inclusion and, similarly, 
all ages of subjects and all type of subject populations were eligible for inclusion. We excluded 
studies examining very short-term BPV (from beat-to-beat BP measures or reading-to-reading 
within-visit BP measures) as well as reviews (narrative, systematic or meta-analyses). 
Data synthesis and analysis 
Short-term BPV. Short-term BPV was quantified from day or awake 24-hour BP monitoring. 
The number of readings and duration of monitoring were estimated based on the protocols 
described by each paper (i.e. if day BPV was monitored from 06:00 am to 22:00 pm using an 
interval of 20 minutes between each reading, the estimated number of readings would be 48 
and the duration would be 16 hours).  
Mid-term BPV. Mid-term BPV was quantified from either morning, evening or day-to-day 
home BP monitoring. The number of readings taken at each occasion from the participants at 
home, as well as the duration in days was used to calculate an estimated number of overall 
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readings used to quantify mid-term BPV (i.e. if participants were instructed to measure their 
BP once every morning for 28 days then the number of readings reported would be 28). For 
studies which have used the average of more than one BP reading to define each session (i.e. 
morning, evening or total day BP level), the number of readings was based on the total averaged 
BP for each session. 
Long-term BPV. Long-term BPV was quantified by visit-to-visit clinic BP monitoring. The 
estimated total number of visits was calculated based on the protocol provided (i.e. if BP was 
measured in clinic 2 times per year and the duration of monitoring was 5 years, the number of 
visits would be 10). Alternatively, we used the mean number of visits if that was reported. As 
there was a substantial number of studies that reported BPV using both SD (n=48) and CV 
(n=26), the analysis was performed for both metrics. 
Analysis. Studies were examined and the main themes were identified; type of BPV, type of 
metric used to quantify BPV, number of BP readings or visits, duration of BP monitoring, age 
and mean BP level of the population under investigation (step 1 as per Arksey and O’Malley).13 
Studies were then identified and selected based on the main themes (2nd and 3rd steps) and 
included in a data chart for further analysis (step 4). In order to construct an overall perspective 
and analytically interpret the evidence, the data were examined based on descriptive statistics 
(frequency, mean or range) and visually inspected using scatter plots and bar charts to identify 
relationships between the variables under examination (step 5). 
1.4 Results 
Literature review. A total of 269 studies on systolic BPV were examined; 110 studies 
examined short-term BPV, 33 studies examined mid-term BPV and 124 studies examined long-
term BPV. The most common metric used across all studies was SD 74%, n=199), followed 
by the CV (43%, n=116) and ARV (22%, n=58), as seen in Figure 1.1 (metric segment). 26 
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studies examining short-term BPV (day or awake BPV), 15 studies examining mid-term BPV 
(morning, evening or day-to-day BPV) and 55 studies examining long-term BPV (visit-to-visit 
BPV) reported mean BPV using SD (Table 1; supplementary material [Appendix 1]).
11 
 
 
Figure 1. 1. Circular representation of the prevalence of various blood pressure variability (BPV) metrics across studies examining 
different types of BPV; short-term (red colour), mid-term (orange colour) and long-term (yellow colour).  
The width of ribbons shows the number of studies which have used a certain metric under a certain type of BPV (i.e. 82 studies examining short-
term BPV, 34 studies examining mid-term and 92 studies examining long-term BPV have used SD). Metric segment show the total studies which 
have used a specific metric, i.e. blue colour show studies which have used SD; n=199, green colour show studies that have used CV; n=116.
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Short-term BPV. Table 1 (supplementary material [Appendix 1]) shows the various protocols 
used to determine the day or awake time periods; the majority of studies used fixed times whilst 
other studies used participants’ diaries to identify day or awake period. Studies used the 
following time intervals between readings; 15 min, 20 min and 30 min, with the most common 
being a 30 min interval (n=10 from 26). The number of readings used to quantify short-term 
BPV ranged from 32 to 64. The duration of day-time monitoring period varied across studies 
with the longest monitoring being 17 hours and the shortest being 10 hours. Mean short-term 
BPV was 13.9 (2.9) mmHg. The magnitude of BPV was not associated with the number of BP 
readings or the duration of BP monitoring. Similarly, BPV was not associated with age, but it 
was positively associated with mean BP levels (Figure 1. 2). 
Mid-term BPV. Mid-term BPV was separately assessed for morning (n=12), evening (n=7) 
and day-to-day BPV (n=7; Supplemental digital content; table 1). The number of readings 
used across studies ranged from 6 to 42 and the duration ranged from 4 to 28 days. Mean 
mid-term BPV was 8.2 (1.4) mmHg for morning, 8.3 (1.04) mmHg for evening and 8.6 (4.2) 
mmHg for day-to-day BPV. The number of readings as well as the duration of monitoring 
were positively associated with all types of mid-term BPV whilst age was positively 
associated only with day-to-day BPV (Figure 3). Although day-to-day BPV appeared be 
positively associated with mean BP levels, there was a weak negative association between 
mean BP level and morning or evening BPV. 
Long-term BPV. The protocols used to quantify BPV are seen in Table 1 (supplementary 
material [Appendix 1]) and varied in terms of number of readings (range from 2 to 46 readings) 
and duration of monitoring (range from 0.2 to 25 years). Mean long-term BPV was 12.0 (5.1) 
mmHg calculated using SD and 9.5 (4.1) % calculated using CV. The number of visits was 
positively associated with long-term BPV whilst there was no association between the duration 
of monitoring and long-term BPV. Long-term BPV was also positively associated with age. 
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Lastly, long-term BPV, calculated as either SD or CV, was positively associated with mean BP 
level (Figure 1. 4).  
 
Figure 1. 2. Short-term BPV. 
Scatter plots and fitted regression lines of the relationships between short-term (day or awake) 
systolic blood pressure variability and the number of blood pressure readings (panel a; r=0.10 
p=0.72); duration of blood pressure monitoring (panel b; r=0.07 p=0.76); age (panel c; r=0.15 
p=0.47); mean blood pressure level (panel d; r=0.53 p=0.01). Scatter plots represent data from 
individual studies. 
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Figure 1. 3 Mid-term BPV.  
Scatter plots and fitted regression lines of the relationship between mid-term systolic blood 
pressure variability (gray circles = morning; black circles = evening and white circles = day-
to-day BPV) and the number of blood pressure readings (panel a [morning: r=0.10, p=0.018; 
evening: r=0.10, p=<0.001; day-to-day: r=0.23, p=0.07]); duration of blood pressure 
monitoring (panel b [morning: r=0.60, p=0.04; evening: r=0.52, p=0.18; day-to-day: r=0.39, 
p=0.44]); age (panel c [morning: r=0.07, p=0.20; evening: r=0.12, p=0.09; day-to-day: r=0.29, 
p=0.008]); mean blood pressure level (panel d [morning: r=-0.041, p=0.03; evening: r=-0.043, 
p=0.095; day-to-day: r=0.37, p=0.01]). Scatter plots represent data from individual studies. 
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Figure 1. 4. Long-term BPV. 
Scatter plots and fitted regression lines of the relationship between long-term systolic blood 
pressure variability (black circles = standard deviation [SD]; gray circles = coefficient of 
variation [CV]) and the number of blood pressure visits (panel a); duration of blood pressure 
monitoring (panel b [SD: r=-0.10, p=0.52; CV: r=-019, p=0.43]); age (panel c [SD: r=0.57, 
p<0.001; CV: r=0.52, p=0.01]) mean blood pressure level (panel d [SD: r=0.49, p=0.001; CV: 
r=0.49, p=0.02]). Scatter plots represent data from individual studies. 
1.5 Discussion 
Although, methodological discrepancies concerning the measurement of BPV have been noted 
by many,10,11suggesting that BPV magnitude may be affected by participant characteristics 
such as age and mean BP level, to our knowledge, this is the first systematic review of 
methodological factors that could affect the assessment and magnitude of short-, mid- and long-
term BPV. The key findings were firstly, the number of BP readings used to quantify mid-term 
BPV and the number of visits used to quantify long-term BPV were positively associated with 
the magnitude of BPV itself. However, the number of BP readings was not associated with the 
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magnitude of short-term BPV. Secondly, the duration of BP monitoring was not associated 
with the magnitude of short- and long-term BPV although there was a weak association 
between the duration of BP monitoring and mid-term BPV. Lastly, long- and mid-term (day-
to-day), but not short-term BPV, were positively associated with age, and importantly, most 
types of BPV were positively associated with mean BP levels. These findings indicate that the 
magnitude of BPV is not only dependent on several methodological factors, but also on 
participant age and mean BP levels. These data emphasise the need to standardize the 
methodology of measuring and quantifying BPV.  
Short-term BPV. The methodology and protocols used to measure mean BP levels using 24-
hour monitoring are well defined and usually require measurements to be taken every 20-30 
minutes during daytime and every 30-60 minutes during night-time, with an interval of 15-30 
minutes generally accepted for use throughout the entire 24-hour period.17 It has been 
suggested though that the quantification of short-term BPV may require a higher frequency of 
measurements with time intervals ≤15 minutes,2 but the exact time interval required for an 
accurate quantification is not clear. Importantly, Di Rienzo, using continuous intra-arterial BP 
monitoring and comparing with BP measurements taken every 5, 10, 15, 30 and 60 minutes, 
concluded that although mean BP levels were correctly quantified using 30-minute intervals, 
short-term BPV could still be erroneous even at sampling intervals of 5 and 10 minutes.18Our 
analysis showed that the number of readings used to quantify day or awake short-term BPV 
was not associated with the magnitude of BPV; however, none of the studies which met our 
inclusion criteria used a time interval <15 minutes. Although some guidelines recommend that 
14 readings may be adequate to accurately estimate short-term BPV,19 there is evidence 
supporting the need for higher frequency of BP sampling. Therefore, future studies examining 
short-term BPV should use a protocol with a sampling time-interval of <15 minutes until 
methodological studies establish a reliable and widely accepted measurement protocol. 
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Moreover, there is no standard definition as to what constitutes the ‘daytime’ period, and 
daytime short-term BPV has been quantified over periods that range from 10 to 17 hours. 
Similar to the number of readings, the duration does not seem to affect the magnitude of short-
term BPV according to the results of this analysis. One of the main methodological issues 
reported for the quantification of short-term BPV, is the relationship of the SD to the mean BP 
levels,20 and our analysis of studies confirms that SD increases as mean BP level increases. 
Although, an association between BPV and mean BP levels has been reported in the past, this 
is the first time that the strength of this association has been quantified. The findings of this 
study show that associations between BPV and mean BP levels ranged from as low as 0.04 to 
as high as 0.5 (quantified by Pearson correlation coefficient), depending on the type of BPV. 
The above highlight the need to keep in mind that a strong association between BPV and mean 
BP level might exist and could result in significant confounding even after adjustment in 
multivariable models. Lastly, short-term BPV is thought to increase with older age,21 but there 
is minimal evidence to support this alleged relationship. Cross-sectional studies reported that 
short-term BPV is positively correlated with age;22 yet contradictive results were reported in a 
5-year follow up study of 162 healthy individuals, which found that short-term BPV decreased 
over time.23 Even though, short-term BPV may appear to be correlated with older age in cross-
sectional studies, this may be due to a higher mean BP level with older age; therefore it is 
important that interactions between age and mean BP level are explored in future studies.  
Mid-term BPV. Similar to short-term BPV, there are no clear recommendations as to how 
many BP measurements or how long the duration of BP monitoring should be undertaken for 
an accurate assessment of mid-term BPV. Our analysis showed that both the number of BP 
readings as well as the duration of BP monitoring were positively associated with mid-term 
BPV. Therefore, it is important that these methodological factors are standardized in order for 
results to be generalizable. Another methodological issue concerns the timing of the 
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monitoring, whether it should be undertaken only in the morning, evening or all-day BP 
measures. Our analysis showed that the magnitude of BPV appeared to be similar when 
assessed using morning or evening BP measures, but BPV was slightly higher when all-day 
measures were used (day-to-day). Additionally, it has been suggested that mid-term BPV is 
affected by age and mean BP levels.11 The results of this analysis confirm a positive association 
of day-to-day mid-term BPV though this was not the case for morning and evening mid-term 
BPV. Similarly, day-to-day BPV was positively associated with mean BP level, although 
paradoxically, morning and evening mid-term BPV appeared to be slightly decreasing with 
higher mean BP level.  
The first paper to identify an outcome-driven cut-off value for mid-term BPV, as quantified by 
day-to-day home BP monitoring, was published recently by Juhanoja et al.4 They concluded 
that a systolic BPV greater than 11.0%, measured using CV, indicates a higher cardiovascular 
risk in European and Asian general populations with a mean age of 60 and a mean BP level of 
128.7 mmHg. The same study reported a primary cut-off value for BPV which was calculated 
using the first morning BP measurements for days 3 to 7 (11.0%) and also reported cut-off 
values which derived from sensitivity analysis using all 7 day measurements or the 
measurements of the first 3 days; 10.7% and 11.5% respectively. Lastly, the authors argued 
that the CV could be used as a universal reference metric due to low computational complexity 
(Table 1. 1) enabling easier calculation in clinical practice. We found that the most common 
metric used in research is the SD, followed by the CV. The reason of SD and CV being the 
most commonly used metrics for the quantification of BPV could indeed be their low 
computational complexity, but it needs to be confirmed if these metrics are interchangeable as 
markers of prognosis.  
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Table 1. 1. Metrics used in blood pressure variability quantification 
Metric Formula Computational 
complexity 
Characteristic 
Standard 
deviation 
(SD)* 1
)( 2


n
xxi
 
Low Reflects the dispersion of values 
around the mean; it may be 
correlated with mean BP level 
(higher BPV may be observed if 
mean BP levels are high and 
vice versa) 
Coefficient of 
variation (CV) 
𝑆𝐷
x
× 100 
Low Reflects the dispersion of values 
around the mean but it takes into 
account the level of mean BP. 
Using CV one could compare 
the variability in measures even 
when the means are different. 
However, CV may retain an 
association with mean BP level, 
although it may be weaker in 
comparison to SD 
Rate of change 
(RC) 
∑
𝑛− 1|𝑟𝑖|
𝑛 − 1
 
 
Where r is the rate 
of change between 
two readings and it 
is computed as 
described by 
Zakopoulos et al.24 
High Reflects the speed of change in 
BP and it shows how fast BP 
changes from reading to 
reading, day to day or visit to 
visit 
Variation 
independent of 
the mean 
(VIM) 
𝑆𝐷
𝑥
𝑐 × 𝑘 
 
Where c is the 
power at which the 
mean BP is raised 
to and derives 
from curve fitting 
and k is a constant, 
computed as 
described by 
Rothwell et al.16  
High This metric is a transformation 
of SD where the mean is raised 
to a certain power in order to 
remove any correlation between 
the SD and the mean BP level. 
This metric is therefore 
considered to be a BPV measure 
independent of the mean BP 
level 
Average real 
variability 
(ARV) 



 

1
1
1
1
1 n
i
ii xx
n
 
Low Accounts for the order in which 
BP readings were taken and it is 
a less sensitive metric of 
variance if BP readings are not 
frequent 
*Standard deviation can be quantified by weighting the different time periods (i.e. weighted 
for daytime and night-time periods for a 24-hour quantification of BP. 
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Long-term BPV. As it has been noted by Whittle in a recent editorial,25 long-term BPV was 
more powerful in terms of prediction of cardiovascular disease26 and events such as stroke and 
coronary events1,27 in comparison to other BPV monitoring techniques (i.e. short-term BPV). 
Despite the plethora of studies investigating the effect of long-term BPV on outcomes, there is 
no consensus as to the protocol for BPV assessment regarding the number of visits or the 
duration of BP monitoring10 and importantly, there are no cut-off values for risk stratification. 
The above issues constitute important barriers in the incorporation of long-term BPV in clinical 
practice.  
It has been reported that the number of visits used to quantify long-term BPV is positively 
related to BPV magnitude.28 Levitan et al. has also reported that the duration of BP monitoring 
as quantified by the time-interval between visits may impact BPV quantification. Our analysis 
confirms that the magnitude of long-term BPV increased as the number of visits increased. On 
the other hand, our study found that the duration of BP monitoring was not associated with the 
magnitude of long-term BPV. Although this might seem contradictory, it is important to note 
that a longer duration of BP monitoring does not necessarily mean a higher number of BP visits 
or readings (a 10-year study might have quantified BPV using BP readings from 3 visits whilst 
a 6-month study might have quantified BPV using BP readings from 6 visits). Levitan et al, 
showed that BPV quantified using 7 visits over 18 months was 6.8 mmHg and 7.5 mmHg when 
the time interval was spaced across 4 years; however, BPV was 7.7 mmHg when BPV was 
quantified using 18 visits and 4 years BP monitoring duration. However, the difference between 
BPV over 4 years quantified by 7 versus 18 visits was not statistically significant. Moreover, 
it is not clear whether and how age and mean BP level could affect the assessment of long-term 
BPV. Our results showed that both SD and CV of long-term BPV were positively associated 
with age and mean BP levels.  
21 
 
Some studies have recommended long-term BPV cut-off values denoting the development of 
renal functional decline9 and chronic kidney disease;29 13.5 mmHg and 14.8 mmHg, 
respectively (both using the SD). These values derived from 3 to 4 visits every year, over a 15 
year follow up duration as reported by Chia et al.9 and from 12 visits as reported by Yokota et 
al.29 (the duration of BP monitoring was not reported in this study). In the latter study, subjects 
were older by a decade (67 versus 56 years old) which could have also accounted for the 
difference observed, on the basis of our findings that age was positively associated with the SD 
in long-term BPV. On the other hand, Kawai et al.30 reported that a BPV of 8.3 – 8.4 mmHg 
(SD) could predict cardiovascular events and a BPV of 13.7 mmHg could predict total 
mortality. BPV in that study was quantified from 6 visits, in a hospital-based cohort with a 
mean age of 62 years. Based on the findings of this current analysis, none of the cut-off values 
reported above are comparable due to the heterogeneity of the methodology used to quantify 
BPV as well as the different population characteristics (i.e. different age). 
Strengths and limitations. The scoping review approach enabled, for the first time, to evaluate 
and quantify the effect of certain methodological factors of BPV assessment on the magnitude 
of BPV itself. On the other hand, the analysis was restricted to studies reporting BPV as 
quantified by SD; this restriction was necessary due to the volume of BPV-related published 
studies and the various metrics used. Therefore, it could be argued that the results may not 
applicable to other measures such as VIM or ARV; however, given that most of the studies did 
not report average BPV and that SD is still the most common metric used in research, we 
believe that this analysis is a reasonable representation of current practice. Nonetheless, given 
that previous research has shown that there is a strong correlation (>0.95)31 between SD and 
other BPV indexes, these results have important implications irrespective of the index of BPV. 
Conclusion and recommendations. In conclusion, the methodology used to quantify BPV, as 
well as age and mean BP level, affects the magnitude of BPV itself. The implications of 
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methodological heterogeneity in measuring BPV as well as data reporting are critical in 
answering the questions of whether BPV and which type of BPV, independently predicts 
outcomes and whether it could be used in risk stratification. Nonetheless, what will ultimately 
guide clinical practice is universal thresholds for each type of BPV that will allow clinicians to 
interpret a patient’s BPV according to certain reference values. Taken altogether, this study 
highlights the need for recommendations for the measurement of BPV, firstly regarding 
methodological factors underlying disparate values and secondly, regarding the type of data 
that should be reported. These recommendations should be followed by large-scale population 
studies that will include the full age and BP spectrum in order to quantify reference ranges and 
cut-off values for risk stratification. We suggest the following: 1) the timing, number of BP 
measurements and duration of BP monitoring should be clearly reported in all studies, 2) as the 
best definition of BPV remains to be established, a metric which has low computational 
complexity (i.e. CV) should always be reported to enable easier translation of results and 
integration in clinical practice, even if other independent of the mean metrics are the primary 
focus of analysis, 3) the statistical analysis should always take into account the effect of age 
and mean BP level by adjusting for these variables and especially, by exploring interactions 
between age and BP level. 
1.6 Contribution of chapter 1 to thesis aims 
Chapter 1 (study 1) was primarily used to review the literature and chart current evidence 
regarding the methodology used to quantify BPV. The results of chapter 1 represent the first 
scoping review of contemporary methodologies used to assess and measure the three main BPV 
types; short-term, mid-term and long-term BPV and it is the first study to identify 
methodological factors that could affect BPV magnitude. Importantly, it has been demonstrated 
that the number of BP measurements or visits used to quantify BPV, as well as the duration of 
BP monitoring, could affect the magnitude of BPV itself. Additionally, this study showed that 
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age and mean BP level are important determinants of the magnitude of BPV. These results 
highlight the need to standardize BPV protocols, particularly regarding the number of BP 
readings and visits.   
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2.1 Abstract 
Blood pressure variability (BPV) is associated with macrovascular complications and stroke, 
but its association with the microcirculation in type II diabetes (T2DM) has not been 
assessed. This study aimed to determine the relationship between BPV indices and retinal 
arteriolar diameter in non-diabetic and T2DM participants. Digitized retinal images were 
analysed to quantify arteriolar diameters in 35 non-diabetic (aged 52[11] years; 49% male) 
and 28 T2DM (aged 61[9] years; 50% male) participants. BPV was derived from 24-hour 
ambulatory BP. Arteriolar diameter was positively associated with daytime rate of systolic 
BP variation (p=0.04) among T2DM participants and negatively among non-diabetics 
(p=0.008) (interaction p=0.001). This finding was maintained after adjusting for age, sex, 
body mass index and mean daytime SBP. These findings suggest that the BPV-related 
mechanisms underlying retinal vascular disease may differ between people with and without 
T2DM. 
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2.2 Introduction 
Quantitative measures of retinal vascular structure, such as vessel diameters may provide 
prognostic information regarding microvascular complications and risk related to vascular 
diseases such as type II diabetes (T2DM). Retinal microvascular changes have been related to 
hypertension32 whilst changes in retinal arteriolar diameters could be an early 
pathophysiological indicator in T2DM.33 Although narrower retinal arteriolar diameters have 
been found to be associated with high blood pressure (BP),34 possibly indicating 
vasoconstriction or inward remodelling in response to elevated BP, wider retinal arteriolar 
diameters were found to be associated with T2DM,35 suggesting impaired arteriolar 
autoregulation36 due to compromised myogenic responses. Negative correlations between BP 
and arteriolar diameters have also been observed in T2DM,37 but evidence suggests these 
relationships may be weaker than in non-diabetic individuals.38  
On the other hand, BP variability (BPV) indices such as the rate of BP variation over time (a 
measure of the speed of BP change), is thought to be an indication of the alterations in 
cardiovascular regulatory mechanisms that could lead to vascular complications irrespective of 
the mean (average) BP level.39 At the same time, increased arterial stiffness and autonomic 
dysregulation, which could both lead to increased BPV, are common complications in 
T2DM.40,41 Nevertheless, the relevance of BPV or mean BP level to retinal arteriolar diameters 
as derived from 24-hour ambulatory BP has never been investigated in individuals with T2DM. 
The aim of this study was to examine the relationship between mean BP levels as well as BPV 
with arteriolar diameters, in individuals with T2DM. We hypothesized that BPV indices may 
play a role in retinal vascular structure, as assessed by the quantification of arteriolar diameter, 
in patients with T2DM. 
2.3 Methods 
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Data from this study was derived from a previously published investigation among 80 
consecutive participants with (n=40) and without T2DM (n=40) recruited from the local 
community.42 This current post-hoc, hypothesis-generating analysis was from the 35 non-
diabetic and 28 T2DM participants where both retinal imaging and 24-hour ambulatory BP 
measurements were available. Exclusion criteria included pregnancy, arrhythmia or a clinical 
history of cardiovascular disease (including coronary artery disease, myocardial infarction, 
heart failure or stroke) or severe pulmonary disease. T2DM was self-reported after diagnosis 
by a doctor. The Human Research Ethics Committee of the University of Tasmania approved 
the study and written informed consent was provided by all participants.  
Retinal imaging. Retinal images were recorded using a non-mydriatic retinal camera (Canon, 
CR-DGi-45NM) and digitised to a resolution of 2800-2400 pixels using a LS100 slide scanner 
(Nikon, Tokyo, Japan). Microvascular parameters were measured using a custom written 
Matlab program, as described previously.43 Good reproducibility of this technique has been 
previously reported.43 The analysis was performed on a series of complete vascular branches, 
either from one eye or both eyes in order to obtain the required number of vessel segments (8, 
range 7-18) and bifurcations (6, range 3-15). Arteriolar diameter was measured in a series of 
intensity cross-sections normal to the vessel at 2-pixel intervals along the entire length of the 
vessel segment. At each cross-section, arteriolar diameter was measured to subpixel accuracy 
using a sliding linear regression filter technique as described previously43 and the average was 
calculated for each vessel. 
24-hour ambulatory BP and BPV indices. 24-hour ambulatory BP was measured every 20 
minutes during the daytime and every 30 minutes during the night-time (TM-2430, A&D 
Medical, Sydney, Australia). Participants were asked to continue their usual daily activities but 
to avoid any strenuous activities. Individual measurements with an error code or those with a 
pulse pressure of less than 20 mmHg were excluded from the analysis. BPV was expressed 
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separately for the periods of daytime, nighttime and 24-hour as the rate of BP variation and 
was calculated based on a modified method described by Zakopoulos et al.44 Rate of BP 
variation was further adjusted for the corresponding mean BP levels ([rate of BP 
variation/mean BP]*100). Calculations involved plotting the slope for the change between SBP 
and DBP readings against time. Daytime was defined as the period between 08:00 to 20:00 and 
night-time as the period between 22:00 to 06:00. The periods from 20:00-22:00 and 06:00-
08:00 were excluded as they represent the steepest diurnal fall and rise in BP respectively and, 
therefore may contribute to BPV measures. BPV was also quantified using the coefficient of 
variation of the corresponding mean BP level (CV; [standard deviation/mean BP]*100). 
Blood biochemistry. Venous blood samples were drawn from the antecubital fossa and 
analytical biochemistry was performed by the Royal Hobart Hospital pathology department 
using accredited laboratory techniques.  
Statistical analysis. Student’s t tests were used to compare retinal and haemodynamic 
variables between diabetic and non-diabetic participants. Linear regression analysis was 
performed to assess the relationship between arteriolar diameter and BP measures, further 
statistical adjustment for possible confounders: age, sex, BMI (and mean SBP for BPV) was 
performed by multivariable linear regression. Statistical interactions between diabetes status 
and BP variables were assessed by testing the statistical significance of the coefficient of a 
product term after adjusted for age, body mass index (BMI), sex and mean daytime SBP 
(diabetes status x BP variable). A P value <0.05 was considered statistically significant. All 
data were analyzed using Stata 12.1 (StataCorp, College Station, Tx).  
2.4 Results 
Participants with T2DM were older, had higher BMI and most were on antihypertensive 
therapy or treatment with statins in comparison to non-diabetic participants (Table 2. 1). 24-
hour ambulatory mean BP and BPV indices were similar between the groups (Table 2. 1) and 
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there were no differences in arteriolar diameters (non-diabetics; 25.54(2.74) pixels vs T2DM; 
25.58(2.71) pixels, p=0.96). Retinal arteriolar diameter was not associated with any of the 
demographic characteristics (age, sex or BMI) among individuals with T2DM or individuals 
without T2DM (all p>0.09). Similarly, no associations were observed between retinal 
arteriolar dimeter and total cholesterol, triglycerides or glucose for individuals with T2DM or 
individuals without T2DM (all p>0.12). 
Table 2. 1 Demographic and clinical characteristics of study participants. 
Variable 
Non-diabetic 
(n=35) 
T2DM  
(n=28) 
P value 
Sex (male) 17(49) 14(50) 0.91 
Age (years) 52(11) 61(9) 0.002 
Body mass index (kg/m2) 24.74(3.12) 31.71(5.55) <0.001 
Current smoker 3(8) 2(7) 0.67 
Diabetes duration (years) - 7(7) - 
Cholesterol (mmol/L)    
Total 5.37(1.02) 4.42(1.10) 0.001 
High density lipoprotein 1.66(0.41) 1.30(0.46) 0.003 
Triglycerides 0.93(0.46) 1.61(0.81) 0.0002 
Glucose (mmol/L) 4.71(0.40) 7.65(1.89) <0.001 
Insulin (mU/L) 2.29(4.61) 10.00(8.62) <0.001 
Glycated haemoglobin (%) 5.52(0.36) 7.16(0.92) <0.001 
Medications    
Antihypertensive medications 0(0) 19(67) <0.001 
Statin 0(0) 19(67) <0.001 
Clinic BP (mmHg)    
Systolic blood pressure 113(9) 123(13) <0.001 
Diastolic blood pressure 65(6) 70(7) 0.004 
24-hour ambulatory BP (mmHg)    
Daytime systolic BP 135(13) 138(13) 0.27 
Night-time systolic BP 117(10) 122(3) 0.06 
24-hour systolic BP 128(11) 132(12) 0.25 
Daytime diastolic BP 84(7) 78(2) 0.008 
Night-time diastolic BP 69(7) 69(8) 0.94 
24-hour diastolic BP 78(6) 75(8) 0.07 
Blood pressure variability (%)    
Daytime rate of systolic BP variation 23.97(4.58) 25.96(5.62) 0.13 
Night-time rate of systolic BP variation 20.31(5.88) 18.83(5.77 0.32 
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24-hour rate of systolic BP variation 23.47(3.12) 25.09(5.35) 0.14 
Daytime rate of diastolic BP variation 29.10(8.54) 29.58(6.75) 0.81 
Night-time rate of diastolic BP variation 22.71(6.89) 24.49(8.16) 0.35 
24-hour rate of diastolic BP variation 28.14(6.18) 29.21(5.89) 0.49 
Data are mean(sd) or numbers (%). BP = blood pressure. 
In univariate regression analysis, arteriolar diameter was associated positively with daytime 
rate of SBP variation among participants with T2DM (β=0.007; p=0.04; R2=0.12) and 
negatively among non-diabetics (β=-0.010; p=0.008; R2=0.17). Additionally, mean daytime 
SBP was negatively associated with arteriolar diameter among participants with T2DM (β=-
0.003; p=0.03, R2=0.16) but not among non-diabetics (β=0.0003; p=0.80). A significant 
interaction between diabetes status and daytime rate of SBP variation was observed and 
remained significant after adjusting for age, sex, BMI and mean daytime SBP (β=0.02; 
p=0.001) (Figure 2. 1). Moreover, the associations between arteriolar diameter and BPV were 
examined using other BPV indexes and measures that could derive from a short-term (24-hour) 
BP monitoring (daytime, night-time and total 24-hour BPV; SD, CV, time-rate and other 
indexes). Similar associations were also observed when CV was used. However, there were no 
significant associations between night-time BPV and retinal arteriolar diameter although there 
were similar, but weaker associations between total 24-hour BPV and the outcomes. Lastly, 
non-linear associations between BP or BPV indexes and retinal arteriolar were observed. 
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Figure 2. 1 Scatter plots and fitted regression lines of the relationship between arteriolar 
diameter and daytime rate of systolic BP variation among non-diabetics and participants with 
T2DM. 
2.5 Discussion 
The main finding of this study was that there were significantly different associations between 
retinal arteriolar diameter and BPV indices among healthy individuals and participants with 
T2DM. Retinal arteriolar diameter was positively associated with daytime SBP variation 
among participants with T2DM but negatively among non-diabetic individuals. These findings 
may suggest different pathophysiological contributions of BPV to adverse retinal arteriolar 
outcomes among people with T2DM compared with non-diabetic controls.  
BPV could play a role in large artery damage and remodelling over and above mean BP levels; 
however, despite its importance in cardiovascular disease and stroke in particular,39 the role of 
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BPV in microvascular disease is still unclear. This is the first study to assess the relationship 
between BPV and retinal arteriolar diameter and the impact of T2DM on that relationship.  
Our findings of a positive relationship between BPV and retinal arteriolar diameter in 
participants with T2DM could be relevant to the mechanism or consequences of increased 
BPV. Arteriolar dilatation in association with higher BPV in T2DM could be an early sign of 
impaired vascular autoregulation36 or early autonomic neuropathy.41 Both are associated with 
increased risk of retinal microvascular damage that could result from exaggerated fluctuation 
in transmitted pressure or flow to the microcirculation. Additionally, the different associations 
between BPV and arteriolar diameter among the two groups may be explained by the different 
level of cardiovascular risk between the two groups (individuals with T2DM are at increased 
cardiovascular risk in comparison to those without T2DM). Some authors have suggested that 
associations between BPV and outcomes may be modified by the level of cardiovascular 
risk.26,39 
These results should be seen in the context of the limitations of this study; the small sample 
size and the retrospective, cross-sectional design which limit the interpretation of the findings. 
The small size of our sample population may underlie the lack of stronger association between 
BP indices and arteriolar diameters. Indeed, further studies, in larger populations, are needed 
to examine associations between central haemodynamics, BP variability parameters and retinal 
arteriolar diameter in patients with T2DM. Similarly, a longitudinal follow-up study could help 
in determining causal relationships among haemodynamic parameters and retinal arteriolar 
diameter in diabetic microvascular disease. 
In conclusion, the findings suggest that increased BP fluctuations may be associated with 
different arteriolar responses in comparison to elevated mean BP levels, with BPV possibly 
playing a role in the pathophysiology of retinal microvasculature in T2DM. Although the 
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mechanisms underlying the relationship between BPV and retinal arteriolar in T2DM remain 
unclear, our findings support the need for further investigation. 
2.6 Contribution of chapter 2 to thesis aims 
Chapter 2 (study 2) represents the first study that used short-term BPV indices as a means to 
try and help explain microvascular complications in people with type II diabetes mellitus. 
Although it was a small post-hoc study, it is the first hypothesis-generating analysis to offer 
evidence that increased short-term BPV may play a role in the pathophysiology of retinal 
microvasculature in type II diabetes mellitus. 
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Pressure variability and prediction of target organ damage in patients with 
uncomplicated hypertension 
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3.1 Abstract 
Background: The average of multiple blood pressure (BP) readings (mean BP) independently 
predicts target organ damage (TOD). Observational studies have also shown an independent 
relationship between BP variability (BPV) and TOD, but there is limited longitudinal data. This 
study aimed to determine the effects of changes in mean BP levels compared with BPV on left 
ventricular mass index (LVMI) and aortic pulse wave velocity (aPWV).   
Methods: Mean BP levels (research-protocol clinic BP [clinic BP], 24-hour ambulatory BP 
and 7-day home BP) and BPV were assessed in 286 patients with uncomplicated hypertension 
(mean age 64 ± 8 SD years, 53% women) over 12 months. Reading-to-reading BPV (from 24-
hour ambulatory BP) and day-to-day BPV (from 7-day home BP) were assessed at baseline 
and 12 months, and visit-to-visit BPV (clinic BP) was assessed from 5 visits over 12 months. 
LVMI was measured by 3D echocardiography and aPWV with applanation tonometry.  
Results: The strongest predictors of the changes in LVMI (ΔLVMI) were the changes in mean 
24-hour systolic BPs (p<0.02). Similarly, the strongest predictors of the changes in aPWV 
(ΔaPWV) were the changes in mean 24-hour ambulatory systolic BPs (p<0.01) and the changes 
in mean clinic systolic BP (p<0.001). However, none of the changes in BPV were 
independently associated with ΔLVMI or ΔaPWV (p>0.05 for all).  
Conclusions: Changes in mean BP levels, but not BPV, were most relevant to changes in TOD 
in patients with uncomplicated hypertension. Thus, from this point of view, BPV appears to 
have limited clinical utility in this patient population.  
  
36 
 
3.2 Introduction 
It is well recognised that hypertensive target organ damage (TOD) and cardiovascular events 
are associated with elevated blood pressure (BP), as determined from the average of multiple 
BP readings (mean BP).45 The extent to which BP fluctuates over time, expressed as blood 
pressure variability (BPV), has been suggested to offer incremental prognostic value, over and 
above mean BP levels.1 However, the independent value of BPV is not yet established and 
results are conflicting between the different ways to assess BPV such as reading-to-reading, 
day-to-day or visit-to-visit BPV.11,46-50 This lack of clarity with respect to the clinical 
significance of different BPV assessment methods may be related to the different 
pathophysiological pathways reflected by each type of BPV.51 Importantly, there has never 
been a longitudinal study to examine the relation of BPV with TOD (for example, cardiac 
structure or aortic stiffness) utilizing more than one way to assess BPV in the same population. 
Therefore, a cause and effect relationship between BPV and TOD has not yet been clearly 
determined. On the contrary, the prognostic relevance of mean BP level as derived from clinic, 
24-hour ambulatory or home BP to TOD is well known.52,53 This study aimed to investigate 
the relationship between the changes in mean BP levels and BPV indices as derived from 
reading-to-reading (from 24-hour ambulatory BP), day-to-day (from 7-day home BP) as well 
as visit-to-visit BP monitoring (clinic BP), on changes in TOD (assessed by left ventricular 
mass index [LVMI] and aortic pulse wave velocity [aPWV]) in patients with uncomplicated 
hypertension followed over 12 months. We hypothesized that changes in BPV will be 
associated with changes in TOD indices and that these associations will be independent of 
mean BP levels. 
3.3 Methods 
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Study population. Data were analysed from 286 patients with uncomplicated hypertension 
who participated in the BP GUIDE study, the design of which has been previously published.54 
Exclusion and inclusion criteria are seen in the supplementary material (Appendix 2). Patients 
gave informed consent prior to any assessments, and each study site was granted ethics 
approval by their local Human Research Ethics Committee. 
Study protocol. Participants attended the study sites on 5 occasions over 12 months, at 3-
month intervals. Clinic and home BP was measured at all 5 occasions and 24-hour ambulatory 
BP, LVMI and aPWV measurements were performed at baseline and at the 12-month visit. 
Complete data for all BP variables, as well as LVMI and aPWV measures were available on 
267 and 250 participants respectively. Antihypertensive therapy was assessed at all 5 visits and 
recommendations regarding medication titration were provided to each patient’s doctor. 
Extensive details on the titration recommendations have been published elsewhere.54  
Target organ damage. Real-time three dimensional imaging was performed using a matrix 
array transducer and left ventricular mass (LVM) measurement was measured using real-time 
3-dimensional echocardiography which has greater accuracy and lower test-retest variation, 
compared to other measurement techniques.55 LVMI derived after indexing LVM to height2.7 
according to guidelines.55,56 Aortic stiffness was assessed using tonometry readings of carotid 
to femoral pulse wave velocity, according to guidelines57 with the patient in a supine position 
(SphygmoCor 8.0, AtCor Medical, Sydney, NSW).  
Clinic BP. The average of two BP measurements taken 1 minute apart was calculated after 10 
minutes of rest, which results in lower average BP that is more clinically relevant than 
averaging BP after 5 minutes rest.58 We used a validated59 automatic device for this purpose 
(Omron HEM-907; OMRON Europe B.V. (OMCE), Hoofddorp, The Netherlands). 
Measurements were recorded using an appropriate size of cuff, with the patients’ arm supported 
at the height of the heart, back supported and feet flat on the floor as per recommendations.45 
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7-day home BP. A validated60 oscillometric device (UA-767, A&D Mercury; A&D Medical, 
Thebarton, South Australia, Australia) was given to participants to record home BP. 
Participants were instructed to record their BP twice after 5 minutes of rest but only record the 
second reading. They were also instructed to take BP in the morning (between 06:00 and 
10:00), in the evening (between 18:00 and 22:00) and at midday if possible.   
24-hour ambulatory BP. A validated61 BP device (TM-2430, A&D Mercury; A&D Medical) 
was used to take BP measurements every 30 minutes during the day and every hour during the 
night. The daytime period was defined as the time between 06:00 to 22:00 and the night-time 
period as the interval between 22:00 to 06:00. Participants were advised to maintain routine 
daily activities but to avoid strenuous physical activities. Data were included for analysis if 
there were more than ten BP measurements and if >80% of readings were valid. Measurements 
with an error code or a pulse pressure <20 mm Hg were excluded from the analysis. 
BPV. Systolic BPV (SBPV) and diastolic BPV (DBPV) calculated as the standard deviation 
(SD) around the mean, as well as the coefficient of variation (CV; [SD/mean]x100), using the 
corresponding mean BP level. Reading-to-reading BPV derived from the 24-hour ambulatory 
BP monitoring and assessed separately for 24-hour, daytime and night-time periods. Day-to-
day BPV was calculated from the 7-day home BP monitoring using all the available 
measurements rather than the average of each day in order to provide a greater number of BPs 
to allow for a better representation of BP fluctuations. Visit-to-visit BPV derived from clinic 
BP measured at 5 visits. The results are presented using the CV as it takes into account the 
relationship between mean BP levels and BPV. 
Antihypertensive medications quantity. The daily defined dose (DDD) of medications was 
calculated as per World Health Organization standards and was recorded at all 5 visits; 
compliance was assessed by the study nurse viewing each participant’s medication packet(s). 
Participants were categorised into groups based on the change in DDD over 12-months follow-
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up; (1) those who had an increase, (2) those who had a decrease and (3) those who had no 
change, according to tertiles of the change in DDD. This enabled quantification of the change 
in DDD as well as the direction of the change (decrease or increase) over time. In this study, 
participants were randomised to have changes in medication guided by either usual care (based 
on clinic, 7-day, and 24-hour ambulatory BP) or additionally using central BP measures.54 
Statistical analysis. The change in BPV and mean BP levels was compared between the upper 
and the lower quartile of ΔLVMI and aPWV in order to examine whether the respective change 
was different among those participants who had a sizeable change (increase versus decrease) 
in target organ damage. The relationships between the changes in LVMI (ΔLVMI) and aPWV 
(ΔaPWV) and the changes in mean BP levels or BPV measures were assessed using linear 
regression analysis which was repeated after adjusting for baseline age, sex and BMI. In order 
to assess if BPV indices were independently predicting changes in the outcomes, multivariable 
models were further adjusted for the changes in mean BP levels. Models were also adjusted for 
the change in DDD. Further sensitivity analyses are detailed in supplementary material 
(Appendix 2). Student’s t-test was used to compare changes in mean BP and BPV variables 
between groups. A p<0.05 was considered statistically significant. Statistical analyses were 
performed using Stata 12.1 (StataCorp, College Station, Tx). 
3.4 Results 
Participant characteristics. Table 3. 1 shows the baseline demographic and clinical 
characteristics of the study participants. A small percentage of patients had type II diabetes 
(8%) whilst almost half of the study population were either current or former smokers. Mean 
LVMI was 31.28(5.54) g/m2.7 and aPWV was 9.41 (2.14) m/s at baseline and values were not 
changed at 12-months on average; 31.30 (5.50) g/m2.7 and 9.35 (2.02) m/s respectively. At 
baseline, the strongest predictor of LVMI was mean 24-hour ambulatory SBP (p=0.03) and 
clinic SBP for aPWV (p<0.001). None of the baseline BPV measures were correlated with 
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either LVMI or aPWV (p≥0.08 for all) whilst further adjustment for mean 24-hour ambulatory 
BP levels did not change these associations. 
Table 3. 1 . Demographic and clinical characteristics of participants at baseline visit (n = 
286) 
Participant clinical characteristics  Mean(SD) or %(n) 
Mean age, y 64(8) 
Body mass index, kg/m2 29(5) 
Females 53 (152) 
Smoking status (current or former) 44(126) 
Type II diabetes mellitus 8(22) 
Antihypertensive medications 
Angiotensin converting enzyme inhibitors 30(85) 
Angiotensin receptor blockers 66(188) 
Calcium channel blockers 30(84) 
Diuretics 39(110) 
Beta blockers 10(29) 
Daily defined dose  2.4(1.3) 
Blood pressure (mmHg) 
24-hour systolic blood pressure  131(12) 
24-hour diastolic blood pressure  76(8) 
7-day systolic blood pressure  128(13) 
7-day diastolic blood pressure  74(8) 
Clinic systolic blood pressure  127(14) 
Clinic diastolic blood pressure  76(10) 
Blood pressure variability (BPV; %) 
24-hour systolic BPV  16(5) 
Daytime systolic BPV  15(5) 
Night-time systolic BPV  13(5) 
24-hour diastolic BPV  22(8) 
Daytime diastolic BPV 20(8) 
Night-time diastolic BPV  16(8) 
41 
 
7-day systolic BPV  7(2) 
7-day diastolic BPV  8(2) 
Associations of mean BP variables with ΔLVMI. Table 3. 2 shows the comparison of the 
change in mean BP levels between the upper and the lower quartile of ΔLVMI. All mean 24-
hour ambulatory BPs indices, except mean night-time DBP were significantly increased among 
participants who had an increase in LVMI compared with those who had a decrease in LVMI. 
None of the changes in clinic or 7-day home BP were significantly different between the 
groups. In univariable analysis, ΔLVMI was positively associated with changes in mean 24-
hour ambulatory, daytime and night-time SBP and remained significant in multivariable 
analyses adjusted for age, sex and BMI (Table 3. 3). No associations were observed between 
ΔLVMI and visit-to-visit mean BP (Table 3. 3). The above results remained unchanged after 
adjustment for changes in DDD. 
Associations of BPV variables with ΔLVMI. 24-hour ambulatory and daytime SBPV were 
paradoxically decreased among participants who had an increase in LVMI compared with those 
who had decrease in LVMI (Table 3. 2). None of the changes in BPV measures were 
significantly different between the groups. Furthermore, a paradoxical, negative and 
independent association was observed between ΔLVMI and the changes in 24-hour SBPV but 
inclusion of the changes in mean night-time ambulatory SBP in the model rendered the 
relationship nonsignificant (p=0.14). None of the visit-to-visit BPV indices were associated 
with ΔLVMI (Table 3. 3). Results were unchanged after further adjustment for the changes in 
DDD.  
Associations of mean BP variables with ΔaPWV.  Table 3. 4 shows the comparison of the 
change in mean BP levels and BPV indices between the upper and the lower quartile of 
ΔaPWV. Mean 24-hour ambulatory, daytime SBP and DBP and mean clinic SBP and DBP 
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were significantly increased among participants who had an increase in aPWV compared with 
those who had a decrease in aPWV. None of the 7-day home BPs were significantly different 
between the groups. In univariable analysis, ΔaPWV was positively associated with changes 
in mean 24-hour ambulatory, daytime and night-time SBP; clinic SBP; and changes in mean 
24-hour ambulatory, daytime, night-time and clinic DBP (Table 3. 3). All of these associations 
remained significant after adjusting for baseline age, sex and BMI (Table 3. 3); however, the 
associations between changes in mean clinic DBP indices and ΔaPWV were not significant 
after adjusting for changes in mean 24-hour ambulatory SBP or changes in mean clinic SBP 
(p>0.05 for all). Changes in mean visit-to-visit SBP and DBP were not associated with ΔaPWV 
(Table 3. 3).   Results were unchanged after further adjustment for the changes in DDD. 
Table 3. 2 Changes in mean BP levels and BPV indices among participants with a decrease 
or increase in LVMI over 12 months 
Variable 
Decrease in 
LVMI (n=67) 
Increase in  
LVMI (n=66) 
P value 
24-hour ambulatory BP (mmHg)    
24-hour systolic BP  -1.03(13.10) 6.00(13.86) 0.01 
Daytime systolic BP  -0.51(13.92) 5.29(13.44) 0.04 
Night-time systolic BP  -1.63(14.63) 7.35(17.60) 0.006 
24-hour diastolic BP  -0.43(8.58) 3.20(7.92) 0.03 
Daytime diastolic BP  -0.63(8.34) 3.16(8.56) 0.03 
Night-time diastolic BP  0.30(11.27) 3.35(9.50) 0.15 
7-day home BP (mmHg)    
Systolic BP  1.08(10.33) 2.39(10.85) 0.49 
Diastolic BP  1.37(6.73) 0.64(5.84) 0.51 
Clinic BP (mmHg)    
Systolic BP 0.08(13.18) 0.18(13.97) 0.97 
Diastolic BP 1.09(6.34) 1.63(5.73) 0.62 
Reading-to-reading BPV (%)    
24-hour systolic BPV  0.51(3.37) -2.07(4.16) 0.001 
Daytime systolic BPV  0.61(4.13) -2.02(4.01) 0.002 
Night-time systolic BPV  -0.88(7.70) -0.21(5.93) 0.63 
24-hour diastolic BPV  0.22(6.97) -1.25(7.29) 0.31 
Daytime diastolic BPV 0.49(7.33) -0.99(7.30) 0.31 
Night-time diastolic BPV  -1.25(12.20) -0.31(7.58) 0.65 
Day-to-day BPV (%)    
Systolic BPV  -0.56(2.42) -0.37(2.07) 0.64 
Diastolic BPV  -0.50(3.13) -0.50(3.12) 0.98 
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Data presented as mean(sd).  
BP = blood pressure; BPV = blood pressure variability; LVMI = left ventricular mass index. A 
decrease or increase in LVMI was defined as changes in LVMI within the lower (a decrease 
greater than or equal to 1.7g/m2.7) or upper (an increase greater than or equal to 1.7g/m2.7) 
quartiles of the change in LVMI over 12 months. 
Associations of BPV variables with ΔaPWV.  There were no significant differences in the 
change in reading-to-reading or day-to-day BPV indices between the upper and the lower 
quartile of the aPWV changes with the exception of the night-time SBPV which was increased 
among participants who had an increase in aPWV (Table 3. 4). None of the changes in BPV 
indices, either reading-to-reading or day-to-day and neither visit-to-visit BPV indices were 
associated with ΔaPWV (Table 3. 3).   
Changes in DDD and mean BP levels and BPV. Figure 3. 1 shows the comparison of the 
changes in mean BP levels and BPV between participants who had an increase and participants 
who had a decrease in DDD over time. As expected, for those participants who had an increase 
in DDD there was a corresponding decrease in all mean systolic and diastolic BP measures, 
whilst an increase in all mean BP levels measures was observed for those who had a decrease 
in DDD (p<0.05 for all). On the contrary, no significant differences were observed between 
groups with increased or decreased DDD in terms of BPV indices, with the exception of the 
day-to-day SBPV which was paradoxically increased for those who had an increase in DDD 
(p=0.03). 
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Table 3. 3 Multivariable associations between mean BP levels and BPV indices with the changes in aPWV and LVMI over time 
Variable 
ΔLVMI (g/m2.7) (n=267) ΔaPWV (m/s) (n=250) 
Univariable Multivariable§ Univariable Multivariable§ 
Change in 24-hour ambulatory BP (mmHg)       
24-hour systolic BP  
0.03 (0.01,0.06)†|| 0.03 (0.01,0.06)† 0.03 (0.01,0.05)† 0.03 (0.01,0.05)† 
Daytime systolic BP 
0.03 (0.01,0.05)* 0.03 (0.01,0.06)* 0.03 (0.01,0.05)† 0.03 (0.01,0.05)† 
Night-time systolic BP 
0.03 (0.01,0.05)† 0.03 (0.01,0.05)† 0.02 (0.01,0.03)* 0.02 (0.01,0.03)* 
24-hour diastolic BP  0.04 (-0.01,0.09) 0.04 (-0.01,0.09) 0.04 (0.08,0.01)† 0.04 (0.01,0.08)† 
Daytime diastolic BP 0.03 (-0.01,-0.08) 0.03 (-0.01,0.08) 0.04 (0.07,0.01)† 0.04 (0.01,0.07)† 
Night-time diastolic BP 0.02 (-0.01,0.06) 0.02 (-0.01, 0.06) 0.02 (-0.03,0.05) 0.02 (-0.04,0.04) 
Change in 7-day home BP (mmHg) 
    
Systolic BP  
0.01(-0.02,0.04) 0.01 (-0.02,0.04) 0.01 (-0.01,0.03) 0.01 (-0.02,0.03) 
Diastolic BP  
0.00 (-0.05,0.05) 0.00 (-0.05,0.06) 0.02 (-0.01.0.06) 0.02 (-0.02.0.06) 
Change in clinic BP (mmHg) 
    
Systolic BP 
0.00 (-0.02,0.02) 0.00 (-0.02,0.02) 0.04 (0.02,0.05)‡ 0.04 (0.02,0.05)‡ 
Diastolic BP 0.02 (-0.01,0.06) 0.02 (-0.01,0.02) 0.05 (0.02.0.07)‡ 0.05 (0.02.0.07)‡ 
Change in reading–to-reading BPV (%)        
24-hour systolic BPV  
-0.08 (-0.16,-0.01)* -0.06 (-0.14,0.01) 0.01 (-0.04,0.06) 0.01 (-0.04,0.06) 
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Daytime systolic BPV  
-0.06 (-0.13,0.01) -0.06 (-0.13,0.01) -0.01 (-0.05,0.05) 0.00 (-0.05,0.05) 
Night-time systolic BPV  
-0.01 (-0.05,0.05) 0.00 (-0.04,0.05) 0.03 (-0.03,0.06) -0.03 (-0.04,0.07) 
24-hour diastolic BPV  0.03 (-0.02,0.08) 0.02 (-0.02,0.07) -0.01 (-0.04,0.02) -0.01 (-0.04,0.02) 
Daytime diastolic BPV  0.02 (-0.02,0.06) 0.02 (-0.02,0.07) 0.01 (-0.03,0.02) 0.01 (-0.03,0.02) 
Night-time diastolic BPV  0.01 (-0.05,0.03) 0.01 (-0.05,0.03) 0.01 (-0.04,0.01) 0.01 (-0.04,0.01) 
Change in day-to-day BPV (%) 
    
Systolic BPV  
-0.01 (-0.15,0.13) -0.01 (-0.15,0.13) 0.03 (-0.07,0.13) 0.04 (-0.06,0.14) 
Diastolic BPV -0.02 (-0.13,0.08) -0.02 (-0.12,0.09) 0.00 (-0.06,0.08) 0.00 (0.01,0.16) 
Visit-to-visit mean BP (mmHg) 
    
Clinic systolic BP 
-0.02 (-0.04,0.01) -0.03 (-0.06,0.01) 0.00 (-0.02,0.02) 0.00 (-0.07,0.08) 
Clinic diastolic BP 
0.00 (-0.03,0.04) 0.00 (-0.04,0.04) 0.00 (-0.03,0.03) 0.00 (-0.03,0.03) 
Visit-to-visit BPV (%) 
    
Clinic systolic BPV  
-0.05 (-0.15,0.06) -0.03 (-0.14,0.08) 0.03 (-0.04,0.11) 0.03 (-0.05,0.11) 
Clinic diastolic BPV (%) -0.01 (-0.03,0.01) -0.01 (-0.03,0.01) 0.06 (-0.07,0.02) 0.01 (-0.09,0.02) 
*p<0.05, †p<0.01, ‡p<0.001. 
§Adjusted for baseline age, sex, BMI. 
||Beta coefficient (95% confidence interval) (all such values).  
ΔLVMI = change in left ventricular mass index; ΔaPWV = change in aortic pulse wave velocity; BP = blood pressure; BPV = blood pressure 
variability.
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Table 3. 4 Changes in mean BP and BPV indices among participants with a decrease or 
increase in aPWV over 12 months. 
Variable 
Decrease in 
aPWV 
(n=63) 
Increase in 
aPWV 
(n=62) 
P value 
24-hour ambulatory BP (mmHg)    
24-hour systolic BP  -1.50(11.94) 6.69(13.10) 0.001 
Daytime systolic BP  -2.04(10.90) 7.06(12.68) <0.001 
Night-time systolic BP  0.15(16.36) 5.96(17.49) 0.08 
24-hour diastolic BP  -0.41(7.50) 3.38(7.14) 0.009 
Daytime diastolic BP  -0.76(6.30) 3.50(7.94) 0.003 
Night-time diastolic BP  1.96(8.62) 3.45(8.91) 0.39 
7-day home BP (mmHg)    
Systolic BP  1.87(10.83) 2.33(10.88) 0.82 
Diastolic BP  -0.33(5.04) 2.70(5.65) 0.002 
Clinic BP (mmHg)    
Systolic BP -6.01(12.92) 5.15(14.23) <0.001 
Diastolic BP -3.37(8.37) 2.39(9.23) <0.001 
Reading-to-reading BPV (%)    
24-hour systolic BP -0.62(3.06) -0.07(3.92) 0.42 
Daytime systolic BPV 3.52(3.88) 4.23(4.56) 0.39 
Night-time systolic BPV  -0.16(4.66) 1.08(5.54) 0.22 
24-hour diastolic BPV -1.52(6.06) -0.12(5.90) 0.23 
Daytime diastolic BPV  -0.45(6.21) -0.14(6.00) 0.79 
Night-time diastolic BPV  -1.33(5.98) 0.14(9.00) 0.33 
Day-to-day BPV (%)    
Systolic BPV  -0.48(2.06) -0.35(2.28) 0.74 
Diastolic BPV  -0.71(2.65) -0.11(2.83) 0.22 
Data presented as mean(sd). 
BP = blood pressure; BPV = blood pressure variability; aPWV= aortic pulse wave velocity. A 
decrease or increase in aPWV was defined as changes in aPWV within the lower (a decrease 
greater than or equal to 0.9m/s) or upper (an increase greater than or equal to 1m/s) quartiles 
of the change in aPWV over 12 months. 
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Figure 3. 1 Comparison of the changes in mean BP and BPV indices among participants 
who had a change in daily defined dose. 
Solic colour represesnts participants who had a decrease in daily defined dose (n = 72) and 
pattern fill represents participants who had an increase (n = 40) over 12 months. (a) Changes 
in mean BP levels and (b) changes in BPV indices. *P < 0.05, †P < 0.01, ‡P < 0.001. BP; 
blood pressure; BPV, blood pressure variability. 
Sensitivity analysis. Comparable results were observed for BPV indices calculated using the 
sandard deviation instead of the CV. Results were unchanged for the reading-to-reading BPV 
indices after exclusion of the periods from 20:00 to 22:00 and 06:00 to 08:00 and, for visit-to-
visit BPV when analysis was repeated using the 7-day home BP instead of the clinic BP 
measures. Comparable results were also observed when day-to-day BPV was assessed 
separately for morning, midday or evening measurements. 
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3.5 Discussion 
To our knowledge, this is the first reported follow-up study that has investigated the concept 
that the changes in TOD over time, as determined from cardiac structure and aortic stiffness, 
may not only depend on the changes in the magnitude of mean BP levels but also on the changes 
in the magnitude of BP fluctuations. Importantly, this is also the first study to investigate the 
effect on TOD from changes in BPV using clinic as well as out-of-office BP measures. The 
main findings were: i) none of the changes in BPV were associated with ΔLVMI or ΔaPWV 
independent of the mean BP levels and ii) only the changes in mean BP levels were related to 
the changes in TOD. Additionally, antihypertensive treatment titration had a clear and expected 
impact only on the changes in mean BP levels (i.e. decreased mean BP with increased DDD 
and vice versa) but with variable and sometimes paradoxical responses on BPV (Figure 3.1). 
These findings suggest that, at least from the point of view of predicting changes in TOD or 
effects of medications, BPV does not provide additional clinical information over and above 
mean BP levels in participants with uncomplicated hypertension.  
Previous cross-sectional studies have also reported a lack of significant associations between 
reading-to-reading or day-to-day BPV measures and LVMI in hypertensive patients.62-66 
Interestingly, one of the most cited works on BPV, in which patients were followed for up to 
7.4 years with BP monitored invasively at baseline, reported a positive association between 
ΔLVMI and baseline reading-to-reading BPV.67 However, the sample size of that population 
was small (n=73) and was limited due to the lack of a follow-up assessment of BPV. A recent 
follow-up study also reported no association between LV hypertrophy (LVH) and long-term 
BPV; however, LVH was defined by electrocardiogram (a less sensitive method than 
echocardiography).68 Other, cross-sectional studies 69-73 have found significant associations 
between reading-to-reading BPV and LVMI, independent of the mean BP levels. It is worth 
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noting though that these studies have used SD to quantify BPV which could have affected the 
results as even small degrees of multicollinearity, resulting from the well-known relationship 
between mean BP level and BPV, could affect the coefficients of the individual predictors in a 
model. Moreover, we are unaware of data available on visit-to-visit BPV with only one cross-
sectional study reporting a lack of significant associations between day-to-day BPV and 
LVMI.66 Lastly, although large artery stiffness has been suggested to affect BPV,51,74 this is 
the first study that has investigated whether ΔaPWV were associated with changes in various 
BPV measures. Changes in BPV did not contribute in ΔaPWV, and our analyses clearly 
supports the dependence of aPWV on mean BP levels, as is well known.53 These findings are 
in line with recent cross-sectional studies reporting no associations between reading-to-reading 
BPV75 and day-to-day BPV,66 although Wei et al. found a significant association between 
reading-to-reading BPV and aPWV in untreated hypertensive patients66 and Webb et al. 
reported a significant association between day-to-day BPV and aPWV in patients with transient 
ischemic attack or minor stroke.75 Additionally, Song et al. found that visit-to-visit BPV was 
associated with ΔaPWV in hypertensive patients, independent of the mean visit-to-visit BP 
levels,76 but this study did not adjust for changes in mean BP levels over the follow-up period, 
something that could attenuate the association observed. Lastly, carotid intima-media 
thickness, a marker of atherosclerosis, was not associated with visit-to-visit BPV in mild-to-
moderate hypertensive patients followed for 4 years.26 
In vivo evidence suggests that an augmented BPV could cause a decrease in arterial 
distensibility and lead to aortic damage that could trigger LVH.77 Similarly, it has been 
proposed that the mechanical stimuli resulting from an increased BPV could trigger the release 
of growth factors through the stimulation of mechanosensitive pathways that involve the local 
renin-angiotensin system and thus cause LVH.78 Furthermore, increased BPV caused by an 
increased number of low BP episodes could deregulate cellular metabolism leading to 
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hypoperfusion and eventually LVH. Indeed, many authors have supported the notion that BPV 
may have some predictive value in humans in relation to TOD, but this could be modified by 
the level of cardiovascular risk.26,39 In this current study population of patients with 
uncomplicated hypertension and a relative healthy vasculature in terms of aortic stiffness 
(baseline aPWV<10 m/s),45 low prevalence of diabetes (<10%), and without conditions such 
as severe LVH or pre-existing coronary artery disease or renal disease, it seems that the 
susceptibility of the heart and large elastic arteries to BPV-related damage is low, at least within 
the timeframe of this study. 
The strengths of this study include the follow-up design that allowed the assessment of the 
relationship between the changes in the outcomes and the changes in BPV measures, as well 
as the variety of BPV types that were assessed in the same population and the concurrent 
assessment of the change in DDD. On the other hand, the analysis relating to reading-to-reading 
BPV may be limited as the time intervals between readings were greater than 20 minutes and 
therefore longer than has previously been recommended.2 However, cross-sectional studies that 
have used time-intervals less than 15 minutes have also reported no significant associations 
between BPV and LVMI.62,66 Additionally, the results of the analysis on the change in DDD 
may be limited by the lack of a sub-analysis on medication class as different classes may have 
different effects on BPV.79 However, an analysis regarding different antihypertensive 
medication classes was not possible due to the lack of statistical power. Moreover, day-to-day 
BPV was quantified using self-report BP monitoring which might be subject to bias. Lastly, 
the follow-up period might not have been adequate to investigate structural changes in LVMI 
and aPWV, and this may also help to explain the weak associations observed between the 
changes in mean BP levels and ΔLVMI.  
This study provides evidence that changes in reading-to-reading, day-to-day BPV as well as 
visit-to-visit BPV do not contribute substantially to ΔLVMI or ΔaPWV and thus may not offer 
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any incremental prognostic value over and above mean BP levels in a population with 
uncomplicated hypertension. This is in agreement with previous suggestions that BPV may not 
have a predictive value in populations with low to moderate cardiovascular risk.26,39 
Additionally, this study shows that when accounting for the change in antihypertensive dose, 
BPV may be a phenomenon which, coupled with the need to keep mean BP levels controlled, 
may not be an easily treatable target by common antihypertensive treatment. In conclusion, the 
main message of this study is that it would seem reasonable for clinicians to remain focussed 
on mean BP levels when tailoring hypertension management decisions rather than BPV in 
patients not subject to cardiovascular risk factors beyond uncomplicated hypertension. 
3.6 Contribution of chapter 3 to thesis aims 
Chapter 3 (study 3) is the first longitudinal follow-up study which has examined the prognostic 
value of the main three types of BPV (short-, mid- and long-term) in the same population. 
Moreover, in contrast to the majority of studies which have investigated BPV in relation to 
cardiovascular risk in patients with high cardiovascular risk, the study sample comprised 
patients with well controlled hypertension and low to moderate cardiovascular risk. This is 
particularly important as the sample allows to specifically test the predictive value of BPV over 
and beyond that of mean BP levels. Study 3 showed that changes in mean BP levels, but not 
BPV, were most relevant to changes in organ damage in patients with uncomplicated 
hypertension. Therefore, BPV appears to offer limited clinical utility in this patient population. 
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Chapter 4 
 
Age-dependent changes in blood pressure over consecutive office measurements: impact 
on hypertension diagnosis and implications for international guidelines 
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4.1 Abstract 
Objectives: Based on anecdotal belief that blood pressure (BP) drops over consecutive 
measurements, guidelines recommend discarding the first BP reading (Canadian Hypertension 
Education Program guidelines; CHEP), or take only one reading if systolic BP (SBP) <140 
mmHg (National Institute for Health and Care Excellence; NICE). However, the extent to 
which SBP fluctuations affect BP classification as well as the potential effect of age, are 
unknown. We sought to assess the change in SBP classification over consecutive measurements 
following different guidelines, among younger (<50 years) and older individuals (≥50 years). 
Furthermore, we aimed to investigate the direction of the change in SBP over consecutive 
measurements (increase or decrease), and the impact of age on SBP differences.  
Methods: BP was measured among 20,716 adults from a general population. SBP was 
classified using the first reading (normal SBP or hypertension) and compared with the average 
SBP using different guideline protocols (reclassification).  
Results: Reclassification from normal SBP to hypertension was greatest with CHEP guidelines 
(3% younger, 12% older individuals) and reclassification from hypertension to normal SBP 
was greatest with NICE guidelines (70% younger, 44% older individuals). SBP increased 
between the first two measures in 37%, decreased in 56% and did not change in 7% of the 
population. Age had a strong interaction with SBP level (p<0.0001) so that younger individuals 
exhibited greater SBP differences over repeated measures.  
Conclusions: This study highlights the need for an improvement in the evidence-base 
regarding the best way to assess office BP for correct hypertension diagnosis.  
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4.2 Introduction 
Blood pressure (BP) measurement in the office remains the principal method for diagnosis and 
management of hypertension.80 Office BP is a less reliable assessment of the true underlying 
BP in comparison to 24-hour ambulatory BP, which is considered the reference standard.81 In 
the United States, an office BP assessment that overestimates or underestimates BP by as little 
as 5 mmHg could result in up to 21 million people being falsely diagnosed with hypertension, 
or up to 27 million people misdiagnosed as normotensive, thus leading to inappropriate 
hypertension management.82,83 A common belief around office BP measurement is that the first 
BP reading overestimates the true BP as a result of a stress reflex response (alarm reaction) to 
the measurement procedure or the presence of the clinician. For this reason, the second and 
third BP measurements are thought to correspond more closely to the true BP. Importantly, 
these beliefs are not based on empirical data from large population samples. 
The lack of empirical data has led to divergent recommendations among different international 
guidelines. Briefly, these recommendations include not taking a second BP if initial office BP 
is ≤140/90 mmHg and discarding the first measurement (Canadian Hypertension Education 
Program guidelines; CHEP),84,85 or recording only the lower of the last two measurements 
(National Institute for Health and Care Excellence; NICE guidelines; Table 4. 1).19 The 
European Societies of Hypertension and Cardiology (ESH/ESC) recommend taking two BP 
readings and only taking a third reading if “the first two are quite different” (>10 mmHg)80 
whilst the 7th report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC–7), recommend taking at least two readings (Table 4. 
1).86 The 2016 Australian guidelines are in part in alignment with the CHEP guidelines 
recommending to take three BP readings and average the last two; however, if readings vary 
more than 10/6 mmHg for SBP/diastolic BP it is recommended to re-measure after 5 minutes 
of rest.87
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Table 4. 1 Office blood pressure measurement protocols according to different international guidelines 
BP level (mmHg) CHEP * NICE † ESH/ESC ‡ JNC-7 § 
If SBP1 <140 No further readings No further readings 
  
If SBP1 ≥140 • Take a 2nd reading • Take a 2nd reading 
  
If |ΔSBP| > 10  • Take a 3rd reading 
• Discard SBP1 
• Consider the average 
of SBP2 and SBP3 
• Take a 3rd reading 
• Discard SBP1 
• Consider the lower of 
SBP2 and SBP3 
• Take a 3rd reading 
• Consider the 
average of SBP1, 
SBP2 and SBP3 
 
    
At least 2 readings 
SBP1 denotes the first reading of systolic blood pressure (SBP); |ΔSBP| denotes the absolute difference between SBP1 and SBP2. *CHEP = 
Canadian Hypertension Education Programme. Hypertension. †NICE = National Institute for Health and Care Excellence.‡ESH/ESC = European 
Society of Hypertension/International Society of Hypertension. §JNC-7 = 7th report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure.
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Importantly, the accuracy of office BP in determining true BP control could be affected by 
spontaneous variability in BP over seconds or minutes.88,89 Moreover, the difference in BP over 
consecutive measurements increases with increasing BP90-92 and age,91,92 and the diagnostic 
accuracy of office BP changes across the age span.93,94 However, the extent to which the 
interaction between BP level and age could affect the magnitude or the direction (increase or 
decrease) of the change in BP over consecutive measurements and, consequently, the diagnosis 
of hypertension using office BP measures, is unknown. This study sought to determine the 
change in SBP classification over consecutive measurements based on guideline protocols 
(CHEP, NICE, ESH/ESC, JNC–7), among younger (<50 years) and older individuals (≥50 
years). We also sought to determine the direction of the change in SBP over consecutive 
measurements as well as the interaction between SBP level and age on the differences in SBP. 
We hypothesised that SBP would not decrease systematically with consecutive readings, and 
that the SBP differences between readings would be dependent on age, thus affecting 
reclassification of diagnosis differently in younger and older individuals. 
4.3 Methods 
Survey population. Data analysed were taken from the Core Content and National Health 
Survey components of the Australian Health Survey (AHS),95 conducted between 2011 and 
2013 by the Australian Bureau of Statistics (ABS). The survey was a nationally representative 
sample of individuals from 20,500 private dwellings across Australia (n=31,837).96 Data on 
20,716 individuals (≥18 years old) who had two BP readings in the AHS were included in the 
primary analysis and secondary analysis was performed among participants who had three BP 
readings (n=5,189). An age threshold of 50 years was used to delineate younger from older 
individuals based on the well documented age-related changes in haemodynamic patterns after 
age 50.97 Additional information on survey design, ethics approval, anthropometry, statistical 
details, BP exclusionary criteria, classification of BP control, anti-hypertensive medications, 
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biomedical measures and health conditions are provided in supplementary material (Appendix 
2). 
Blood pressure. Duplicate BP readings were taken by non-clinicians using a validated,98 
automated BP monitor (A&D:UA-851) on the left arm using an appropriate cuff size at the end 
of a survey interview with participants seated and relaxed. If there was a difference between 
the first and second BP reading of >10 mmHg in either SBP or DBP, then a third reading was 
taken.99 BP measurements were consecutive; the precise time of each measurement was not 
recorded. BP readings were excluded if they were outside the extremes of physiological range 
and/or measurement error was suspected. These exclusion thresholds were: SBP >260 or <70 
mm Hg, DBP >150 or <40 mm Hg, and pulse pressure (PP) >150 or <20 mm Hg. Participants 
with only one BP measure were excluded from this analysis. The above measurement protocol 
enabled assessment of BP classification using all the international guidelines previously 
mentioned. Primary outcomes and measures included the reclassification of BP category, the 
direction of change from first (SBP1) to second SBP (SBP2) readings and the absolute 
difference between the SBP1 and SBP2 readings (|ΔSBP|). Reclassification of BP category 
was defined as the change of a participants’ BP status either from hypertension at SBP1 (≥140 
mmHg) to normal average SBP (average SBP<140 mmHg) based on the above protocols, or 
from normal SBP1 (<140 mmHg) to hypertension (average SBP≥140 mmHg) based on the 
above protocols. Therefore, for the purpose of examining reclassification; when BP is 
classified based on one reading we use the term “normal SBP1” or “high SBP1”. When BP is 
classified based on the average of more than one readings we use the term “normal average 
SBP” or “high average SBP”. The cut-off of 140 mmHg was chosen to show normality of SBP 
based on the ESH/ESC guidelines; however, we acknowledge that other definitions may apply 
according to other guidelines (i.e. 130-139 mmHg might refer to prehypertension). Table 4. 1 
summarizes the CHEP, NICE, ESH/ESC and JNC-7 hypertension guideline recommendations.  
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Hypertension definition and classification of blood pressure category. For the primary 
analysis, hypertension was defined as SBP ≥140 mmHg based on five protocols relevant to 
international guidelines and the goals of this study.  The five protocols presented in Table 4.1 
required either one, two or three BP readings for BP classification and were compared based 
on reclassification as described previously: 1) the average of SBP1 and SBP2 (not taking into 
account the magnitude of ΔSBP), 2) the average of SBP1 and SBP2 if ΔSBP≥10 mmHg, 3) 
the average of SBP1, SBP2 and third SBP (SBP3) readings if ΔSBP≥10 mmHg, 4) the average 
of SBP2 and SBP3, discarding SBP1 and; 5) the lower of the last two SBP readings if ΔSBP≥10 
mmHg. Following hypertension classification based on SBP, classification based on DBP ≥90 
mmHg was also undertaken. SBP was classified as; low (SBP <90 mmHg), normal (90-129 
mmHg), high normal (130-139 mmHg), grade I (140-159 mmHg), grade II (160-179 mmHg) 
and grade III (≥180 mmHg) hypertension. Similarly, DBP was classified as; low (<60 mmHg), 
normal (60-84 mmHg), high normal (85-89 mmHg), grade I (90-99 mmHg), grade II (100-109 
mmHg) and grade III (≥110 mmHg) hypertension.  
Health conditions. Participants were asked whether they had been diagnosed with a medical 
or health condition and whether this condition was: 1) still-current and long-term, 2) still 
current but not long-term or 3) not current.100 The specific classification of long-term health 
conditions reported by the participants was based on the International Classification of 
Diseases.101  
Anti-hypertensive medications. 20,500 of the individuals participating in the Australian 
Health Survey had also provided detailed information regarding the use of medications 
(including antihypertensives) which was retrieved from the National Health Survey, 2011-2012 
component of the survey. Information regarding the use of medications as collected by the 
National Health Survey has been previously published.102 
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Statistical analysis. Means (continuous data) and percentages (categorical data) are reported 
as summary measures, together with 95% confidence intervals because analyses were weighted 
using weights supplied by the ABS. The analysis utilised person-weights96 provided by the 
ABS, which ensured that any disproportionate sampling of certain groups was taken into 
account. Replicate weights provided by the ABS were used to calculate standard errors and 
95% confidence intervals using the Jackknife delete-1 method. Linear regression was used to 
estimate the relationship of |ΔSBP| with SBP1 and age as predictor variables, with the square 
of SBP1 included to capture non-linearities and product terms (age x SBP1, age x squared of 
SBP1) used to capture interactions between age and SBP1. Final models included covariates 
to adjust for sex and body mass index. Further analysis was performed to evaluate the effect 
of cardiovascular disease or antihypertensive medications on the main findings. Analysis was 
also performed on secondary outcomes (supplementary material, [Appendix 2]; the difference 
between SBP2 and SBP3; the overall variability in 3 SBP measures [coefficient of variation; 
SBP CV]; the difference between DBP readings; the difference between pulse pressure (PP) 
readings). Stata 10 was used for all analyses (StataCorp, College Station, Tx). A two-sided p 
value <0.05 was considered significant. 
4.4 Results 
Population characteristics. The mean age of sample was 45 years (95%CI 45,46; range: 18-
85), 50% male. Blood and urine biomarkers were within normal range on average (Table 4. 2). 
The prevalence of cardiovascular diseases was low (Table 4. 2). The prevalence of measured 
high SBP differed across age groups and across hypertension guidelines with the greatest 
prevalence observed using the JNC-7 protocol (Figure 4. 1). The differences in prevalence of 
high SBP across JNC-7, ESH/ESC, CHEP and NICE guidelines were greatest in the oldest old 
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(≥80 years old; Figure 4. 1; 49% [95%CI 44,54], 48% [95%CI 44,53], 44% [95%CI 40,48] 
and 43% [95%CI 39,47]). 
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Table 4. 2 Population demographic and clinical characteristics 
Variable N Mean or % (95%CI *) 
Age (years) 20716 45 (45,46) 
Male (%) 9829 50 (50,51) 
Body mass index (kg/m2) 19768 27 (27,28) 
Systolic blood pressure (mmHg)  20716 124 (123.62,123.8) 
Diastolic blood pressure (mmHg) 20716 77 (76.6,77.0) 
Medical conditions (self-reported; still, current and 
long-term) 
   
Diabetes (%)† 1347 5.7 (5.3,6.1) 
High cholesterol levels (%) 1641 7.1 (6.7,7.5) 
Heart disease (%)‡ 385 1.6 (1.4,1.8) 
Stroke (%) 169 0.7 (0.5,0.8) 
Low blood pressure (%) 170 0.8 (0.7,0.9) 
Cardiovascular disease biomarkers    
Total cholesterol (mmol/L) 8932 5.07 (5.04,5.10) 
High density lipoprotein cholesterol (mmol/L)  8932 1.34 (1.33,1.35) 
Fasting low density lipoprotein cholesterol (mmol/L) 7078 3.13 (3.10,3.15) 
Fasting triglycerides (mmol/L)  7160 1.28 (1.26,1.31) 
Apolipoprotein B (g/L) 8930 0.96 (0.95,0.97) 
Diabetes biomarkers  
 
Fasting plasma glucose (mmol/L)  7161 5.10 (5.07,5.13) 
Glycated hemoglobin (mmol/mol)  8915 36.13 (35.98,36.29) 
Kidney disease biomarkers   
Albumin creatinine ratio (mg/mmol) 8467 1.81 (1.56,2.06) 
Estimated glomerular filtration (mL/min/1.73m2)  8927 85.62 (85.38,85.86) 
Data are presented as mean or % (95%CI) *CI = confidence interval. Proportions and means are 
weighted to provide population estimates. †Includes type I, type II or high blood/urine sugar 
levels. ‡Includes ischaemic disease, heart failure and other heart disease. 
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Figure 4. 1 Prevalence of high systolic blood pressure across age groups and different 
international protocols. 
CHEP = Canadian Hypertension Education Programme. Hypertension. NICE = National 
Institute for Health and Care Excellence. ESH/ESC = European Society of 
Hypertension/International Society of Hypertension. JNC-7 = 7th report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 
Reclassification of BP from normal SBP1 to high SBP. This reclassification was 
consistently greater for older individuals across all guideline protocols (Table 4. 3). When only 
two BP measures were used, 3% (95%CI 2,3) and 1% (95%CI 1,2) of older individuals with 
normal SBP1 were reclassified to high SBP according to JNC-7 and ESH/ESC guidelines, 
whilst such reclassification was observed in only 0.7% (95%CI 0.5,0.9) and 0.4% (95%CI 
0.03,0.6) of younger individuals. The reclassification was greater when all three BP readings 
were used, and ranged from 7% to 12% for older individuals and 1% to 3% for younger 
individuals. The greatest reclassification from normal SBP1 to high SBP was observed using 
the CHEP guidelines (3% [95%CI 2,4] in younger versus 12% [95%CI 5,10] in older 
individuals). 
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Table 4. 3  Prevalence of hypertension and percentages of the population re-classified by use of each guideline protocol relative to classification 
based on a single systolic blood pressure reading as values of at least 140 mmHg 
 Prevalence of hypertension* Re-classification by guideline protocol * 
Guideline † (number of 
subjects with required 
data) 
SBP1≥140 mmHg 
From high SBP1 to normal average 
SBP 
From normal SBP1 to high average 
SBP 
Age<50yrs Age≥50yrs Age<50yrs Age≥50yrs Age<50yrs Age≥50yrs 
JNC-7 † 9% 35% 25% 10% 0.7% 3% 
(n=20,716) (8%, 9%) (33%, 36%) (21%, 29%) (9%, 11%) (0.5%,0.9%) (2%, 3%) 
ESH/ESC ‡ 6% 31% 14% 5% 0.4% 1% 
(n=15,527) (6%, 8%) (30%, 32%) (11%, 18%) (4%, 7%) (0.3%,0.6%) (1%, 2%) 
ESH/ESC § 16% 46% 51% 25% 1% 7% 
(n=5,189) (14%, 18%) (44%, 49%) (45%, 57%) (22%, 29%) (1%, 2%) (5%, 10%) 
CHEP || 16% 46% 64% 35% 3% 12% 
(n=5,189) (14%, 18%) (44%, 49%) (57%, 71%) (31%, 39%) (2%, 4%) (9%, 14%) 
NICE ¶ 16% 46% 70% 44% 2% 7% 
(n=5,189) (14%, 18%) (44%, 49%) (63%, 76%) (41%, 47%) (1%, 2%) (5%, 9%) 
*Data are presented as % (95%CI). SBP1 denotes the first reading of systolic blood pressure and SBP denote the average systolic blood pressure 
according to each guideline. †JNC-7 = 7th report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure. Hypertension defined as (SBP1+SBP2)/2 ≥ 140 mmHg. ‡ESH/ESC = European Society of Hypertension/International Society of 
Hypertension. Hypertension defined as (SBP1+SBP2)/2 ≥ 140 mmHg. §ESH/ESC. Hypertension defined as (SBP1+SBP2+SBP3)/3 ≥ 140 mmHg. 
||CHEP = Canadian Hypertension Education Programme. Hypertension defined as (SBP2+SBP3)/2 ≥ 140 mmHg. ¶NICE = National Institute for 
Health and Care Excellence. Hypertension defined as min(SBP2, SBP3) ≥ 140. 
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Reclassification of BP from high SBP1 to normal SBP. In contrast to the reclassification 
from normal SBP1 to high SBP, reclassification from high SBP1 to normal SBP occurred more 
frequently across all guideline protocols in younger individuals (range 14% to 70%) than in 
older individuals (range 5% to 44%) (Table 4. 3). The greatest reclassification was observed 
using the NICE guidelines (70% [95%CI 63,76] in younger versus 44% [95%CI 41,47] in older 
individuals). Differences among guideline protocols were observed when all three SBP 
readings were used (Table 4. 3). 
Overall reclassification of BP. The overall reclassification from SBP1 (either, from normal 
SBP1 to high SBP or from high SBP1 to normal SBP) ranged from 1% to 12% for younger 
individuals and 3% to 24% for older individuals across guideline protocols. As expected 
overall reclassification was low when only SBP1 and SBP2 were used; for example 3% 
(95%CI 2,3) and 1% (95%CI 1,2) for younger individuals according to JNC-7 and ESH/ESC 
and 5% (95%CI 5,6) and 3% (95%CI 2,3), respectively, for older individuals. However, the 
differences in reclassification across guidelines became greater when all three SBP readings 
were used. The overall reclassification for younger individuals was 9% (95% CI 8,11), 12% 
(95%CI 10,14) and 12% (95%CI 11,14), according to ESH/ESC, CHEP and NICE guidelines, 
respectively. The overall reclassification for older individuals was 16% (95% CI 14,18), 21% 
(95%CI 19,23) and 24% (95%CI 22,26), according to ESH/ESC, CHEP and NICE guidelines, 
respectively.  
Prevalence of increase versus decrease and no change from SBP1 to SBP2. Thirty-seven 
percent (95%CI 36,38) of the population had an increase, 56% (95%CI 55,57) had a decrease 
and 7% (95%CI 7,8) had no change in SBP from SBP1 to SBP2. When a tolerance of 5 mmHg 
was allowed so that an increase or decrease was defined as an SBP change of at least ≥5 mmHg 
in the respective direction, 18% (95%CI 18,19) had an increase, 33% (95%CI 32,33) had a 
decrease and 49% (95%CI 48,50) had no change in SBP (|ΔSBP| -4 to 4 mmHg). The 
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proportion of the population with an increase in SBP from SBP1 to SBP2 became lower with 
greater SBP1 (Figure 1, panel A; supplementary material [Appendix 2]). However, this 
proportion became higher with increasing age (Figure 1, panel B; supplementary material 
[Appendix 2]). The age-dependent direction for the change in SBP (increase or decrease) was 
similar when ΔSBP was redefined as a change of at least 5 mmHg in the respective direction 
(Figure 2; supplementary material [Appendix 2]).  
BP variability indices. The overall mean ΔSBP was -1.67 (95%CI -1.81,-1.53) and the overall 
mean change irrespective of direction (absolute value) was 4.86 mmHg (95%CI 4.77,4.95). 
The difference observed between the overall magnitude of ΔSBP and |ΔSBP| was due to a high 
prevalence of an increase from SBP1 to SBP2 among the population; ΔSBP was smaller than 
the |ΔSBP| and did not accurately capture the magnitude of the change from SBP1 to SBP2.  
The overall SBP CV among three SBP readings was 6.56 mmHg (95% CI 6.42,6.70). 
Interaction between the level of SBP1 reading and age. There was a statistically significant 
interaction between age and SBP1 level (p<0.0001) that resulted in younger individuals with 
higher SBP1 having greater changes from SBP1 to SBP2 (Figure 4. 2) than older individuals 
with comparable SBP1. As examples, the estimated |ΔSBP| for a person with SBP1 of 190 
mmHg was 19.80 mmHg (95% CI 15.73,23.86) at age 35 years but 7.07 mmHg (95%CI 
6.86,8.06) at age 75 years (Figure 4. 2; panel A). Similarly, when the overall direction of 
change is taken into account, the estimated ΔSBP for a person with SBP1 of 190 mmHg was -
16.93 mmHg (95% CI -21.44,-12.44) at age 35 years but -5.52 mmHg (95%CI -6.97,-4.07) at 
age 75 years (Figure 4. 2; panel B).  
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Figure 4. 2 Modifying effect of age on the relationship of the absolute difference (Panel 
A) or difference (Panel B) between first and second systolic blood pressure (SBP) readings 
and the level of the first SBP reading. 
The corresponding absolute difference between the first and second SBP reading when the first 
SBP is 190 mmHg decreases from 20 mmHg for a 35 year old (red dotted line; panel A) to 7 
mmHg for a 75 year old individual (black dotted line; panel A). The corresponding difference 
between the first and second SBP reading when the first SBP is 190 mmHg is -17 mmHg for a 
35 year old (red dotted line; panel A) and -6 mmHg for a 75 year old individual (black dotted 
line; panel A). 
Additional analysis. Results were unchanged when analysis was confined to the differences 
between SBP2 and SBP3 or when analysis took into account the total variation within three 
consecutive measurements (Figure 3; supplementary material [Appendix 2]). Results were also 
unchanged after adjustment for cardiovascular diseases. The interaction between age and SBP1 
was further assessed in a sub-group of individuals who had information on anti-hypertensive 
medications; findings remained unchanged after adjusting for different classes of anti-
hypertensive medications including antiarrhythmics, beta blockers, calcium channel blockers, 
diuretics, angiotensin receptor blockers, angiotensin converting enzyme blockers or other 
antihypertensive classes.  ΔSBP was not significantly different across different anti-
hypertensive medication classes (p=0.10) and results were similar when the difference was 
adjusted for mean SBP1 level and age (p=0.14). Analyses were also conducted using the DBP 
Panel A  Panel B 
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or PP instead of the SBP readings; however, as compared to the SBP, there were no age-related 
patterns, nor were similar relationships observed in relation to the DBP difference between 
measurements. (supplementary material [Appendix 2]).  
4.5 Discussion 
Accurate measurement of office BP is critical in the diagnosis and management of 
hypertension. The assumption that an alarm reaction to BP measurement could affect the 
accuracy of office BP has led to uncertainty regarding the number of readings required for 
diagnosis. We observed substantial differences in reclassification across NICE, CHEP, 
ESH/ESC and JNC-7 guideline BP measurement protocols. In contrast to the assumption of a 
consistent alarm reaction resulting in BP dropping with repeat measurement, we found that 
SBP actually increased from SBP1 to SBP2 in more than a third, and did not change in 7% of 
the population. When we broadened the tolerance to define SBP change to be ≥5 mmHg 
between SBP1 and SBP2, 18% of the population still had an increase in SBP, whereas a third 
of the population had a decrease in SBP. Notably, there was a strong age modification effect 
on the relationship between ΔSBP and SBP1, indicating that the difference in SBP with repeat 
measurements decreased with increasing age. Altogether these data are highly relevant to 
international guideline recommendations on BP measurement for further evaluation or 
initiation of hypertension treatment.80,84,19,85,86  
The NICE and CHEP hypertension guidelines recommend taking only one reading if SBP1 is 
<140 mmHg. However, based on our results (Table 4. 3), 7% and 12% of the older participants 
would have been misclassified as normotensive at SBP1 using NICE or CHEP guidelines 
respectively, whereas hypertension would have been diagnosed if a third reading had been 
taken. If we take the example of a 60-year-old individual with only one BP reading recorded 
as 138 mmHg then, based on either NICE or CHEP guidelines, they would be classified as 
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normotensive without any further assessments. However, as approximately 40% of older 
individuals have an increase from SBP1 to SBP2 (Figure 1, panel B; supplemental material 
[Appendix 2]), there is a reasonable possibility that such an individual would have SBP greater 
than 140 on repeat measurement and thus reclassified as hypertensive. While keeping in mind 
the value of management based on absolute cardiovascular risk assessment, older individuals 
have a 3-4 fold increase in cardiovascular disease risk,86 and it is important to avoid missing a 
diagnosis of hypertension. On the other hand, our data suggest that younger individuals have 
greater propensity towards false positive hypertension diagnosis and potentially having 
unnecessary treatment initiated. Although all guideline BP measurement protocols that used 
three BP readings resulted in sizeable reclassification from high SBP1 to normal SBP among 
younger individuals, there were significant differences among ESH/ESC, CHEP and NICE BP 
measurement protocols. Indeed, using three BP readings, 50% of younger individuals with high 
SBP1 would reclassify to having normal SBP based on the ESH/ESC guidelines, 64% based 
on CHEP and 70% based on NICE guidelines.   
Since office BP methods involving only a few BP readings over several minutes have been 
used for global estimates of hypertension prevalence, as well as in most BP-related 
epidemiological studies, it is difficult to directly compare BP statistics across different 
guideline protocols, and especially across age ranges. To our knowledge there is no evidence 
to support the diagnostic accuracy of any international hypertension protocols compared with 
the gold standard technique of 24 hour ambulatory BP or other out-of-office BPs such as home 
BP. Our data show that limiting BP assessment to only one BP reading is a flawed approach 
for assessing BP control and also support the argument that out-of-office BP methods should 
become part of routine BP assessment.17,103,104 Automated unobserved office BP105,106 
measures may also be an appropriate alternative to more accurately measure and determine risk 
related to BP. 
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Short-term changes in BP under resting conditions result from a combination of homeostatic 
mechanisms.89,107 Indeed, it is expected for persons with a lower-than-average first BP 
measurement to have a higher second measurement on average, and for those with a higher-
than-average first BP to have a lower second reading on average (see Figure 1, panel A, 
supplementary material [Appendix 2]), indicating a biologically plausible regression towards 
the mean. Nonetheless, the impact of ageing on BP regulation is complex. It has been suggested 
that short-term BP regulation is under increased influence of sympathetic nerve activity (SNA) 
in older individuals, which could result in increased short-term BP variability.108 However, 
smaller resting SBP changes in response to increased SNA have been shown in older 
individuals at rest,109 in response to head-up tilt test110 or to the Valsalva manoeuvre.111 The 
attenuation in the level of BP changes observed in older individuals at rest is suggested109,112 
to be the result of a decreased effectiveness of SNA, due to either decreased α-adrenergic 
sensitivity or reduced norepinephrine release triggered by SNA associated with healthy ageing. 
On the basis of this we speculate that the smaller SBP differences observed with advanced age 
in this study may reflect a lower minute-to-minute BP regulatory ability in older individuals. 
Strengths of our study include the large sample of nationally representative data from a 
population-based survey, as well as the BP measurement procedure which reflects the 
recommended way to perform office BP. Secondly, BP was assessed by non-clinicians and this 
may have lessened the “white coat response” triggered by the presence of a clinician.113,114 On 
the other hand, the above may also be a limitation as a different ΔSBP response may have 
occurred if measurement was made by clinicians. Furthermore, it could be argued that the 
results may have been affected by using oscillometry as compared to auscultation; however; 
oscillometry takes out the effect of digit preference and operator's bias, thus may have 
strengthened the results. Moreover, although it is recommended for office BP measures to use 
the arm with the highest BP readings, the left arm was used for all participants as it was not 
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feasible to test BP in both arms during such a time-intensive large population study. However, 
large inter-arm differences are more likely to affect individuals with arterial diseases115 and 
given that the results were unchanged after correcting for diseases of arteries, arterioles, and 
capillaries, we expect that this is not a major study limitation. Additionally, multiple office 
visits or out-of-office BP measures were not available to help confirm hypertension diagnosis, 
but results are still relevant to an office visit using methods similar to that employed in this 
study. Lastly, secondary analysis using all three BP readings has been performed on an 
incomplete data set because a third reading was only taken if there was ≥10 mmHg difference 
between the first and second BP readings, and was not a predefined methodological protocol. 
Thus, the results of analyses which included all three BP measures could be more relevant to 
populations with increased BP variability.  
In conclusion, the assessment of BP is subject to marked and unpredictable variability leading 
to increased measurement and diagnostic uncertainty. Notably, the assumption that BP drops 
with consecutive measurements is incorrect. Furthermore, age significantly affects the 
difference in SBP observed in office BP measures with potential consequences for correct 
hypertension diagnosis. Altogether these findings underscore the importance of BP 
measurement guidelines that are evidence-based in order to avoid assumptions leading to 
diagnostic error. Lastly, our study highlights the need to use out-of-office BP measures (i.e. 
home or 24-hour BP) to confirm hypertension diagnosis. 
4.1 Contribution of chapter 4 to thesis aims 
Chapter 4 (study 4) represents the first study to evaluate the impact of within-visit BP 
fluctuations with repeat measurements on hypertension classification by comparing clinic BP 
protocols as defined by four international hypertension guidelines. This study indicated that 
BP does not necessarily decrease with repeat measurement and that both age and the level of 
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BP significantly affect the accuracy to correctly classify hypertension status. The need for an 
improvement in the evidence-base regarding the best way to assess office BP for correct 
hypertension diagnosis was underscored by the findings of this study.  
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Chapter 5 
 
Influence of blood pressure level and age on within-visit blood pressure variability in 
children and adolescents 
 
At the time of thesis submission, this chapter is under peer-review with Pediatric Research 
 
Veloudi P., Blizzard L., Srikanth VK., Breslin, M., Schultz MG., Sharman JE. 
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5.1 Abstract 
Objective. Blood pressure (BP) is variable in children and this could affect BP assessment, but 
the magnitude of within-visit BP variability (BPV) over consecutive measurements has never 
been investigated. This study aimed to determine the direction and magnitude of, and factors 
affecting, within-visit BPV in children and adolescents. 
Study design and setting. BP was recorded among 3047 children (aged 12 years [95%CI; 
12,13], males 52%) from the 2011-2013 Australian Health Survey. BPV was defined as the 
absolute difference (∆SBPABS) between the first (SBP1) and second systolic BP (SBP2), and 
the overall variability in three measures (SBPV). 
Results. On average, ∆SBPABS was 6.7 mmHg (95%CI 6.3,7.0) and SBPV was 8.2 % (95%CI 
10.0,11.2). ∆SBPABS was greater with higher BP levels but lower with older age. From first to 
second measurements, SBP decreased in 58% (95%CI 56,60); did not change in 10% (95%CI 
9,12), and increased in 32% (95%CI 29,34) of the population. 
Conclusions. BP is highly variable in children and adolescents, with the magnitude of 
variability being associated with both age and BP level. SBP increases on repeat measurement 
in a substantial proportion of the population. The optimal protocol of BP assessment to address 
this increased BPV needs to be determined. 
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5.2 Introduction  
Elevated blood pressure (BP) in childhood and adolescence predicts development of future 
hypertension116,117 and is associated with surrogate markers of cardiovascular disease risk, such 
as increased large artery stiffness,118 left-ventricular hypertrophy,119,120 increased carotid 
intima medial thickness,121 atherosclerotic lesions122,123 and retinal arteriolar narrowing.124 
However, accurate BP assessment in children and adolescents may be influenced by within-
visit BP variability (BPV).125,126 To date, there are no data outlining the magnitude of BPV, nor 
the factors affecting BPV among young people. Furthermore, it is also believed that accurate 
assessment of BP in childhood is affected by an increased rate of false-positive readings due to 
the normalization of BP with consecutive measurements.127 Indeed, it has been suggested that 
BP systematically decreases with repeat measures within a visit, due to an ‘accommodation 
effect,128,129 whereby individuals become familiar with the BP measurement process and 
therefore better accommodate the stress related to this process. Also, current hypertension 
guidelines recommend repeated BP measurements,130 but the number of measurements is not 
specified.  
A lack of epidemiological studies with hard clinical end-points (cardiovascular events and 
mortality) among children and adolescents has led to the development of BP assessment criteria 
that rely on age, sex and height probabilistic criteria (children with BP values greater than a 
specific percentile are classified as having high BP). According to the Fourth Report of the 
National High Blood Pressure Education Program, pre-hypertension in youth is defined if BP 
is ≥90th or ≥ 120/80 mmHg and hypertension is defined if BP is ≥95th percentile of age, sex 
and height dependent BP criteria.130 Importantly, the difference between the 90th and 95th 
percentiles is only 3-4 mmHg, thus the magnitude of within-visit BPV could substantially 
affect the diagnosis of hypertension. Previous work from our group131 showed that within-visit 
BPV in adults was highly influenced by age and BP level and we hypothesized that the same 
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effect would be evident among in youth. Therefore, this study aimed to investigate the direction 
and magnitude of within-visit BPV indices as well as factors (e.g. age and BP level) affecting 
BPV indices among children and adolescents. 
5.3 Participants and methods 
Data on 3047 children and adolescents, aged 5 to 17 years old, from a nationally representative 
sample of 31 837 individuals from the Australian Health Survey 2011-2013132 who had two or 
three BP readings were analyzed. Detailed information on survey design, data management 
and data accessibility was previously published131 and is summarized in the supplementary 
material (Appendix 3). 
Anthropometry. Body mass index (BMI; kg/m2) was calculated as weight (kg) divided by 
height2 (m2). For validation purposes, 10% of the participants were randomly selected for a 
second height measurement and if there was a difference greater than one centimetre then a 
third reading was taken.133 Waist circumference (cm) was also measured, according to 
guidelines.134 Height and BMI percentiles for age and sex were defined according to the United 
States Centers for Disease Control clinical growth charts.135 Overweight status was defined 
based on a BMI at, or above the 85th BMI percentile for age and sex as recommended.135  
Blood pressure. Duplicate BP readings were taken by non-clinicians using an automated BP 
monitor (A&D:UA-851)98 on the left arm and using an appropriate cuff size at the end of a 
survey interview with participants seated and relaxed. If there was a difference between the 
first and second BP reading of >10 mmHg in either SBP or DBP, then a third reading was taken 
(n=929).99 Hypertension category was based on the average of the first two BP readings 
because a third reading was not available for all participants. Hypertension was defined if the 
average of the first two SBP or DBP readings were ≥ 95th percentile of BP reference values for 
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age, sex and height.136 Normal BP included pre-hypertension levels (≥90th percentile of BP 
reference values).  
Blood pressure variability (BPV). The primary measures were defined as the difference 
(ΔSBP) between the first (SBP1) and second SBP (SBP2) readings, or the absolute difference 
(∆SBPABS) between SBP1 and SBP2, which did not take into account the direction of the 
change, and the overall variability in three BP measurements calculated as the coefficient of 
variation (SBPV; [standard deviation/mean SBP]x100). 
Statistical analysis. Linear regression was used to test for between-groups differences. Linear 
regression was used to estimate the relationship of ΔSBP and ∆SBPABS with SBP1 and age as 
predictor variables. The square of SBP1 was included to capture non-linearity and, product 
terms (age x SBP1, age x square of SBP1) were used to capture interactions between age and 
SBP1. Final models included covariates to adjust for height, sex and body mass index. 
Differences in the product terms (age x SBP1, age x square of SBP1) among female and male 
participants were assessed by including sex and three-way interaction terms among age, sex 
and the level of SBP1 (age x sex x SBP1, age x sex x squared SBP1) in a fully saturated model. 
Analyses was repeated on the overall variability in 3 SBP measures (SBPV) or the difference 
between DBP readings. Stata 10 was used for all analyses (StataCorp, College Station, Tx).  
5.4 Results  
The population was on average 12 years old (95%CI 12,13) and 52% male. The prevalence of 
hypertension was 6% (95%CI 5,7). Demographic and clinical characteristics of the population 
are presented in Table 5. 1. Mean SBP and DBP increased with age (p<0.001); however, SBPV 
and DBPV decreased with age (p<0.001; Table 5. 1). 
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Table 5. 1 Demographic and clinical characteristics of the population (n=3047). 
Variable 
5-7 yrs 
(n=261) 
8-10 yrs 
(n=510) 
11-13 yrs 
(n=864) 
14-17 yrs 
(n=1414) 
Between-
group p value 
Age (years) 6.1 (6.0,6.3) 9.1 (9.0,9.2) 12.0 
(11.9,12.1) 
15.6 
(15.5,15.7) 
<0.0001 
Male (%) 57 
(49,64) 
52  
(47,56) 
52  
(59,55) 
52  
(49,54) 
0.64 
BMI (kg/m2) 17.7 
(17.1,18.4) 
18.9 
(18.5,19.2) 
20.5 
(20.2,20.8) 
22.4 
(22.1,22.7) 
<0.0001 
Overweight (%) 41  
(32,49) 
37 (31,43)1 32  
(28,35) 
26  
(23,30) 
0.015 
*Hypertension 
(%) 
8  
(3,12) 
7  
(4,9) 
5  
(3,7) 
6  
(4,8) 
0.40 
†SBP (mm Hg) 96.9 
(94.2,99.6) 
100.4 
(98.9,101,8) 
105.5 
(104.5,106.6) 
110.9 
(110.0,111.8) 
<0.0001 
†DBP (mm Hg) 60.6 
(58.4,62.8) 
63.4 
(62.3,64.5) 
65.7 
(64.9,66.6) 
67.0 
(66.3,67.7) 
<0.0001 
∆SBPABS (mm 
Hg) 
7.07 
(5.1,9.0) 
7.2  
(6.2,8.2) 
6.5  
(6.1,7.0) 
6.5  
(6.0,6.9) 
0.56 
∆DBPABS (mm 
Hg) 
6.01 
(4.7,7.3) 
5.7 (5.0,6.3) 5.1 (4.6,5.6) 5.3  
(5.0,5.7) 
0.34 
‡SBPV (%) 11.8 
(8.7,14.8) 
9.1 (8.0,10.2) 8.2 (7.4,9.04) 7.0  
(6.6,6.9) 
<0.001 
‡DBPV (%) 16.5 
(13.0,20.0) 
11.3 
(10.0,13.0) 
9.7  
(9.0,11.0) 
9.7 
(9.0,11.0) 
<0.001 
Data are presented as mean (95% CI) or % (95%CI). BP denotes blood pressure; SBP denotes 
systolic BP; DBP denotes diastolic BP; ∆SBPABS denotes the absolute difference between the 
first and second SBP readings; ∆DBPABS denotes the absolute difference between the first 
and second DBP readings; SBPV denotes systolic BP variability; DBPV denotes diastolic BP 
variability. *According to age-, sex- and height-dependent blood pressures thresholds. †Based 
on the average of two blood pressure readings. ‡Estimates are based on a subpopulation with 
three blood pressure readings (n=929). 
On average, ΔSBP was -2.4 mmHg (95%CI -2.0,1.7) and ∆SBPABS was 6.7 mmHg (95%CI 
6.3,7.0). For the population with three BP readings, the overall SBPV was 8.2 (95%CI 
10.0,11.2). The magnitude of SBPV and ∆SBPABS were greater among children with 
hypertension compared to children with normal BP (SBPV; 10.5 % [95%CI; 8.4,12.3] vs 7.8 
% [95%CI; 7.5,8.3], p=0.005 and ∆SBPABS; 11.7 mmHg [95%CI; 8.4,15.0] vs 6.4 mmHg 
[95%CI; 6.0,6.7]; p=0.002). Additionally, there was some evidence that the magnitude of 
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SBPV and ∆SBPABS were greater among males compared with females (SBPV; 8.6 % [95%CI; 
7.9,9.3] vs 7.7 % [95%CI; 7.1,8.2], p=0.04 and ∆SBPABS; 7.1 mmHg [95%CI; 6.6,7.6] vs 6.2 
mmHg [95%CI; 5.7,6.7]; p=0.01). 
A non-linear association was observed between ∆SBPABS or ΔSBP and the first SBP reading 
which was modified by age for both female and male participants (p<0.0001 and p=0.0002 
respectively; Figure 5. 1). The interaction between age and the level of the first SBP reading 
indicated a smaller difference in SBP for adolescents compared with younger children for any 
given level of first SBP reading, with differences across age being more pronounced among 
female participants (Figure 5. 1; p=0.037). A similar interaction was observed between mean 
SBP level and the total SBPV in the subpopulation with 3 BP readings, resulting in a 
modification effect of age on the relationship between mean SBP level and overall SBPV over 
3 readings (p=0.03 for male and p=0.004 for female participants). When SBP was replaced by 
PP, the same interaction was observed between the level of initial PP and the difference 
between the first and second PP readings (interaction p<0.001 and p=0.026, for males and 
females, respectively). No age-dependent relationships were observed for either the DBP 
difference between measurements or the overall variability in three DBP readings when 
analysis was performed using DBP instead of SBP. 
From the first to second measurement, SBP decreased in 58% (95%CI 56,60); did not change 
in 10% (95%CI 9,12), and increased in 32% (95%CI 29,34) of the population. Allowing for a 
tolerance in the difference between the first to second SBP measurements of 5 mmHg or more, 
still resulted in 34% (95%CI 33,37) experiencing a decrease in SBP, whereas 16% (95%CI 
14,17) had an increase and 50% (95%CI 48,52) had no change in SBP (ΔSBP -4 to 4 mmHg).  
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Figure 5. 1 Modifying effect of age on the relationship of the difference between first and 
second systolic BP (SBP) readings and the level of the first SBP reading among female and 
male children and adolescents. 
5.5 Discussion 
Although BP is thought to be highly variable in childhood, data assessing the magnitude of 
within-visit BPV among youth are limited. Moreover, BP is thought to systematically decrease 
over consecutive measurements due to a reduction in anxiety related to the measurement 
process. The main findings of this study indicate that within-visit BPV among youth is highly 
affected by age, such that older children had smaller changes between consecutive BP 
measures, at any given BP level, in comparison to younger children. Secondly, assumptions 
that BP decreases over consecutive measurements is misleading because BP was observed to 
increase in about one third of those tested, whereas it did not change in 10% of participants in 
this large representative population of young people. Overall, these findings have implications 
regarding the accuracy of BP measurement and hypertension diagnosis in children and 
adolescents. 
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To our knowledge, this is the first study to report within-visit BPV indices such as the absolute 
change in BP over consecutive measurements and the overall BPV among three BP 
measurements. In this population, average ΔSBP (taking into account the direction of change) 
was -2.4 mmHg, whereas average ∆SBPABS was 6.7 mmHg and average SBPV was 8.2 %. The 
ΔSBP appears to be misleadingly small (-2.4 mmHg) owing to 10% of the population having 
no change and 32% having an increase from SBP1 to SBP2. The most meaningful measures in 
terms of magnitude of BP change is best quantified using the absolute BP change or the overall 
BP variability (defined in this analysis as the coefficient of variation; a measure of the 
distribution of values around the mean). To our knowledge, only one study has previously 
reported ΔSBP and this was among 10-19 year old adolescents (SBP change from SBP1 to 
SBP2: -3.8 mmHg and SBP change from SBP2 to SBP3: -1.2 mmHg);137 however, as said 
above, based on this study’s findings which show that BP will not systematically decrease over 
consecutive readings, these measures do not allow for the best indication of the full magnitude 
of ΔSBP. Within-visit BP variance in children was firstly studied in 1987 by Rosner et al.126 
among 780 children aged 8-18 years. The within-visit variance components (defined as the 
squared deviation from the mean value [σ2]) were derived from a nested random effects model 
of three BP measures repeated at 4 visits (assessed using a sphygmomanometer), and although 
the level and dispersion of BP data in the context of BP assessment would be easier interpreted 
using either standard deviation or coefficient of variation, these data provided the first evidence 
of a highly variable BP profile in childhood.  
Although it is believed that children have greater BPV in comparison to adults, there are limited 
data to support this notion. Rosner et al.126 compared within-visit BP variance components 
among 780 children with previously published results among 434 adults and concluded that 
within-visit BP variance was considerably higher in childhood. However, this comparison was 
made from two different studies with the adult population having a narrow age range (30-39 
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years). Our group recently investigated the impact of BP level and age on within-visit BPV 
indices among >20,000 adults aged 18-85 years using the same population survey methodology 
used in this analysis.131 Compared with children, adults had smaller changes from SBP1 to 
SBP2 and smaller overall variability (∆SBPABS = 4.9 mmHg; ΔSBP = -1.7 mmHg and SBPV 
= 6.56 %).131 This lower BPV among adults (despite considerably higher BP levels) may be a 
normal physiological process of cardiovascular ageing, perhaps reflecting diminished minute-
to-minute BP regulatory ability.131 Interestingly, the findings of this current study suggest that 
even in youth there is an adverse impact of higher BP on the normal inverse relationship 
between BPV and age.  
Remarkably, the proportion of adults with either a decrease, increase or no change from SBP1 
to SBP2 among the AHS 2011-2013 survey was very similar to that observed among young 
people (adults; 56%, 37% and 7% respectively, children; 58%, 32% and 10% respectively). 
Although we cannot speculate as to the reasons underlying the direction of BP changes over 
consecutive measurements, it seems unlikely to be driven solely by a participant’s stress levels 
if one takes into account the high proportion of individuals with an increase or no change from 
SBP1 to SBP2. Additionally, the younger population, being less exposed to the BP 
measurement process as compared to adults, may be expected to have a different stress 
response and therefore have a different direction of SBP change if it was driven by the stress 
level, but this was not the case. Lastly, our findings among both youthful and adult populations 
are similar to previously published data which assessed within-visit home BPV and found a 
decrease in SBP among 60% of the population, but an increase among 30%, and no change 
among 10% of the population.138 Out-of-clinic BP assessment, such as home BP, minimizes 
the procedural stress and alerting response to the measurement,80 therefore the similar patterns 
observed in SBP change in both home and clinic BP, support the unlikelihood of this being 
only the result of anxiety or stress. 
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Importantly, the prevalence of hypertension depends on the number of BP readings used for its 
estimation.131 Although repeated measurements are recommended for BP assessment in 
children and adolescents, the exact number is not specified. Additionally, the number of 
measurements vary across health care providers139 but also across research studies reporting 
prevalence of hypertension. The number of readings used for BP assessment vary from two140-
142 and three BP,143-146 to four147 readings. Studies have also used the average of second and 
third readings discarding the first one,148 or recorded the lower of three readings.149 However, 
with the difference in BP across percentiles of BP classification being very small (3-4 mmHg), 
especially between the 90th (pre-hypertension stage) and 95th (hypertension stage) percentiles, 
the assessment and classification of high BP will substantially vary depending the number of 
readings, particularly with increased BPV. Indeed, depending on the number of readings used 
for BP assessment, Wirix et al. reported a range of hypertension prevalence from 32.5% to 
12.4% among overweight children, and from 21.2% to 4.6% among non-overweight children 
(using either the first BP only, the mean of two BP readings, the mean of three BP readings, 
the median of three BP readings or the lowest of three BP readings).149 Our findings, in the 
context of data on hypertension prevalence among children and adolescents, underscore the 
need to use out-of-clinic BP monitoring to confirm clinic BP readings, as well as the need for 
more accurate clinic BP measurement protocols (e.g. automated, unobserved BP).150 
Strengths of this study include the survey design and large sample size which allow for 
representative estimates of a general population. Additionally, this is the first study to provide 
estimates of within-visit BPV which are directly comparable to adults, using results derived 
from the same assessment protocol in both children and adults.131 On the other hand, a 
limitation arises from the BP measurement process which was undertaken by trained non-
clinicians in the home rather than under strict laboratory conditions or by clinicians. These 
different approaches to study design may have affected the level of BP, for example, by 
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lessening the white coat effect had readings been taken by clinicians in the office. However, 
the effect on BPV cannot be predicted. Lastly, analysis using all three BP readings has been 
performed on an incomplete dataset because a third reading was only taken if there was ≥10 
mmHg difference between the first and second BP readings, and was not a predefined 
methodological protocol. Thus, the results of analyses which included all three BP measures 
could be more relevant to populations with increased BP variability. 
In conclusion, within-visit BPV is highly affected by age in children and adolescents, with 
older children having smaller changes for any given BP level, in comparison to younger 
children. Employing the same clinic BP assessment protocols in children and adolescents as in 
adults may not be ideal due to physiological differences in short-term BP behavior over 
consecutive measurements. Additionally, it is important to keep in mind that BP will not drop 
with repeated measurements for a sizeable proportion of the population, and thus BP 
measurement protocols should allow for the detection of a possible increase in BP. As precision 
in BP measurement is critical;151 the need for better measurement protocols is underscored. 
Further research should aim in determining the optimal required number of readings for an 
accurate clinic BP assessment; however, until reliable clinic BP methods are established, out-
of-clinic BP measures (i.e. home or 24-hour BP) should be used to confirm diagnosis. 
5.6 Contribution of chapter 5 to thesis aims 
Chapter 5 (study 1), represents the first study to examine the direction and magnitude of within-
visits BP fluctuations over consecutive measurements, as well as factors affecting these 
fluctuations, in a nationally representative sample of more than 3,000 children and adolescents 
from the Australian Health Survey. The key findings were that BP is highly variable. However, 
the magnitude of change in BP over consecutive measurement was greater among children and 
adolescents with higher BP levels, but lower with older age. Moreover, in contrast to 
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expectations that BP should always drop over consecutive measurements, systolic BP increased 
on repeat measurement among a significant proportion of the population. These observations 
are highly relevant to the correct clinical determination of BP control among children and 
adolescents.  
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6.1 Abstract  
Background. Increased aortic stiffness, peripheral and central blood pressure (BP) predict 
cardiovascular events and mortality. Observational studies report inverse associations between 
vitamin D levels, aortic stiffness and BP, but there are limited intervention data.  
Objectives. This study aimed to determine the effect of vitamin D supplementation on aortic 
stiffness, peripheral and central BP indices, as well as visit-to-visit BP variability (BPV).  
Methods. In a double-blind, placebo-controlled trial, 241 individuals (mean[SD] age 63[7] 
years, 49% female) with vitamin D deficiency (43.12[12.24] nmol/L) and knee osteoarthritis 
were randomized to 12-months vitamin D 50,000 IU/month (n=118) or matching placebo 
(n=123). Our primary outcomes were aPWV (carotid-femoral pulse wave velocity; aPWV), 
peripheral BP and central BP and were measured at baseline, 6- and 12-months. Visit-to-visit 
BPV was calculated from three visits over 12-months.  
Findings. Vitamin D supplementation significantly increased serum vitamin D compared with 
placebo (45.10 [95%CI 40.20 to 49.93] vs 7.99 [95%CI 4.32 to 11.66] nmol/l; p<0.001). 
However, relative to placebo there were no significant differences for changes in aPWV (-0.10 
[95% CI -0.47 to 0.26] vs 0.05 [95%CI -0.33 to 0.42] m/s; p=0.56]), peripheral systolic BP (-
3.00 [95%CI -5.60 to -0.40] vs -2.94 [95%CI -5.59 to -0.30] mmHg; p=0.98) or any other 
peripheral or central BP indices, or visit-to-visit BPV (all p>0.05).  
Conclusions. Despite many observational studies suggesting that vitamin D supplementation 
could be useful for improving aortic stiffness and BP, 12-months intervention yielded no 
improvement in older people with vitamin D deficiency and osteoarthritis. Registration 
number: ClinicalTrials.govidentifier: NCT01176344. 
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6.2 Introduction 
Increased aortic stiffness 152, peripheral blood pressure (BP) 153 and central hemodynamic 
parameters 154 (such as augmentation index [AIx]), independently predict cardiovascular events 
and all-cause mortality. Moreover, BP variability (BPV) has recently been shown to be an 
independent predictor of cardiovascular risk. 155. Observational studies show detrimental 
associations between aortic stiffness 156, peripheral BP 157 and central BP 158 and low vitamin 
D levels among different patient populations. It has also been shown that low vitamin D may 
adversely affect BPV via increased large artery stiffness 76. Experimental data suggest that 
vitamin D could directly benefit the vasculature 159 in addition to acting as a negative regulator 
of the renin-angiotensin system to influence BP control 160, and thereby change large artery 
stiffness 53.   
Data from intervention studies assessing the effects of vitamin D on aortic stiffness and BP 
indices are sparse and inconclusive. A number of randomized-controlled clinical trials testing 
the effect on aortic stiffness (as measured by aortic pulse wave velocity [aPWV], the current 
‘gold standard’ measure) 57 have recently been published 161-164 but results are equivocal. 
Probable reasons for this are study design issues, including small sample size 161,164 and short-
term duration (<6 months) 162,163. Similar problems of short-term intervention 165-168, low 
vitamin D dose 169 or small sample sizes 170-173 are evident in studies investigating the effect of 
vitamin D supplementation on peripheral BP (only two studies of appropriate dose, sample size 
and intervention period found no effect of vitamin D supplementation on peripheral BP 174,175. 
Effectiveness of vitamin D supplementation on central hemodynamics is unknown, with only 
small, short-term (<4 months) interventions reporting no effect on central BP or AIx in 
postmenopausal women 162, or patients with peripheral arterial disease 176 or chronic kidney 
disease 164. There are no vitamin D intervention studies targeting visit-to-visit BPV.  
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People with osteoarthritis (OA) are more likely to be vitamin D deficient 177 and this may 
increase progression of knee OA 178. OA is associated with increased propensity for 
macrovascular atherosclerotic disease (carotid artery intima media thickness and plaque 
severity, and coronary artery calcification) 179,180 and increased large artery wall thickness 181. 
The progression of OA has also been shown to independently relate to accumulation of 
cardiovascular risk factors, including hypertension 182. Mechanisms that contribute to OA (i.e. 
inflammation and oxidative stress) may overlap with development of adverse arterial changes 
leading to large artery stiffness and increased BP 183. Furthermore, medications for OA can 
increase cardiovascular risk through BP raising effects 184 and this can have major health 
consequences for which treating clinicians need to weigh risk versus benefit 185. Taken 
altogether, people with OA represent a population enriched with vascular risk factors that may 
be amenable to benefit with treatment from vitamin D supplementation. This current study is a 
sub-study of a trial investigating the effect of vitamin D supplementation on musculoskeletal 
outcomes among older people with vitamin D deficiency and osteoarthritis 186. Its aim was to 
determine the effects of vitamin D supplementation in this population on aPWV, peripheral 
and central BP measures, including BPV. 
6.3 Methods 
Study design. This was a sub-study of the VItamin D Effects on Osteoarthritis, (VIDEO) study, 
a randomized, double-blind, placebo-controlled trial, the rationale and design of which has 
been published 186. Briefly, the rationale of a vitamin D intervention targeting osteoarthritis 
among older people is based on the potential benefits of vitamin D on knee structure, bone and 
muscle health in a population where knee osteoarthritis is common and vitamin D deficiency 
prevalence reaches 30% or more 186. The primary end-points of the VIDEO study were knee 
cartilage volume measured by magnetic resonance imaging (MRI) and Western Ontario and 
McMaster Universities Index of Osteoarthritis (WOMAC) score.  We considered that the 
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VIDEO study design presented an opportunity to determine the effect of vitamin D on BP and 
vascular endpoints. The only major protocol change of the sub-study was failure to measure 24 
hour ambulatory BP due to insufficient resources. The complete study was performed between 
2010 and 2013 and there were 400 participants allocated to either intervention or placebo from 
two major centres (Hobart, Tasmania and Melbourne, Victoria). Sub-study data relating to this 
paper were collected at the Hobart site only. The study was approved by the Tasmania Health 
and Human Medical Research Ethics Committee (reference number H1040).  
Participants. Exclusion/inclusion criteria have been described previously in detail 186. Briefly, 
inclusion criteria were: having knee osteoarthritis; aged 50 – 79 years; relatively good health, 
with a score of 0 to 2 on a 5-point Likert scale (0 indicating very good health and 4 indicating 
very poor health); serum vitamin D levels > 12.5 nmol/L and < 60 nmol/L; and knee pain. 
Exclusion criteria were: severe knee osteoarthritis, severe knee pain on standing or significant 
knee injury; any contradiction to having MRI; hypersensitivity to vitamin D; any condition 
possibly affecting oral drug absorption; rheumatoid or psoriatic arthritis, lupus or cancer; 
severe cardiac or renal impairment; and history of taking vitamin D supplements within the 
previous 30 days. All participants provided written, informed consent. 
Randomization and masking. Allocation was based on computer-generated random numbers 
in a ratio of 1:1. Allocation was double-blind and concealment was achieved using a secure 
central automated allocation procedure blinded to all investigators. Statistical analyses were 
performed by a person (PV) blinded to allocation until after completion of all data analysis. 
Procedures. Participants were randomized to receive intervention (monthly capsule of 50,000 
IU [1.25 mg] of vitamin D3 [cholecalciferol]) or an identical inert placebo. aPWV, peripheral 
and central BP were measured at baseline, 6 and 12 months. All measures were recorded in a 
quiet, temperature-controlled room. Safety and adverse events (AEs) were assessed at each 
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follow-up visit and information related to cause or intensity of the AEs as well as 
hospitalization admission was recorded. 
Outcomes. Our primary outcomes were aPWV, peripheral BP and central BP, specified a priori 
before commencing recruitment 186, with visit-to-visit BPV added as a hypothesis generating 
analysis on the basis of the clinical relevance of stabilizing BPV 187, which may be possible 
with improved vascular stiffness 188. Supine aPWV was assessed in duplicate using 
electrocardiogram-gated carotid to femoral tonometry readings according to guidelines 57 using 
customized equipment (SphygmoCor 8.0, AtCor Medical, Sydney, NSW). Brachial BP was 
measured by the average of two consecutive BP readings taken after 5 minutes of seated rest 
using a validated automatic device (Omron HEM-907; OMRON Europe B.V. (OMCE), 
Hoofddorp, The Netherlands). Measurements were recorded using an appropriate sized cuff, 
with the participants’ arm supported at heart level, with their back supported and feet flat on 
the floor. Radial applanation tonometry was used to measure central BP (SphygmoCor 8.1, 
AtCor Medical, Sydney, Australia), immediately after each peripheral BP measurement. 
Central BP was derived from the aortic pressure waveform which was reconstructed using a 
validated generalized transfer function applied to the radial artery waveform 189 and the average 
of two readings was used for analysis. Augmentation pressure (AP) was calculated from the 
aortic pressure waveform as P2 (late systolic peak) – P1 (early systolic peak) and indexed to 
pulse pressure (PP) for calculation of AIx. Since AIx is heart rate-dependent, this variable was 
also corrected to a standard heart rate of 75 beats per minute (AIx@75). PP was calculated as 
the difference between systolic BP and diastolic BP. PP amplification was defined as peripheral 
PP/central PP. The mean of peripheral systolic, diastolic, PP and mean arterial pressure (MAP) 
as well as central systolic BP from each visit over 12 months was used to calculate visit-to-
visit BPV for each variable. This was determined from the standard deviation (SD) around the 
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mean, as well as the coefficient of variation (CV; [SD/mean]x100) for the BP values among 
those participants who completed all three visits. 
Serum vitamin D levels at baseline and 3 months were measured from serum samples treated 
initially with acetronitrile to rapidly extract 25-hydroxyvitamin D [25-(OH)D]. 25-(OH)D was 
then assayed utilizing a Liquid Phase radioimmunoassay (Immunodiagnostics Systems Ltd, 
Boldon, Tyne & Wear, UK).  
Statistical analysis. We sought to recruit as many participants as possible from within VIDEO, 
with a minimum of 100 participants in each arm allowing for a between-group clinically 
significant detectable difference of at least 0.5 m/s for aPWV (with the predicted standard 
deviation as 1.6 190 [α=0.05, β=0.20]). Based on our previous data 191, this sample size was 
predicted to detect a between-group difference of at least 4.5 mmHg for peripheral and central 
systolic BP.  The intervention effect on outcome measures was assessed based on the assigned 
treatment at randomization on all participants who were randomized, regardless of adherence 
or study retention (intention-to-treat approach). Between-group differences in the change in 
outcome measures over each visit during the 12 months follow up were assessed using mixed-
effects linear regression models with random intercepts. In keeping with published evidence 
53, the changes in aPWV were also estimated after adjusting for the changes in MAP in order 
to account for the known contribution of MAP to aPWV. The maximum likelihood approach 
was applied to address missing data uisng the ‘xtmixed’ Stata command. Student t-tests were 
used to compare visit-to-visit BPV between groups. Sensitivity analyses were performed in 
order to test the potential effects of deviation from the protocol (also analyzed per protocol) 
and different definitions to delineate abnormality of outcome variables (also analyzed using 
different cut-off values; post hoc analyses). The post-hoc analysis model for the changes in 
aPWV was also adjusted for the change in MAP over time. A p value <0.05 was considered 
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statistically significant. All data were analyzed using Stata 12.1 (StataCorp, College Station, 
Tx). The trial was registered (ClinicalTrials.govidentifier: NCT01176344). 
6.4 Results 
Figure 6. 1 depicts the trial profile. From 422 people screened for eligibility, 265 were 
randomly assigned to either intervention matching placebo. 24 individuals were either lost to 
follow-up or discontinued the intervention. 241 participants were included in the analysis of 
aPWV and BP measures (mean [SD] age 63[7] years, 49% female); 118 were assigned to 
intervention and 123 were assigned to matching placebo. Participant characteristics are 
described in Table 6. 1.  Characteristics of participants in each group were similar other than 
participants in the placebo group having a slightly higher prevalence of high cholesterol (41.2% 
vs 47.0%). There were no between-group differences for any other characteristic, including 
age, sex or body mass index (BMI). Almost half of the participants in each group self-reported 
high BP. A small percentage in each group self-reported a previous history of myocardial 
infarction or stroke. The percentage of missing data from the total population for aPWV and 
BP measures at baseline was 2.1% and 5.4%, at month 6 was 15.5% and 9.6% and at month 12 
was 18.0% and 11.7% respectively. For all participants, baseline serum vitamin D was 
43.1(12.2 nmol/L); there were no differences between the intervention and the placebo group. 
Serum vitamin D increased significantly more with intervention compared to placebo (45.10 
[95%CI 40.20 to 49.93] vs 7.99 [95%CI 4.32 to 11.66] nmol/L; p<0.001). 
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Figure 6. 1 Flow of the study participants. 
*Intervention: vitamin D 50,000 IU/month 
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Table 6. 1 Baseline demographics and clinical characteristics of study participants 
Participant clinical characteristics 
Intervention 
(n=118) 
Placebo 
(n=123) 
Mean age (years) 63.3(7.2) 62.4(7.3) 
Body mass index (kg/m2) 29.4(5.2) 29.6(4.4) 
Female, %(n)  50.4(59) 47.2(58) 
Participant-reported, %(n)   
     High blood pressure  50.9(60) 48.0(60) 
     High cholesterol  41.2(49) 47.0(57) 
     Type II diabetes mellitus  7.0(8) 7.6(9) 
     Asthma  21.1(25) 17.6(22) 
     Myocardial infarction  4.4(5) 1.7(2) 
     Stroke  1.8(2) 2.5(3) 
Serum vitamin D concentration (nmol/L) 42.4(11.8) 43.8(12.6) 
Aortic stiffness   
Aortic pulse wave velocity (m/s) 9.2(2.5) 9.1(2.0) 
Peripheral blood pressure (mmHg)   
Systolic blood pressure 128.5(15.4) 128.2(15.0) 
Diastolic blood pressure 73.2(8.6) 72.8(9.7) 
Mean aortic pressure 95.3(10.4) 94.9(10.5) 
Pulse pressure 54.5(10.8) 55.4(12.4) 
Central blood pressure (mmHg)   
Systolic blood pressure 117.1(15.2) 117.1(15.0) 
Pulse pressure 42.4(10.3) 43.0(11.7) 
Augmentation pressure 11.3(5.9) 11.1(6.9) 
Augmentation index (%) 20.8(8.2) 21.5(8.8) 
Data presented as mean(SD) unless otherwise stated. 
There was no significant between-group difference in change in aPWV; with a decrease of 0.22 
m/s for the intervention group and a slight increase of 0.06 m/s for the placebo group at follow 
up (Table 6. 2). The difference between the groups attenuated when the model was adjusted 
for the changes in MAP (-0.10 [95% CI -0.47 to 0.26] vs 0.05 [95%CI -0.33 to 0.42] m/s; 
p=0.56). Unadjusted post-hoc analysis confined to only those participants with high baseline 
aPWV according to guidelines45 (>10 m/s; intervention n=34 vs placebo n=33) showed a near 
significant effect of intervention (intervention; -1.77 [95%CI -2.57 to -0.97] vs placebo; -0.72 
[95%CI -1.50 to 0.07] m/s; p=0.065). However, this difference attenuated when adjusted for 
the change in MAP (p=0.14). Results of per protocol analyses were similar.  
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Table 6. 2 Changes over 12 months in aortic stiffness, peripheral and central hemodynamic 
parameters by study arm 
Variable Intervention (n=118) Placebo (n=123) P* 
aPWV (m/s) -0.26(-0.62,0.10)† 0.06(-0.30,0.43) 0.22 
Peripheral SBP (mmHg) -3.00(-5.60,-0.40) -2.94(-5.59,-0.30) 0.98 
Peripheral DBP (mmHg) -1.47(-3.00,0.06) -0.53(-2.09,1.03) 0.40 
MAP (mmHg) -2.08(-3.93,-0.24) -1.48(-3.36,0.39) 0.66 
Peripheral PP(mmHg) -2.48(-4.35,-0.61) -0.95(-2.76,0.85) 0.25 
Central SBP (mmHg) -2.77(-5.42,-0.11) -2.90(-5.59,-0.22) 0.94 
AP (mmHg) -0.84(-1.86,0.17) -0.16(-1.17,0.86) 0.35 
Central PP (mmHg) -2.10(-4.03,-0.18) -0.93(-2.81,0.95) 0.40 
AIx@75 0.54(-1.75,0.68) 0.77(-0.45,1.99) 0.14 
*P value for the interaction between group and time, as derived from mixed-effects linear 
regression. 
†Beta coefficient (95% confidence interval) (all such values). 
aPWV = aortic stiffness; SBP = systolic blood pressure; DBP = diastolic blood pressure; 
MAP = mean arterial pressure; PP = pulse pressure; AP = augmentation pressure; AIx@75 = 
augmentation index adjusted for heart rate; PPA = PP amplification. 
The changes in peripheral systolic BP did not differ significantly between intervention and 
placebo (-3.00 [95%CI -5.60 to -0.40] vs -2.94 [-5.59 to -0.30 mmHg; p=0.98, Table 6. 2). 
Similarly, no significant between-group differences were observed for changes in peripheral 
systolic BP when analysis was repeated for participants with baseline systolic BP≥140 mmHg 
(intervention n=33 vs placebo n=34, p=0.37). No significant between-group differences were 
observed for changes in any other peripheral or central BP measure or PP amplification (Table 
6. 2). Analysis of the central BP measures was repeated after recalibration of the radial pressure 
waveforms with mean arterial pressure (MAP; derived by 40% form factor) and diastolic BP; 
however, results were similar to those where central BP was derived by calibration using 
brachial systolic BP and diastolic BP (data not shown). None of the above findings were altered 
when analyzed per protocol.  
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BPV could be assessed in 194 people who completed all three visits. There were no significant 
between-group differences in the visit-to-visit BPV in either peripheral or central BP measures 
(Table 6. 3; p>0.17 for all).  
Table 6. 3 Between-group comparison of visit-to-visit variability in BP indices 
Variable Intervention (n=102) Placebo (n=92) P 
Peripheral systolic BP SD 8.64(5.40) 7.67(5.92) 0.23 
Peripheral systolic BP CV 6.90(4.49) 6.07(4.67) 0.21 
Peripheral diastolic BP SD 5.10(2.87) 4.69(2.99) 0.36 
Peripheral diastolic BP CV 7.16(4.14) 6.52(4.08) 0.28 
Mean aortic pressure SD 6.16(3.53) 5.47(3.95) 0.20 
Mean aortic pressure CV 6.64(3.93) 5.84(4.20) 0.17 
Central systolic BP SD 8.31(5.09) 7.96(6.66) 0.67 
Central systolic BP CV 7.21(4.39) 6.91(5.34) 0.67 
Data presented as mean(SD). 
BP = blood pressure; SD = standard deviation; CV = coefficient of variation. 
24 participants in the intervention group and 20 participants in the placebo group reported one 
or more AEs during the 12-months follow-up period (20.34% and 16.26%, respectively; 
p=0.43). The total AEs reported were 64; 35 in the intervention group and 29 in the placebo 
group. 5.71% of the total AEs reported in the intervention group and 6.90% of the total AEs in 
the placebo group were classified as serious AEs (p=0.86). Table 6. 4 shows the classification 
of all serious and non-serious AEs per group. 
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Table 6. 4 Adverse events among participants 
  Intervention (n=118) Placebo (n=123) 
Serious adverse events (n=20)   
Death (non-cardiovascular) 0.85 (1) 0.00(0) 
Cancer 3.39(4) 1.63(2) 
Myocardial infarction 0.00(0) 0.81(1) 
Coronary artery bypass 0.00(0) 0.81(1) 
Cerebrovascular accident 0.85(1) 0.00(0) 
Hospitalisation after suspected stroke 0.85(1) 0.00(0) 
Severe infection 0.00(0) 1.63(2) 
Nephrolithiasis 0.85(1) 0.00(0) 
Gastrointestinal disorder 0.85(1) 0.00(0) 
Major depression 1.69(2) 0.00(0) 
Hospitalisation after a fall 1.69(2) 0.00(0) 
Total 11.02(13) 4.88(6) 
Non-serious adverse events (n=97)   
Hypercalcaemia 5.08(6) 1.63(2) 
Hematologic disorder 0.00(0) 0.81(1) 
Nephrolithiasis 0.00(0) 0.81(1) 
Falls 1.69(2) 0.00(0) 
Hyperparathyroidism 0.85(1) 0.00(0) 
Renal  2.54(3) 0.00(0) 
Urinary 0.85(1) 0.81(1) 
Neurological 4.24(5) 2.44(3) 
Gastrointestinal 3.39(4) 4.07(5) 
Musculoskeletal 0.85(1) 0.81(1) 
Respiratory 1.69(2) 1.63(2) 
Ocular/visual 1.69(2) 1.63(2) 
Infection 5.93(7) 2.44(3) 
Cardiac arrhythmias 2.54(3) 0.00(0) 
Chest pain 2.54(3) 4.07(5) 
Pain 6.78(8) 2.44(4) 
Allergy/immunology 0.00(0) 1.63(2) 
Other events* 8.47(10) 5.69(7) 
Total 49.15(58) 31.71(39) 
Data are presented as %(n). 
*Includes: headache, lethargy, flu symptoms and other events. 
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6.5 Discussion 
This study provides definitive evidence that vitamin D supplementation does not improve large 
artery stiffness or BP control in a vitamin D deficient older aged population enriched with risk 
factors to identify an effect. It is the first study that has had adequate sample size to detect 
clinically important effects on aPWV and central BP outcomes, each of which representing 
major independent risk factors for cardiovascular events and mortality 152,154. Our findings also 
add novel information on visit-to-visit BPV and confirm recent work showing no effect of 
vitamin D on peripheral BP 167,174. Importantly, the substantial increase in serum vitamin D 
levels in the intervention group ensures that the lack of effect is not due to poor compliance or 
inadequate dose. Altogether, the difference in the changes in aPWV and BP measures were 
neither statistically significant nor likely to be clinically important. 
The previously reported positive effects of vitamin D on cardiovascular outcomes in 
observational data could have been influenced by the relationship of vitamin D with other 
factors. For example, low physical activity 192 or obesity 193 could be associated with low 
vitamin D levels, but be the causative factors with respect to increased cardiovascular risk (i.e. 
increased risk of diabetes). This is the longest vitamin D intervention trial assessing the effect 
on aPWV and the result is concordant with previous negative studies of considerably shorter 
duration 162-164. Importantly, when accounting for the effect of BP on aPWV 53 by adjusting for 
the changes in MAP, the treatment effect decreased from -0.26 to -0.10 m/s, which suggests 
that the initially unadjusted treatment effect on aPWV was not independent of BP changes. 
Additionally, analysis restricted to those participants with high baseline aPWV according to 
guidelines (>10 m/s) and adjusted for the change in MAP, showed no significant differences 
among the groups. This study is also the longest intervention trial to test the effects of vitamin 
D supplementation on central BP indices, and the results confirm negative effects in smaller 
studies of select patient populations 176, 162, 164.  
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Strengths of our study include the randomised, double-blind design, as well as an appropriately 
lengthy duration and the effectiveness of intervention in increasing serum vitamin D above 
deficiency levels. Moreover, the patient population was replete with clinical characteristics 
amenable to showing an effect of vitamin D, and this is the only study appropriately powered 
to observe clinically significant differences in aPWV. The study limitations include the 
possibility that participants could have had increases in endogenous vitamin D through higher 
exposure to sunlight or artificial ultraviolent radiation treatment, but this is unlikely to affect 
or results given the double-blind randomisation protocol and the fact that serum vitamin D 
levels were substantially higher in the supplemented group. Secondly, we did not measure 24 
hour ambulatory BP, which is a stronger marker for cardiovascular outcomes than clinic BP, 
and thus cannot exclude a differential impact on this variable. However, vitamin D has been 
shown to be ineffective for reducing 24 hour ambulatory BP in patients with isolated systolic 
hypertension 175. Additionally, the findings pertaining visit-to-visit BPV may have been 
affected by the number of BP readings used in this analysis (three BP readings). Nevertheless, 
there are no guidelines as to how many numbers are needed for accurate quantification of visit-
to-visit BPV. Lastly, as a sub-study of a larger trial specifically designed to determine the 
effects of vitamin D among people with osteoarthritis and vitamin D deficiency, the findings 
may not be generalizable to people outside this selection criteria. However, as alluded above, 
the treatment effects would be expected to be smaller in a population without vitamin D 
deficiency. Similarly, as there is evidence suggesting that osteoarthritis is associated with 
increased cardiovascular risk 194,195, the effect of a vitamin D treatment in a population with 
osteoarthritis becomes more meaningful rather than in a general population.  
Conclusions. In conclusion, this study found no effect of vitamin D supplementation on 
aPWV, BP, or BPV among older people with vitamin D deficiency and osteoarthritis. Despite 
a plethora of observational data supporting a relationship between vitamin D and 
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cardiovascular health via pathways involving BP and large artery stiffness, evidence from our 
high quality randomised-controlled clinical trial and other existing trials do not support the use 
of vitamin D supplementation as an intervention to improve these endpoints. The previously 
documented associations between vitamin D, aPWV and BP are likely to be epiphenomena 
rather than causative and vitamin D supplementation for these aspects of cardiovascular health 
cannot be recommended.  
6.1 Contribution of chapter 6 to thesis aims 
Chapter 6 (study 6) represents the first study to investigate the efficacy of targeted central 
arterial stiffness lowering interventions on long-term BPV indices (both brachial and central 
BPV indices). Study 6 explored the effect of vitamin D supplementation on long-term BPV, 
aortic stiffness, peripheral and central BP indices. Despite many observational studies 
suggesting that vitamin D supplementation could be useful for improving cardiovascular 
health, 12-months intervention yielded no improvement in long-term BPV or mean BP levels 
of aortic stiffness in older people with vitamin D deficiency and osteoarthritis.  
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Summary and future directions 
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This research project has shown that the methodology of measuring and quantifying BPV could 
significantly affect the magnitude of BPV itself and this could have various clinical 
implications. Contrary to expectations, this thesis does not support the hypothesis that BPV is 
clinically important in patients with uncomplicated hypertension and lower cardiovascular risk. 
However, this work offers some evidence that BPV may be a potentially modifiable target for 
microvascular damage in high-risk populations. Moreover, this thesis shows unequivocal 
evidence that BPV could also affect the measurement and assessment of mean BP levels and 
therefore the classification of high BP; this could have major clinical consequences. Lastly, it 
has been shown that vitamin D supplementation was not an effective intervention in lowering 
long-term BPV.  
In chapter 1, the methodology of measuring BPV was explored for the first time using a scoping 
review and the results indicate that certain methodological factors (i.e. the number of BP 
measurements or the duration of BP monitoring) as well as participants’ age and mean BP 
level, could significantly affect BPV magnitude. Although methodological discrepancies and 
heterogeneity have been suggested to be among the reasons of conflicting results among 
studies,10,11 there has never been a systematic approach to quantify their impact on BPV 
assessment. Therefore, these results could offer the foundations for standardizing the protocols 
and methodology of measuring BPV, which is necessary in order to compare results among 
studies but also to enable research integration into clinical practice. The abundance of studies 
investigating BPV in relation to various research questions (i.e. organ damage, 
antihypertensive treatment, physiological correlates of BPV) and the plethora of methodologies 
used across these studies have led to further confusion rather than clarity. An inevitable 
question is, as noted by Whittle;25 “now what?” Should we measure BPV in clinical practice 
and if yes, how should we measure it? Based on the results of chapter 1, the next step would 
be to offer recommendations on how to assess each type of BPV based on methodological 
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factors that were outlined in this analysis, such as the number of BP readings or visits, or the 
duration of the monitoring which is required for the assessment. The recommendations should 
also clarify which type of data should be reported by studies. For example, most studies report 
the primary results using the standard deviation but the majority do not report average BPV 
levels. Within the scoping review, we recommended that studies should report average BPV 
levels using a metric with low computational complexity (i.e. coefficient of variation) to enable 
easier translation of results and integration in clinical practice; however, other metrics 
independent of the mean should also be used. Minimizing methodological heterogeneity would 
enable better comparison of the results and eventually it will allow systematic meta-analyses 
to draw stronger conclusions with respect to the measurement of BPV in clinical practice. At 
the same time, it is critical to identify age-specific cut-off values for risk stratification, taking 
into account the level of mean BP. The final step would be to establish reliable cut-off values 
based on standardized protocols that would allow the interpretation of evidence and enable 
translation into clinical practice.  
The results of chapter 2 represent the first evidence of potential implication of short-term BPV 
in the pathophysiology of microvasculature, in patients with type II diabetes mellitus. Given 
that many scholars have highlighted the possibility of BPV being a modifiable target, especially 
in people with higher cardiovascular risk (i.e. individuals with type II diabetes mellitus), these 
results could have potential clinical implications. On the other hand, as this was a small, cross-
sectional, post-hoc, hypothesis generating analysis, future research should explore the 
associations between BPV and microvascular pathophysiology in large-scale, longitudinal 
studies in order to determine causative relationships. Furthermore, it has been suggested that 
the pathophysiology of microvasculature could play a role in the relationship between 
macrovascular damage and BPV.196 The hypothesis that BPV is dependent on large artery 
stiffness has not been unequivocally supported;26,66,197 therefore, the discrepancies seen across 
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studies may reflect a more complex phenomenon representing interrelationships between the 
micro- and macrovasculature and BPV which needs to be further explored in appropriately 
large and well-designed studies. Findings from chapter 3 shed more light towards the 
association between BPV and the macrovasculature in a population with low to moderate 
cardiovascular risk.198 
The results of chapter 3 represent the first study to show that longitudinal changes in BPV 
(short- and mid-term) as well as long-term BPV were not predictive of organ damage (heart 
structure and macrovascular markers, such as aortic stiffness) in patients with uncomplicated 
hypertension and low to moderate cardiovascular risk. Advancing the evidence around the 
hypothesis that BPV is associated with large artery stiffness, these results may indicate that 
some organs are less susceptible to BP fluctuations than other (i.e. microvasculature versus 
microvasculature or heart versus eyes or brain). Alternatively, these results are in alignment 
with suggestions that BPV could offer prognostic information, over and above that of mean BP 
levels, in individuals with higher rather than lower cardiovascular risk. Nevertheless, the results 
of chapter 3 represent the first study to examine the effect of changes in the three main types 
of BPV on changes in heart structure and aortic stiffness over a one year follow-up period, in 
this population. This is extremely important as it addresses one of the main research gaps in 
the current literature around BPV; whether it is short-, mid- or long-term BPV that correlates 
with organ damage indices? This research question stems from the hypothesis that different 
types of BPV may represent a different pathophysiology;51 therefore, correlating to different 
organ damage indices. However, further research needs to explore the changes in different BPV 
and changes in organ damage markers in populations with high cardiovascular risk in order to 
determine whether certain BPV types are superior than other types in predicting certain organ 
damage, or cardiovascular events and mortality. Furthermore, although this study was the first 
one to explore longitudinal associations between BPV and organ damage, it may be argued that 
105 
 
a longer follow-up duration (>1 year) was needed to draw solid conclusions as to whether BPV 
changes affect organ damage. Therefore, future studies should address these issues using 
follow-up periods longer than 1 year. Lastly, future research should also investigate 
longitudinal associations between changes in BPV and changes in other organ damage markers 
(i.e. kidney dysfunction), in order to clearly establish whether there is a causative relationship 
between BPV and the wider spectrum of organ damage. Nevertheless, the results support the 
view that clinical practice should remain focused on mean BP levels for patient management 
decisions, until further evidence can be derived. 
Chapter 4 represents the first analysis investigating the impact of very short-term BPV (within-
visit BP fluctuations) on hypertension classification and examined the magnitude and direction 
of change in BP over consecutive measures in a nationally representative sample of more than 
20,000 participants from the Australian Health Survey. The principal goal was to determine 
how the changes in BP over consecutive measures may impact on the diagnosis of hypertension 
according to international guidelines. The major novel findings were contrary to anecdotal 
belief that BP will drop over consecutive measurements, and that the first BP is almost always 
higher than next measure due to an alarm reaction. Indeed, we found that BP may increase over 
consecutive measurements in a sizeable percentage of the population. Importantly, the 
magnitude of BP change was highly age- and BP-dependent, and the variability between 
measures resulted in significant diagnostic reclassification of hypertension across international 
guidelines. The clinical and financial implications of these findings are potentially major, taken 
into account that clinic BP measurement remains the most common method for hypertension 
diagnosis among epidemiological studies, but also in estimating prevalence of hypertension at 
national levels. It has been estimated that even a 5 mmHg overestimation or underestimation 
of BP levels could result in up to 21 million people being falsely diagnosed with hypertension 
or up to 27 million people misdiagnosed as normotensive in the United States.82 The need for 
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evidence-based recommendations on how to measure clinic BP with minimal loss of clinical 
information has also been reinforced by the results of a recent high-profile clinical study 
(Systolic Blood Pressure International Trial; SPRINT).199,200 SPRINT used a clinic BP 
measurement protocol based on a series of automated, unobserved BP readings; a method 
which minimizes the white-coat effect on mean BP levels. The conclusion of the study was that 
lowering systolic BP level below 120 mmHg as compared to the commonly used 140 mmHg 
target, reduces cardiovascular risk.201 However, the question – which is highly relevant to the 
results of this study - was whether one could compare a target of 120 mmHg measured using 
an automated clinic BP protocol with the target of 140 mmHg measured by other clinic BP 
protocols. Research investigating automated clinic BP measurement protocols is 
promising105,106 but future research should establish the exact number of BP readings, as well 
as the duration of monitoring required to reliably assess BP. At the same time, future research 
will need to define BP thresholds using automated clinic BP protocols which should be 
comparable to current international clinic BP protocols in order to enable research translation 
in clinical practice. However, until reliable clinic BP protocols are established, the assessment 
of BP and diagnosis of hypertension should ideally be confirmed with out-of-clinic BP 
measures (i.e. home or 24-hour BP). 
The results derived from SPRINT have raised similar questions regarding BP measurement 
and BP thresholds in children and adolescents.202 Prehypertension in adolescence is determined 
by a threshold of BP greater than the 90th percentile of age, height and sex-based criteria or a 
BP greater or equal to 120/80 mmHg. Although the conclusions and implications of SPRINT 
are not directly applicable to children and adolescents, the question of which BP threshold to 
use and how to measure BP (i.e. how many readings should be used?) in this population is still 
relevant. Chapter 5 examined the direction and magnitude of the changes in BP over 
consecutive measurements, as well as factors affecting within-visit BPV, in a nationally 
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representative sample of more than 3,000 children and adolescents from the Australian Health 
Survey. This is the first descriptive study to quantify very short-term BPV in children and 
adolescents using a nationally representative sample. The results showed that BPV is highly 
variable in this population; however, the magnitude of change in BP over consecutive 
measurement was greater among children and adolescents with higher BP levels, but lower 
with older age. Moreover, as observed among adults, and in contrast to expectations that BP 
should always drop over consecutive measurements, systolic BP increased on repeat 
measurement among a significant proportion of the population. The highly variable BP 
observed in children and adolescents underscores the need for further research to establish BP 
thresholds from reliable assessment protocols that take into account this variability. A crucial 
aspect of clinic BP protocols that remains to be clarified is the number of BP readings required 
for a reliable assessment. The number of readings used for BP assessment in this population 
vary from two140-142 and three BP,143-146 to four147 readings. Studies have also used the average 
of second and third readings discarding the first one,148 or recorded the lower of three 
readings.149 This heterogeneity in the methodology of BP measurement in clinic affects the 
estimation of hypertension prevalence among children and adolescents and has potentially 
important implications for the diagnosis of hypertension in clinical practice. Additionally, 
protocols based on automated, unobserved clinic BP assessment should also be explored in 
children and adolescents with the aim to establish BP thresholds that are less biased by the 
white-coat effect. Nevertheless, these results highlight the need for out-of-clinic BP monitoring 
in order to confirm the diagnosis of elevated BP among children and adolescents. 
Chapter 6 represent the first study to examine the effect of novel destiffening interventions 
(vitamin D supplementation) on long-term BPV, in a patient population that was vitamin D 
deficient and enriched with vascular risk factors that should have been amenable to benefit 
from treatment with vitamin D, based on a plethora of cross-sectional studies and small-scale 
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clinical trials. The results were that vitamin D supplementation was ineffective in lowering 
long-term BPV or aortic stiffness. The results of Study 6 (which was a sub-study of a multi-
cantered trial [VIDEO study] as described in the methodology), seen in the context of the 
overall results of the VIDEO, show that vitamin D supplementation is ineffective in improving 
osteoarthritis related outcomes but also in improving cardiovascular health outcomes in an 
older population with symptomatic knee osteoarthritis and low serum 25-hydroxyvitamin D 
levels. Moreover, the results of this study are confirmed in study 7 (presented in Appendix 4) 
which showed that the majority of randomized controlled trials exploring the effect of vitamin 
D supplementation on cardiovascular health outcomes are ineffective, despite the sample size, 
vitamin D dose and the absence or presence of vitamin D deficiency. Further evidence 
supporting our results on the lack of efficacy of vitamin D supplementation has been recently 
published from the first large-scale (n=5,108), high-dose randomized controlled trial (100 000 
IU of vitamin D; median follow-up 3.3 years) with a priori outcomes of incident cardiovascular 
disease and death (secondary outcomes were myocardial infarction, angina, heart failure, 
hypertension, arrhythmias, arteriosclerosis, stroke, and venous thrombosis).203 Nevertheless, a 
definite answer as to whether vitamin D supplementation could improve cardiovascular health 
will be provided in the near future as several large-scale trials are ongoing.204 
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Table 1. Data chart 
Supplementary table 1. Data chart 
 
Short-term BPV (using 24-hour BP monitoring over hours) 
Author Year 
Type of 
BPV 
BPV 
(mmHg) 
Age 
(years) 
SBP 
(mmHg) Readings 
Duration 
(hours) 
Saito, et al.205 2016 Awake 13.1 68.8 120 NC 
Used 
diaries 
Ruan, et al.206 2016 Day 11.3 61.4 125.9 3/hour 16 
McDonald, et 
al.207 2016 Day 11.2 70 131.35 2/hour 10 
Juhanoja, et 
al.208 2016 Day 13.6 54 138.4 4/hour 12 
Boardman, et 
al.209 2016 Day 15 31 122.1 2/hour 16 
Wu, et al.210 2016 Day 11.8 57.7 125.7 2/hour 16 
Kang, et al.211 2016 Day 15.4 52.4 138.6 NC 16 
Miroslawska, 
et al.212 2015 Day 23 53 157 3/hour 15 
Madden, et 
al.213 2015 Awake 12.8 60.2 131.4 NC 
Used 
diaries 
Karpov, et 
al.214 2015 Day 9.3 52.7 155 4/hour 16 
Johansson, et 
al.215 2015 Day 13.5 47.8 NR 4/hour 17 
Symonides, et 
al.216 2014 Day 12 45.4 130 4/hour 17 
Stabouli, et 
al.217 2014 Day 11.3 12 119.5 NC 14 
Tatasciore, et 
al.218 2013 Day 12.7 54.9 138.1 4/hour 16 
Leoncini, et 
al.219 2013 Day 18.5 47.1 146 4/hour 16 
Ciobanu, et 
al.220 2013 Day 17 57.4 148 NC 14 
Zuern, et al.221 2012 Day 15.1 68.9 155 3/hour 12 
Cahan, et 
al.222 2012 Day 14 55 141 3/hour 17 
Kotsis, et 
al.223 2011 Day 12.5 21.3 116.8 NC 14 
Eguchi, et 
al.224 2009 Day 18 67.8 145 NC NR 
Masuda, et 
al.225 2009 Awake 13.3 61.2 152 NC 
Used 
diaries 
Verdecchia, et 
al.226 2007 Day 13.1 51.2 142 4/hour 12 
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Tatasciore, et 
al.72 2007 Day 13 53.2 139.9 4/hour 16 
Shintani, et 
al.227 2007 Awake 15.3 66.2 130.5 NC 
Used 
diaries 
Ichihara, et 
al.228 2006 Day 19 53.3 153 2/hour 16 
Abramson, et 
al.229 2006 Day 10.2 43.3 117.4 2/hour 16 
Mid-term BPV (using home BP monitoring over days) 
Author Year 
Type of 
BPV 
BPV 
(mmHg) 
Age 
(years) 
SBP 
(mmHg) Readings 
Duration 
(Days) 
Okada, et 
al.230 2014 Morning 7.4 70 135.4 1 7 
  Evening 8.5 70 129.5 1 7 
Liu, et al.231 2015 
Day-to-
Day 14.7 84.35 146.25 3 7 
Fukui, et al.6 2013 Morning 10.2 65.9 NR 3 14 
  Evening 10.7 65.9 NR 3 14 
Hashimoto, et 
al.232 2012 Morning 8.4 58.6 127.8 1 28 
Hoshide, et 
al.233 2012 
Day-to-
Day 12.9 65.7 145.9 3 7 
Okada, et 
al.234 2012 Morning 7.2 66 136 1 7 
  Evening 7.9 66 130.2 1 7 
Kikuya, et 
al.235 2008 Morning 8.6 59.4 124.6 1 26 
Ishikura, et 
al.236 2012 Morning 7.9 67 135.8 1 14 
Kato, et al.237 2010 Morning 8.6 62 123.4 1 28 
  Evening 8.8 62 121 1 28 
Satoh, et al.7 2015 Morning 8.3 61.9 121 1 28 
Shin, et al.238 2016 Morning 7.9 56.2 138.8 1 6 
  Evening 8.4 56.2 137.57 2 6 
Juhanoja, et 
al.208 2016 
Day-to-
Day 5.7 54 130 1 7 
Karpov, et 
al.214 2015 Morning 7.7 52.7 148.4 1 6 
  Evening 7.5 52.7 147 1 6 
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Day-to-
Day 7.6 52.7 NR 2 6 
Johansson, et 
al.239 2010 
Day-to-
Day 6.4 56.4 129.7 3 7 
Johansson, et 
al.215 2015 
Day-to-
Day 4.5 47.8 118.1 1 7 
  Morning 6 47.8 NR 1 7 
  Evening 6.2 47.8 NR 1 7 
Long-term BPV (using clinic BP monitoring over visits) 
Author Year 
Type of 
BPV 
BPV 
(mmHg) 
Age 
(years) 
SBP 
(mmHg) Visits 
Duration 
(years) 
Chia, et al.9 2016 
Visit-to-
visit 14.2 55.5 136.7 
3 to 4 
/year 15 
Tedla, et al.240 2016 
Visit-to-
visit 8.7 57 113.5 3 to 5 9.5 
Sohn, et al.8 2016 
Visit-to-
visit 12.7 53.7 134.5 6 3.5 
Wang, et al.241  2016 
Visit-to-
visit 10.9 48 128.1 
1 visit 
every 2 
years 6 
Faramawi, et 
al.242 2016 
Visit-to-
visit 5.8 37 NR 2 NR 
Wang, et al.243 2016 
Visit-to-
visit 10.93 51 NR 4 4 
Nagai, et al.244 2016 
Visit-to-
visit 32.5 79.7 145.7 12 1 
Ogliari, et 
al.245 2016 
Visit-to-
visit 16.74 75.2 153.7 7 1.5 
Yano, et al.246 2016 
Visit-to-
visit 7.8 44 126.8 3 0.42 
Takao, et 
al.247 2015 
Visit-to-
visit 10.7 55.7 129.1 
9 
(median) 1 
Rossignol, et 
al.248 2015 
Visit-to-
visit 11.05 64 126.3 12 6.8 
Gondo, et 
al.249 2015 
Visit-to-
visit 10.2 69 129 4 0.5 
Darabont250 2015 
Visit-to-
visit 6.16 47.14 132.37 2 NR 
Jo, et al.251 2015 
Visit-to-
visit 12.9 46.9 130.3 >12 visits 1.66 
Nakano, et 
al.252 2015 
Visit-to-
visit 14.3 62.7 128.6 10 NR 
Chang, et 
al.253 2015 
Visit-to-
visit 11.9 NR NR 2 to 5 NR 
Okada, et 
al.230 2014 
Visit-to-
visit 13.4 70 129.2 10 2 
Lau, et al.254 2014 
Visit-to-
visit 16 70 142 12 6.5 
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Yokota, et 
al.255 2014 
Visit-to-
visit 18.3 67 151 12 2.7 
Lau, et al.256 2014 
Visit-to-
visit 14 66 134 18 6.75 
Faramawi, et 
al.257 2014 
Visit-to-
visit 6.82 43 NR 2 NR 
Faramawi, et 
al.258 2014 
Visit-to-
visit 6.79 42 NR 2 NR 
Cao, et al.259 2014 
Visit-to-
visit 10.35 50.44 126.99 3 6 
Noshad, et 
al.260 2014 
Visit-to-
visit 9.86 52 122.04 NR 2.6 
McMullan, et 
al.261 2014 
Visit-to-
visit 12 59.5 146.2 4 0.25 - 1 
Song, et al.262 2014 
Visit-to-
visit 17.36 54 156.5 4 1 
Yano, et al.263 2014 
Visit-to-
visit 8.7 25 118.8 8 25 
Yu, et al.264 2014 
Visit-to-
visit 8.87 64 NR at least 6 4 
Masugata, et 
al.265 2014 
Visit-to-
visit 10 73 130 NR 1 
Lattanzi, et 
al.266 2014 
Visit-to-
visit 8.33 76 137.16 5 1 
Selvarajah, et 
al.267 2014 
Visit-to-
visit 17.4 66 144 24 0.25 
Lau, et al.268 2014 
Visit-to-
visit 14 68 131 18 NR 
Chowdhury, 
et al.269 2014 
Visit-to-
visit 13 48.3 168 
8 
(median) 4.1 
Poortvliet, et 
al.270 2014 
Visit-to-
visit 14.4 75.2 153.4 9 3.2 
Yokota, et 
al.29 2013 
Visit-to-
visit 15.3 69.5 140 12 NR 
Sabayan, et 
al.271 2013 
Visit-to-
visit 14.8 75.3 153.1 
every 3 
months 3.2 
Obara, et 
al.272  2013 
Visit-to-
visit 6.9 66.1 137.8 2 0.08 
Mallamaci, et 
al.273 2013 
Visit-to-
visit 11 64 134 2 to 7 3 
Muntner, et 
al.274 2013 
Visit-to-
visit 6.3 47.9 115.2 6 0.06 
Hata, et al.275 2013 
Visit-to-
visit 11 66 138 6 2.4 
Levitan, et 
al.31 2013 
Visit-to-
visit 6.8 48 133.5 7 4 
Kawai, et 
al.276 2013 
Visit-to-
visit 11.42 61.7 138.6 6 0.5 - 1 
Epstein, et 
al.277 2013 
Visit-to-
visit 11.4 75.2 133.1 
up to 7 
visits 3 
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Suchy-Dicey, 
et al.278 2013 
Visit-to-
visit 9 72 NR 5 5 
Rossignol, et 
al.279 2012 
Visit-to-
visit 14.82 66 142.7 17 2 
Eguchi, et 
al.280 2012 
Visit-to-
visit 13.7 67 154 37 5.6 
Poortvliet, et 
al.281 2012 
Visit-to-
visit 14.1 75.2 153.7 5 1 
Levitan, et 
al.28 2012 
Visit-to-
visit 5.6 48.9 NR 3 1.5 
  
Visit-to-
visit 6.8 48.9 NR 7 1.5 
  
Visit-to-
visit 7.5 48.9 NR 18 1.5 
Mancia, et 
al.48 2012 
Visit-to-
visit 8.6 56 140.9 at least 7 4 
Shimbo, et 
al.282 2012 
Visit-to-
visit 10.9 NR 125.8 8 5.4 
Muntner, et 
al.283 2011 
Visit-to-
visit 13.5 75 135.2 7 
2.8 
(median) 
  
Visit-to-
visit 12.2 75 135.4 4 NR 
Nagai, et al.284 2011 
Visit-to-
visit 32.4 79.9 145.6 12 1 
Masugata, et 
al.285 2011 
Visit-to-
visit 11 69 129.12 
every 1 
or 2 
months 1 
Muntner, et 
al.286 2011 
Visit-to-
visit 7.7 NR NR 3 NR 
Yeh, et al.287 2016 
Visit-to-
visit 14.8 63.4 136.8 45 10 
 
NC=could not be calculated; NR = not reported; BPV = blood pressure variability 
(calculated as standard deviation); SBP = systolic BPV. 
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Survey design and ethics approvals  
The AHS used a random multistage sampling strategy, details of which has been previously 
published.96 All the data used in this analysis were provided by the ABS through 
Confidentialised Unit Record Files (CURFs) which were accessible via the Remote Access 
Data Laboratory (RADL) in order to monitor the amount and information of data being released 
and restrict information that may enable identification of individuals (i.e. instead of reporting 
home of business address, CURFs report the State).288 
Approximately 9,000 participants had blood and urine tests completed for a range of 
biomedical markers. Ethics approval for the National Health Measures Survey, which included 
the physical measures and biomedical tests, were provided by the Australian Government 
Department of Health and Ageing’s Departmental Ethics Committee.289 Participants were 
provided written information on the survey and signed informed consent. 
Anthropometry 
Height and weight were measured and body mass index (BMI; kg/m2) calculated as the weight 
(kg) divided by the height2 (m2). For validation purposes, 10% of the participants were 
randomly selected for a second height measurement and if there was a difference greater than 
one centimetre then a third reading was taken.133 Waist circumference (cm) was also measured 
according to guidelines.134 
Biomedical measures 
Participants were referred to a collection clinic for blood and urine tests, or if unable to attend 
a collection clinic, provided samples at home environment. All samples were analysed at a 
central laboratory.289 For plasma glucose, low-density lipoprotein cholesterol and triglycerides, 
samples were provided after a fasting period of 8 hours. The blood and urine samples were 
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analysed to provide risk information on cardiovascular disease, diabetes, kidney disease and 
liver function.290 
Secondary analyses 
The interaction between age and SBP1 remained significant after adjusting for age, sex, body 
mass index and other cardiovascular risk factors (cardiovascular disease status, smoking status, 
cholesterol levels; p<0.0001). As there was a very strong correlation between PP and SBP we 
did not adjust for the level of PP to avoid multicollinearity issues. Cardiovascular disease 
included conditions that could affect ΔSBP or secondary outcomes: 
1. Diabetes (including type I, type II or having high blood/urine sugar levels) 
2. High cholesterol levels 
3. Hypertension 
4. Heart disease (ischaemic heart disease, heart failure, other heart diseases) 
5. Tachycardia 
6. Stroke 
7. Other cerebrovascular diseases 
8. Diseases of arteries, arterioles, and capillaries 
9. Low BP 
10. Kidney disease  
Results pertaining to the interaction between SBP level and age were unchanged when analysis 
was confined to the differences between the SBP2 and SBP3 or, when analysis took into 
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account the total variation within three consecutive measurements as reflected by the 
coefficient of variation (SBP CV; [standard deviation/mean]*100) (Figure 3). Analyses were 
also conducted using the DBP instead of the SBP readings; however, as compared to the SBP, 
there were no age- or BP-related patterns, nor were similar relationships observed in relation 
to the DBP difference between measurements. Testing the effect of age and the level of first 
PP (PP1) on the difference between PP1 and PP2 revealed a similar interaction as with age and 
SBP1 (p<0.0001); however, it did not remain significant when the difference between PP1 and 
PP2 was plotted against the average level of PP1 and PP2 (p=0.11).  
 
Figure 1. The direction of change in SBP from first to second SBP readings across BP 
categories classified from the first SBP readings (Panel A) and across age groups (Panel B). 
SBP was classified as following; normal (90-129 mmHg), high normal (130-139 mmHg), 
grade I (140-159 mmHg), grade II (160-179 mmHg) and grade III (≥180 mmHg). Low BP was 
defined as SBP <90 mmHg. 
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Figure 2. The direction of change in SBP from first to SBP readings across age groups (Panel 
B). 
 
 
 
Figure 3. Modification effect of age on the relationship between the variability in systolic 
blood pressure across three readings and the level of mean systolic blood pressure as defined 
by the average of first, second and third readings. 
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Survey design and ethics approvals  
The Australian Health Survey used a random multistage sampling strategy, details of which 
has been previously published.96 All the data used in this analysis were provided by the ABS 
through Confidentialised Unit Record Files (CURFs) which were accessible via the Remote 
Access Data Laboratory (RADL) in order to monitor the amount and information of data being 
released and restrict information that may enable identification of individuals (i.e. instead of 
reporting home of business address, CURFs report the State).288 
Weighting 
The analysis utilised person-weights96 provided by the ABS, which ensured that any 
disproportionate sampling of certain groups was taken into account. Replicate weights 
provided by the ABS were used to calculate standard errors and 95% confidence intervals using 
the Jackknife delete-1 method. 
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Abstract 
There is a plausible physiological theory, supported by many observational studies, that 
vitamin D supplementation should be effective for improving cardiovascular end points, such 
as blood pressure (BP), large artery stiffness, atherosclerosis, endothelial function and clinical 
events. However, results from randomised controlled trials (RCTs) have been inconsistent. In 
this review, we evaluated the evidence regarding the effectiveness of vitamin D 
supplementation for cardiovascular surrogate and hard clinical end points. RCTs were assessed 
in terms of sample size, duration of supplementation, baseline vitamin D level inclusion criteria 
(i.e., absence of vitamin D deficiency), dosage of vitamin D and population under investigation. 
Forty-five RCTs were identified. Eight RCTs with BP and 6 RCTs with large artery stiffness 
as the end points were found to comply with guidelines for the optimal design of clinical trials 
evaluating nutrient effects. Only 2 of the RCTs with an optimal design were effective in 
decreasing BP with vitamin D supplementation, although these were of moderate sample size 
(<150) and very short duration (8 weeks for both), whilst no RCT was effective in reducing 
large artery stiffness. Similar results were observed for atherosclerotic and endothelial function 
markers as end points. Only 1 RCT reported cardiovascular events as an end point and found 
neither increased nor decreased incident cardiovascular events over 7 years of follow-up. In 
conclusion, results from published RCTs indicate that vitamin D supplementation is ineffective 
in improving cardiovascular health among various patient populations, including in the 
presence or absence of vitamin D deficiency. 
  
124 
 
Introduction 
Vitamin D (VitD), a lipid-soluble vitamin, plays a well-recognised role in musculoskeletal 
health,291,292 but evidence also suggests a critical role in blood pressure (BP) regulation and 
vascular health.293 In vivo and in vitro studies have suggested a number of pathways by which 
VitD could directly benefit the vasculature159,294,295 in addition to acting as a negative regulator 
of the renin-angiotensin system to influence BP control160,296 and modify large artery 
stiffness.53 Observational data during the last decade suggest a relationship of low VitD levels 
with cardiovascular end points, including coronary artery disease, myocardial infarction (MI), 
heart failure (HF), stroke and cardiovascular death. Additionally, more than 4 decades of cross-
sectional research generally show a consistent inverse association between VitD levels and 
surrogate cardiovascular markers of BP, large artery stiffness, atherosclerotic burden and 
endothelial function. Nevertheless, the highest level of evidence, derived from well-designed 
randomised controlled trials (RCTs), has been inconsistent as to whether VitD exerts 
cardioprotective effects. In this short narrative review, we sought to summarise the 
observational data and critique evidence from published RCTs on the effect of VitD 
supplementation on cardiovascular surrogate and hard clinical end points, with particular 
consideration of study design (i.e., sample size, duration of supplementation, selection of VitD-
deficient subjects, VitD dose and population under investigation). 
Summary of Observational Data on the Relationship between Serum VitD and 
Cardiovascular Disease Outcomes 
Cardiovascular Events and Cardiovascular Death 
Studies examining whether VitD is associated with cardiovascular events or cardiovascular 
death are seen in Figure 1. VitD deficiency has been associated with an increased risk of death, 
HF, MI or stroke in healthy postmenopausal women,297 as well as with an increased risk of 
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sudden cardiac death or fatal or non-fatal stroke, non-fatal MI and death related to other heart 
diseases among diabetic patients with chronic kidney disease (CKD).298 In a small study of 
patients with acute coronary syndrome, VitD deficiency was also independently associated 
with in-hospital cardiovascular death.299 In general population studies, low VitD levels were 
associated with an increased incidence of coronary artery disease, MI, HF, stroke and all-cause 
death,300 as well as increased cardiovascular death.301 Several other studies have demonstrated 
an increased risk of cardiovascular death associated with low VitD levels among different 
patient groups including HF outpatients (in a small study),302 patients with metabolic syndrome 
and cardiovascular symptoms,303 and patients with chronic obstructive pulmonary disease.304 
Furthermore, data extracted from medical records of 126 men with moderate CKD and VitD 
deficiency showed that VitD treatment was associated with decreased cardiovascular events.305 
In this study, the treatment group was defined based on an increase in serum VitD levels by 
25% from baseline within 6 months, whilst the remaining patients were considered as controls. 
The risk of cardiovascular death was also lower among haemodialysis patients regularly using 
VitD supplements in a Japanese hospital (the VitD dose varied according to prescription).306 
Overall, these data suggest fairly consistently that low VitD levels are associated with an 
increased risk of cardiovascular events, including death; in addition, the data hint towards the 
potential for VitD supplementation possibly reversing the adverse cardiovascular effects of low 
VitD. 
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Figure 1. Longitudinal cohort and case-control studies on the association between vitamin 
D and incidence of cardiovascular events or cardiovascular mortality according to sample 
size and population characteristics.  
Blue bars indicate studies that reported significant associations between vitamin D and 
cardiovascular end points, and grey bars indicate studies that reported no significant 
associations. 
BP and Large Artery Stiffness 
Brachial BP, large artery stiffness (as measured by carotid-to-femoral pulse wave velocity 
[cfPWV], an estimate of aortic pulse wave velocity and the current “gold standard” measure of 
large artery stiffness)57 and central hemodynamic parameters (such as augmentation index 
[AIx], a marker of central systolic loading) are independent predictors of cardiovascular 
risk.153,154 Many observational studies have reported an inverse association between low VitD 
levels and brachial BP in large samples from the general population,157,307,308 but also among 
Peruvian adolescents,309 middle-aged individuals,310 people aged >60 years and the 
elderly,311,312 pregnant women and women aged 20--80 years.313,314 Similarly, the evidence 
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from medium to large observational studies shows strong and independent inverse associations 
between serum VitD and cfPWV among diverse study populations.156,315-320 Other markers of 
regional arterial stiffness, including increased carotid-radial pulse wave velocity and brachial-
ankle pulse wave velocity, have been associated with lower VitD levels among people with 
type 2 diabetes mellitus (T2DM).321,322 An inverse association between VitD levels and AIx 
has also been shown in pre-diabetic individuals and cardiac or kidney clinic outpatients.323,324 
In summary, observational evidence is consistently and strongly supportive of an association 
between VitD, BP and vascular health. 
Markers of Atherosclerotic Burden and Endothelial Function 
Strong relationships have also been observed between VitD level, atherosclerotic burden and 
endothelial function markers. Carotid intima medial thickness (CIMT), a marker of large artery 
atherosclerosis, known to be predictive of cardiovascular events,325 was found to be inversely 
associated with low VitD levels among different populations, including apparently healthy, 
predominantly white older individuals,326 relatively healthy Chinese women327 and patients 
with peripheral arterial disease.328 Additionally, endothelial flow-mediated dilation (FMD; the 
change in vessel diameter during reactive hyperaemia after cuff release), a marker of nitric 
oxide-mediated endothelial function, has been shown to be decreased in the presence of low 
serum VitD levels in patients with T2DM,329 end-stage renal disease330 and CKD.331 
Altogether, the above observational evidence points to the need for intervention trials to 
determine if there is a causative link between low VitD and poor cardiovascular health. 
Summary of RCT  
Data on the Effect of VitD Supplementation on Cardiovascular Diseases Outcomes 
Cardiovascular Events and Cardiovascular Death, BP and Large Artery Stiffness 
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A total of 45 RCTs on the effect of VitD supplementation on cardiovascular surrogate and hard 
clinical end points were identified through an English language search of PubMed and Google. 
To our knowledge, only 1 RCT has investigated the effects of VitD supplementation on hard 
clinical end points, which included incident MI, stroke and death related to coronary heart 
disease. This study randomised 36,282 postmenopausal women to 200 IU VitD plus calcium 
carbonate twice daily or placebo for 7 years and found that VitD supplementation did not 
improve cardiovascular risk.332 Importantly, this study was criticised for using a low VitD dose 
and not measuring serum VitD levels.333,334 In terms of effects on BP, some RCTs have reported 
significant improvements in brachial BP after short-term supplementation of VitD among 
participants encompassing a variety of clinical characteristics, including patients with 
hypercalcaemia335 or impaired glucose tolerance,173 patients with primary 
hyperparathyroidism,336 patients with T2DM,171,337,338 patients with elevated BP and VitD 
deficiency339 and women with VitD deficiency.165 However, the majority of RCTs have been 
ineffective in improving brachial BP in a range of populations as shown in Table 1.161-
163,166,168,174,176,340-351 Indeed, a recent individual-level meta-analysis of RCTs concluded that 
VitD was ineffective in lowering BP.352 
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Table A4.1 Effect of vitamin D supplementation on cardiovascular outcomes in randomised controlled trials in various populations 
Study [ref.], 
year 
Population (group n) 
Vitamin D 
level; in- 
clusion cri- 
teria, ng/mL 
Effect 
on 
brachial 
BP† 
Effect 
on cBP† 
Effect 
on 
cfPWV† 
Effect on 
AIx† 
Dalan et al. 
[63], 2016  
Individuals with T2DM and hypovitaminosis D (treatment = 
33, control = 31) 
<30 Null – – Increase 
Zaleski et al. 
[85], 2015 
Individuals with pre-hypertension and vitamin D deficiency 
(low dose = 22, high dose = 19) 
≤25* Null – Null Decrease 
Veloudi et al. 
[77], 2015 
Older individuals with osteoarthritis and vitamin D deficiency 
(intervention = 118, control = 123) 
<24* Null Null Null Null 
Pilz et al. 
[92], 2015 
Individuals with hypertension (intervention = 100, control = 
100) 
<30 Null –   
McGreevey et al. 
[84], 2015 
Individuals with vitamin D deficiency (low dose = 60, high 
dose = 50) 
<20* –  Null Decrease 
Gepner et al. 
[62], 2015 
Healthy postmenopausal Native American women (low dose = 
49, high dose = 49) 
<60 Null Null – Null 
Thethi et al. 
[90], 2015 
Individuals with T2DM and stage 3 or 4 CKD (treatment = 30, 
control = 30) 
No 
restrictions 
Null – – – 
Arora et al. 
[94], 2015 
Individuals with pre-hypertension or stage 1 hypertension and 
low vitamin status (low dose = 188, high dose = 175) 
≤25* Null – – – 
Witham et al. 
[95], 2014 
Patients aged >70 years with orthostatic hypotension 
(intervention = 38, control = 37) 
<30 Null – – – 
Witham et al. 
[116], 2014 
Patients with resistant hypertension (intervention = 31, control 
= 30) 
<30 Null – – – 
Scragg et al. 
[68], 2014 
Healthy adults (intervention = 161, control = 161) 
No 
restrictions 
Null – – – 
Ryu et al. 
[64], 2014 
Individuals with T2DM (intervention = 40, control = 41) <20* Null – Null Null 
Nasri et al. 
[58], 2014 
Individuals with T2DM (intervention = 30, control = 30) 
No 
restrictions 
Decrease  – – 
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Mozaffari- 
Khosravi et al. 
[59], 2015 
Patients with elevated BP and vitamin D deficiency 
(intervention = 19, control = 20) 
<30 Decrease – – – 
Martins et al. 
[75], 2014 
Overweight and obese African Americans with elevated BP 
(intervention = 65, control = 65) 
10–25* – – – Decrease 
Dreyer et al. 
[70], 2014 
Patients with CKD (intervention = 20, control = 18) <16* Null – Null – 
Yiu et al. [65], 
2013 
Individuals with T2DM (intervention = 50, control = 50) <30 Null – – – 
Witham et al. 
[96], 2013 
Older patients with isolated hypertension (intervention = 80, 
control = 79) 
<30 Null – – – 
Witham et al. 
[73], 2013 
Patients with a history of myocardial infarction (intervention = 
39, control = 36) 
No 
restrictions 
Null – – – 
Forman et al. 
[79], 2013 
Black individuals (intervention 1,000 IU/day = 68, intervention 
2,000 IU/day = 73, intervention 4,000 IU/day = 70, control = 
72) 
No 
restrictions 
Decrease‡ – – – 
Breslavsky et al. 
[66], 2013 
Individuals with T2DM (intervention = 24, control = 23) 
No 
restrictions 
Null – – Decrease 
Marckmann et al. 
[71], 2012 
CKD patients with hypovitaminosis D (intervention = 25, 
control = 24) 
<20* Null – Null Null 
Stricker et al. 
[72], 2012 
Patients with peripheral arterial disease (intervention = 31, 
control = 31) 
<30 – – – Null 
Witham et al. 
[69], 2012 
Stroke patients with well-controlled BP (intervention = 30, 
control = 28) 
<30 Null – – – 
Gepner et al. 
[61], 2012 
Postmenopausal women (intervention = 55, control = 54) <60 Null Null Null Null 
Larsen et al. 
[83], 2012 
Individuals with hypertension (intervention = 55, control = 57) 
No 
restrictions 
Null Decrease Null Null 
Witham et al. 
[57], 2010 
Individuals with T2DM (intervention 100,000 IU = 19, 
intervention 200,000 IU = 20, control = 22) 
<40 Decrease – – – 
Jorde et al. 
[76], 2010 
Overweight and obese subjects (intervention 40,000 IU = 150, 
intervention 10,000 IU = 139, control = 149) 
No 
restrictions 
Increase – – – 
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Dong et al. 
[74], 2010 
Black youth (intervention = 23, control = 21) 
No 
restrictions 
Null – Decrease – 
Daly et al. 
[78], 2009 
Men aged >50 years (intervention = 73, control = 67) 
No 
restrictions 
Null – – – 
Zittermann et al. 
[97], 2009 
Healthy overweight subjects with inadequate vitamin D status 
(intervention = 82, control = 83) 
No 
restrictions 
Null – – – 
Sugden et al. 
[56], 2008 
Individuals with T2DM and low vitamin D levels (intervention 
= 17, control = 17) 
<20* Decrease – – – 
Margolis et al. 
[93], 2008 
Postmenopausal women (intervention = 15,176, control = 
18,106) 
No 
restrictions 
Null – – – 
Pfeifer et al. 
[60], 2001 
Women with vitamin D deficiency (intervention = 74, control 
= 74) 
<20* Decrease – – – 
Scragg et al. 
[67], 1995 
Healthy adults (intervention = 95, control = 94) 
No 
restrictions 
Null  – – – 
Pan et al. 
[117], 1993 
Elderly individuals (intervention Ca = 14, intervention vitamin 
D = 14, intervention Ca + vitamin D = 15, control = 15) 
No 
restrictions 
Null – – – 
Orwoll et al. 
[98], 1990 
Normotensive men (intervention = 35, control = 30) 
No 
restrictions 
Null – – – 
Lind et al. 
[118], 1989 
Patients with essential hypertension (n = 39, allocation not 
reported) 
No 
restrictions 
Null – – – 
Lind et al. 
[55], 1988 
Patients with primary hyperparathyroidism (intervention = 15, 
control = 16) 
No 
restrictions 
Decrease – – – 
Lind et al. 
[54], 1988 
Men with impaired glucose tolerance (intervention = 33, 
control = 32) 
No 
restrictions 
Decrease – – – 
Lind et al. 
[53], 1987 
Patients with marginal, intermittent hypercalcaemia 
(intervention = 29, control = 57) 
No 
restrictions 
Decrease – – – 
cBP = central blood pressure; cfPWV = carotid-to-femoral pulse wave velocity; AIx = augmentation index; T2DM = type II diabetes mellitus. 
*Vitamin D deficiency (<25 ng/ml). †Statistically significant increase or decrease, or no change (null) with vitamin D supplementation. 
‡No longer statistically significant after adjustment for BP differences at baseline. This article is not an all-inclusive systematic review and results 
may not reflect all trials investigating the outcomes of interest.
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Organ damage is more closely associated with central BP (cBP) than brachial BP353 and, whilst 
individuals could have similar brachial systolic BP levels, central systolic BP may significantly 
differ.354 Only 1 study has shown VitD supplementation to be effective in decreasing cBP 
(Table 1),355 whereas others have shown no improvement in older individuals with 
osteoarthritis350 or among postmenopausal women.162,340 VitD supplementation was also 
ineffective in changing visit-to-visit BP variability.350 Central arterial stiffness is strongly 
associated with BP,53 and there is a need for interventions aimed at improving central arterial 
stiffness independent of BP changes. Virtually all RCTs investigating the effect of VitD 
supplementation on cfPWV reported no improvement162,342,346,347,350,355-357 apart from 1 study 
in black youths.161 The results from RCTs on AIx are more contradicting; no improvement was 
reported in the majority of studies.162,176,340,342,347,350,355 Alternatively, decreases in AIx were 
observed among patients with T2DM,344 overweight people with elevated BP,163 people with 
VitD deficiency356 and those with pre-hypertension and VitD deficiency.357 Conversely, 1 
study reported significant increases in AIx in patients with T2DM and hypovitaminosis.341 No 
improvements were reported in a small number of RCTs for carotid-radial PWV and brachial-
ankle PWV.161,163,342,343 In summary, the majority of evidence from RCTs is not supportive of 
VitD treatment for improving BP control or large artery stiffness. 
Markers of Atherosclerotic Burden and Endothelial Function 
RCTs examining markers related to atherosclerotic burden as measured by CIMT are limited. 
No improvement in CIMT was reported among postmenopausal women; however, in this trial 
the supplementation regimen contained both VitD and vitamin K.358 In terms of brachial FMD, 
improvements were reported among African Americans359 and patients with T2DM,337 whilst 
brachial FMD was improved after 8 weeks in stroke patients, but this did not persist at 16 
weeks.345 No improvements in brachial FMD were observed among patients with coronary 
artery disease,360 patients with T2DM,338,343 HIV-infected individuals361 and postmenopausal 
133 
 
women.162,362 Lastly, VitD was found to have no effect on the reactive hyphaemia index in 
patients with T2DM or after MI.341,348 Based on current evidence, VitD supplementation 
appears to be ineffective in improving CIMT or FMD. 
Critical Factors to Consider Regarding the Interpretation of RCT Data 
Adequate Sample Size 
Sample size should be adequate to determine a clinically relevant change from intervention, 
and this will vary depending on outcomes. With respect to BP, we have calculated that at least 
100 participants in each randomisation arm are needed to detect at least 4.5 mm Hg between-
group change in brachial BP or cBP.363 Figure 2 depicts RCTs in relation to their sample size 
and effectiveness of VitD treatment for cardiovascular end points. Generally, most of the 
effective trials were of a smaller sample size. Seven RCTs with an apparently appropriate 
sample size have investigated the effects of VitD on brachial BP, and from these, 6 reported 
no significant improvement.169,174,349,350,364,365 Only 1 trial reported significant BP lowering, 
and this was in a population of black individuals;166 importantly though, this effect was no 
longer significant after correcting for between-group differences in BP at baseline. We recently 
published the largest RCT investigating changes in cBP, cfPWV and AIx, which found no 
significant effects of VitD (Figure 2).350 Overall, Figure 2 shows that in the larger RCTs with 
a sample size >200, VitD has been ineffective in improving cardiovascular surrogate markers.
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Figure 2. Randomised controlled trials (RCTs) with vitamin D supplementation as the 
intervention according to sample size and the outcome in terms of effective or no effect 
on cardiovascular endpoints (reported either as primary or secondary outcomes). 
Each grey dotted circle represents a different cardiovascular end-point and the size of the circle 
is proportional to the number of RCTs for each end-point. Blue circles indicate a significant 
improvement with vitamin D supplementation (effective RCTs) and grey circles indicate RCTs 
had no significant effect on respective endpoints. Numbers above the circles represent the 
corresponding RCT reference number. bBP = brachial blood pressure; RHI = reactive 
hyperaemia index; FMD = flow-mediated dilation; DC = distensibility coefficient of the carotid 
artery; CIMT = carotid intimal medial thickness; AIx = augmentation index; crPWV = carotid-
radial pulse wave velocity; cfPWV = carotid-femoral pulse wave velocity; baPWV = brachial-
ankle pulse wave velocity; cBP = central blood pressure; BPV = visit-to-visit blood pressure 
variability. This article is not an all-inclusive systematic review and results may not reflect all 
trials investigating the outcomes of interest. 
Adequate Length of Intervention Period 
The generalizability of RCT findings must be interpreted in the context of the duration of 
intervention, given that a short-term RCT may produce results discordant with long-term 
effects. Although there is no consensus as to the minimum duration of VitD intervention for 
maximum improvements in BP, interventions of <6 months may not be adequate to modify the 
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structural characteristics of the large arteries (i.e., improving arterial stiffness independent of 
BP). The majority of the RCTs included in this review had a duration of ≤6 months (76%), 
whilst approximately half of these short-term RCTs had a duration of ≤3 months. Figure 3 
shows RCTs according to trial duration and effect of estimated monthly dose on brachial BP 
and cfPWV. Only 10 RCTs examining the effects of treatment on brachial BP had a duration 
≥12 months. Importantly, none of these longer-term RCTs observed an improvement in 
brachial BP with VitD supplementation.174,175,344,349-351,366-368  Additionally, the only longer-
term (1 year) RCT investigating the effects of VitD on cfPWV was ineffectual.350 Although 
Breslavsky et al.,344 showed an improvement in AIx after 1 year of supplementation among 
patients with T2DM, this was a small study (n = 47). Lastly, a long-term RCT (3 years) among 
postmenopausal women, with CIMT as the outcome, found no significant effects.358 When 
RCT duration is taken into account, it is clear that intervention durations >6 months have been 
ineffective in improving cardiovascular outcomes.
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Figure 3. Randomised controlled trials (RCTs) on the effect of vitamin D supplementation according to trial duration and estimated 
monthly dose on brachial blood pressure (panel A) and carotid-femoral pulse wave velocity (panel B). 
Randomised controlled trials (RCTs) on the effect of vitamin D supplementation according to trial duration and estimated monthly dose on brachial 
blood pressure (panel A) and carotid-femoral pulse wave velocity (panel B). Blue bars indicate effective RCTs (significant reduction in end points), 
and grey bars indicate RCTs that had no effect on end points. Black dotted horizontal line indicates adequate dose to raise serum vitamin D levels 
above deficiency levels. Black dotted vertical line indicates RCT duration of 6 months. Monthly dose was calculated using the highest dose if there 
was more than 1 vitamin D supplementation group. IU, international units. * Vitamin D2 supplementation. 
† Vitamin D plus calcium. ‡ Single dose. 
§ Vitamin D/calcium-fortified milk.
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Baseline VitD Level 
A series of rules regarding optimal design of RCTs examining nutrient effects has recently 
been introduced.369 Rule 1 states that individuals with low baseline nutrient levels should be 
recruited. This is based on the pharmacological dose-response curve of nutrient intake; if 
baseline nutrient levels are deficient, then an increase in these levels is expected to produce a 
clinically meaningful and measurable effect on outcomes, whereas if baseline levels are within 
optimal ranges, then a further increase will produce no significant effects. Conversely, if 
baseline levels are high, then intervention could cause adverse effects due to toxicity. Overall, 
among the 45 RCTs included in this review, only 27% (n = 12) included patients with VitD 
deficiency (defined as <25 ng/ml; according to Mayo Medical Laboratories reference 
ranges).370 The remaining 73% of studies placed no restrictions on baseline serum VitD levels 
or included a combination of deficient and non-deficient participants (i.e., <30,<40 or <60 
ng/ml), which could confound the results. Among the RCTs that included VitD-deficient 
participants and investigated the effects on brachial BP (n = 8), 6 had no significant 
effects342,346,347,350,357,365 and 2 (very short-term; ≤3 months) trials reported an improvement in 
brachial BP165,337 (Table 1). None of the RCTs appropriately addressing rule 1 found a 
significant effect on cfPWV,342,346,347,350,356,357 carotid-radial PWV163 or brachial-ankle 
PWV.342 With respect to AIx, among the trials that have recruited VitD-deficient participants, 
2 short-term RCTs showed an improvement,163,356 2 RCTs with longer duration failed to find 
significant effects342,350 and 1 RCT reported a paradoxical increase in AIx among individuals 
with T2DM.341 FMD was improved in 1 RCT, 8 weeks after a single oral VitD dose,337 but was 
not improved in 2 RCTs meeting rule 1.360,361 In brief, VitD interventions that have recruited 
VitD-deficient participants generally failed to show significant treatment effects. 
Adequate VitD Dose 
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Rules 2 and 3 of Heaney369 require that the intervention dosage should be sufficient to change 
nutrient status (from deficient levels at baseline to sufficient levels at follow-up) and that the 
change in nutrient status must be reported. All (n = 12) but 1 RCT357 that recruited VitD-
deficient subjects were effective in increasing average VitD levels above deficiency, and all 
these RCTs reported the changes in serum VitD levels. In order to change baseline VitD levels 
from being deficient at baseline to being sufficient at follow-up, the dose of VitD should be 
adequate to raise serum VitD. Supplementation of 1,000--2,000 IU or lower, taken once or 
twice weekly (which translates to approximately 8,000--16,000 IU/month), has been shown to 
be insufficient for raising plasma 25-hydroxyvitamin D levels (the most objective biomarker 
for VitD nutritional adequacy)371 higher than those of individuals who are not taking VitD 
supplements.372 It is recommended that the VitD dose should be at least 50,000 IU/month in 
order to successfully raise baseline (deficient) serum VitD levels above 30 ng/mL (75 nmol/L; 
the lowest sufficient threshold).373 Importantly, these recommendations are based on 
expectations for improving skeletal health outcomes and may not be relevant to cardiovascular 
related outcomes. Nonetheless, Figure 6. 3 shows clearly that irrespective of the dose, the 
majority of RCTs failed to improve brachial BP or cfPWV. 
Rule 4 aims to ensure that the effect of a trial is a result of the change in the nutrient from the 
study intervention rather than a change in the diet. Although all 12 RCTs that met rules 1--3 
reported changes in serum VitD levels, they did not state whether other steps were employed 
in order to monitor and adjust for issues related to adherence, such as variations in individual 
VitD absorption, changes in diet or other conditions that may have affected the change in serum 
VitD levels (i.e., physical activity, obesity or amount of exposure to sunlight).192,193 Rule 5 
considers confounding effects induced by changes in co-nutrient levels known to affect the 
outcomes (i.e., changes in serum calcium levels are monitored so that results are not biased by 
confounding effects). Among RCTs meeting rule 1--3, 7 studies monitored calcium and 
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phosphorous levels but did not adjust the final results for the changes in calcium levels. None 
of the RCTs meeting rules 1--3 adjusted the final outcomes for changes in these factors. Thus, 
it cannot be excluded that the results from RCTs that met rules 1--3 may have been confounded 
by significant uncontrolled factors influencing nutrient status. 
High-Risk Populations 
The interpretation of RCTs may also be complicated by the selection of individuals without a 
high-risk profile in terms of cardiovascular disease or VitD deficiency. Table 1 shows the effect 
of VitD interventions on brachial and cBP, cfPWV and AIx in various populations. It can be 
seen that VitD is ineffective in improving cardiovascular health, irrespective of the population 
risk profile. Further examination among those RCTs meeting rules 1--3 as per Heaney369 shows 
that VitD supplementation is ineffective in VitD-deficient individuals with pre-hypertension, 
hypertension, T2DM or CKD. Our own work found that VitD supplementation was not 
beneficial among older individuals with VitD deficiency and osteoarthritis, a condition 
associated with increased cardiovascular   a population enriched with vascular risk factors that 
should be most amenable to benefit from treatment. 
Systematic Reviews and Meta-Analyses 
Several systematic reviews concluded that VitD supplementation does not have a significant 
effect on systolic BP (included RCTs: n = 46;352 n = 8;374 n = 10;375 n = 16),376 whilst a small 
meta-analysis of 4 RCTs showed evidence of a statistically significant effect on systolic BP,377 
and others showed a statistically significant effect on diastolic BP (included RCTs: n = 8;374  n 
= 15;378 n = 16)379. At the same time, recent systematic reviews and meta-analyses concluded 
that VitD has no effect on markers of arterial stiffness (included RCTs: n = 7;380 n = 13)381 or 
markers of endothelial function (included RCTs: n = 16).379 In alignment with this narrative 
review, almost all of the published systematic reviews highlight the significant methodological 
140 
 
heterogeneity in terms of dose and duration of treatment, which limits the interpretation of the 
findings and raises the need for a critical appraisal, over and beyond the reported results. 
Although some systematic reviews have used criteria to establish the quality of study design 
(i.e., allocation concealment, blinding, baseline comparability of groups, description of 
dropouts and intention-to-treat analysis), none of them have pooled the data according to the 
guidelines by Heaney.369 Nevertheless, sensitivity analyses among the above analyses looking 
separately at either the effect of dose or duration of supplementation or baseline VitD status 
did not alter the null-effect findings.352,379,381 
Conclusions 
In summary, after consideration of the discrepancies in the study design of RCTs (i.e., sample 
size, duration of supplementation, selection of VitD-deficient subjects, VitD dose and 
population under investigation), VitD supplementation appears to be ineffective in improving 
brachial BP, large artery stiffness or central haemodynamics. This conclusion, though, cannot 
be generalised to other forms of contributions to endogenous VitD. The lack of evidence from 
large-scale RCTs with a priori primary measures of cardiovascular disease does not exclude 
the possibility of small but yet clinically meaningful VitD effects. Several large-scale RCTs in 
general populations (n >18,000; duration of 5 years) are underway and should provide a more 
definite answer to this question.204 Despite a lack of large and long-term studies investigating 
atherosclerotic burden and endothelial function markers, evidence from RCTs also contradicts 
observational data that support a role of VitD in improving these markers. Thus, this review 
supports the notion that the inverse associations seen in observational studies between low 
VitD levels and cardiovascular end points are likely to be epiphenomena rather than true cause-
and-effect relationships. 
 
141 
 
References 
1. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of 
variability, instability, and episodic hypertension. Lancet 2010;375:938-48. 
2. Mancia G. Short- and long-term blood pressure variability: present and future. 
Hypertension 2012;60:512-7. 
3. Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-
pressure variability. Nat Rev Cardiol 2013;10:143-55. 
4. Juhanoja EP, Niiranen TJ, Johansson JK, et al. Outcome-Driven Thresholds for 
Increased Home Blood Pressure Variability. Hypertension 2017. 
5. Wang J, Shi X, Ma C, et al. Visit-to-visit blood pressure variability is a risk factor for 
all-cause mortality and cardiovascular disease: a systematic review and meta-analysis. J 
Hypertens 2017;35:10-7. 
6. Fukui M, Ushigome E, Tanaka M, et al. Home blood pressure variability on one 
occasion is a novel factor associated with arterial stiffness in patients with type 2 diabetes. 
Hypertens Res 2013;36:219-25. 
7. Satoh M, Hosaka M, Asayama K, et al. Association between N-terminal pro B-type 
natriuretic peptide and day-to-day blood pressure and heart rate variability in a general 
population: the Ohasama study. J Hypertens 2015;33:1536-41. 
8. Sohn MW, Epstein N, Huang ES, et al. Visit-to-visit systolic blood pressure 
variability and microvascular complications among patients with diabetes. J Diabetes 
Complications 2017;31:195-201. 
9. Chia YC, Lim HM, Ching SM. Long-Term Visit-to-Visit Blood Pressure Variability 
and Renal Function Decline in Patients With Hypertension Over 15 Years. J Am Heart Assoc 
2016;5:e003825. 
142 
 
10. Muntner P, Levitan EB. Visit-to-visit variability of blood pressure: current knowledge 
and future research directions. Blood Press Monit 2013;18:232-8. 
11. Stergiou GS, Ntineri A, Kollias A, Ohkubo T, Imai Y, Parati G. Blood pressure 
variability assessed by home measurements: a systematic review. Hypertens Res 
2014;37:565-72. 
12. Anderson S, Allen P, Peckham S, Goodwin N. Asking the right questions: scoping 
studies in the commissioning of research on the organisation and delivery of health services. 
Health Res Policy Syst 2008;6:7. 
13. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J 
Soc Res Methodol 2005;8:19-32. 
14. Diehl HS, Lees HD. The variability of blood pressure: Ii. a study of systolic pressure 
at five minute intervals. Arch Intern Med 1929;44:229-37. 
15. Rothwell PM, Howard SC, Dolan E, et al. Effects of beta blockers and calcium-
channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet 
Neurol 2010;9:469-80. 
16. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit 
variability, maximum systolic blood pressure, and episodic hypertension. Lancet 
2010;375:895-905. 
17. Head GA, McGrath BP, Mihailidou AS, et al. Ambulatory blood pressure monitoring 
in Australia: 2011 consensus position statement. J Hypertens 2012;30:253-66. 
18. di Rienzo M, Grassi G, Pedotti A, Mancia G. Continuous vs intermittent blood 
pressure measurements in estimating 24-hour average blood pressure. Hypertension 
1983;5:264-9. 
19. Hypertension: Clinical management of primary hypertension in adults. National 
Institute for Health and Care Excellence 2011. (Accessed 10/06/2015, at 
143 
 
http://www.nice.org.uk/guidance/cg127/chapter/1-recommendations#measuring-blood-
pressure.) 
20. Asayama K, Wei FF, Hara A, Hansen TW, Li Y, Staessen JA. Prognosis in relation to 
blood pressure variability: con side of the argument. Hypertension 2015;65:1170-9. 
21. Mancia G, Verdecchia P. Clinical value of ambulatory blood pressure: evidence and 
limits. Circ Res 2015;116:1034-45. 
22. Cicconetti P, Cacciafesta M, Migliori M, et al. Influence of sex and age on blood 
pressure variability. Arch Gerontol Geriatr 2000;30:225-36. 
23. Goldstein I. A 5-year follow-up of ambulatory blood pressure in healthy older adults - 
blood pressure variability & age. Am J Hypertens 2003;16:640-5. 
24. Zakopoulos NA, Tsivgoulis G, Barlas G, et al. Time rate of blood pressure variation is 
associated with increased common carotid artery intima-media thickness. Hypertension 
2005;45:505-12. 
25. Whittle J. Blood Pressure Variability Predicts Clinical Outcomes Now What? 
Hypertension 2017;69:Epub ahead of print. 
26. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability, 
carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on 
Atherosclerosis. Circulation 2012;126:569-78. 
27. Tao Y, Xu J, Song B, et al. Short-term blood pressure variability and long-term blood 
pressure variability: which one is a reliable predictor for recurrent stroke. J Hum Hypertens 
2017;Epub ahead of print. 
28. Levitan EB, Kaciroti N, Oparil S, Julius S, Muntner P. Blood pressure measurement 
device, number and timing of visits, and intra-individual visit-to-visit variability of blood 
pressure. J Clin Hypertens 2012;14:744-50. 
144 
 
29. Yokota K, Fukuda M, Matsui Y, Hoshide S, Shimada K, Kario K. Impact of visit-to-
visit variability of blood pressure on deterioration of renal function in patients with non-
diabetic chronic kidney disease. Hypertens Res 2013;36:151-7. 
30. Kawai T, Ohishi M, Ito N, et al. Alteration of vascular function is an important factor 
in the correlation between visit-to-visit blood pressure variability and cardiovascular disease. 
J Hypertens 2013;31:1387-95; discussion 95. 
31. Levitan EB, Kaciroti N, Oparil S, Julius S, Muntner P. Relationships between metrics 
of visit-to-visit variability of blood pressure. J Hum Hypertens 2013;27:589-93. 
32. Wong TY, Klein R, Klein BE, Tielsch JM, Hubbard L, Nieto FJ. Retinal 
microvascular abnormalities and their relationship with hypertension, cardiovascular disease, 
and mortality. Surv Ophthalmol 2001;46:59-80. 
33. Wong TY. Retinal vessel diameter as a clinical predictor of diabetic retinopathy 
progression: time to take out the measuring tape. Arch Ophthalmol 2011;129:95-6. 
34. Wong T, Mitchell P. The eye in hypertension. The Lancet 2007;369:425-35. 
35. Nguyen TT, Wang JJ, Sharrett AR, et al. Relationship of retinal vascular caliber with 
diabetes and retinopathy: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 
2008;31:544-9. 
36. Kim YS, Immink RV, Stok WJ, Karemaker JM, Secher NH, van Lieshout JJ. 
Dynamic cerebral autoregulatory capacity is affected early in Type 2 diabetes. Clin Sci 
(Lond) 2008;115:255-62. 
37. Klein R, Klein B, Moss S, Wong T, Sharrett A. Retinal Vascular Caliber in Persons 
with Type 2 Diabetes The Wisconsin Epidemiological Study of Diabetic Retinopathy: XX. 
Ophthalmology 2006;113:1488-98. 
145 
 
38. Harrison WW, Chang A, Cardenas MG, et al. Blood pressure, vessel caliber, and 
retinal thickness in diabetes. Optometry and vision science : official publication of the 
American Academy of Optometry 2012;89:1715-20. 
39. Parati G, Ochoa JE, Lombardi C, Bilo G. Blood pressure variability: assessment, 
predictive value, and potential as a therapeutic target. Curr Hypertens Rep 2015;17:537. 
40. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic 
syndrome: a pathway to cardiovascular disease. Diabetologia 2008;51:527-39. 
41. Valensi P, Paries J, Attali JR, French Group for R, Study of Diabetic N. Cardiac 
autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and 
microangiopathic complications - the French multicenter study. Metabolism 2003;52:815-20. 
42. Climie RE, Srikanth V, Keith LJ, Davies JE, Sharman JE. Exercise excess pressure 
and exercise-induced albuminuria in patients with type 2 diabetes mellitus. Am J Physiol 
Heart Circ Physiol 2015;308:H1136-42. 
43. Chapman N, Witt N, Gao X, et al. Computer algorithms for the automated 
measurement of retinal arteriolar diameters. Br J Ophthalmol 2001;85:74-9. 
44. Zakopoulos NA, Tsivgoulis G, Barlas G, et al. Impact of the time rate of blood 
pressure variation on left ventricular mass. J Hypertens 2006;24:2071-7. 
45. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the 
management of arterial hypertension: the Task Force for the management of arterial 
hypertension of the European Society of Hypertension (ESH) and of the European Society of 
Cardiology (ESC). J Hypertens 2013;31:1281-357. 
46. Diaz KM, Tanner RM, Falzon L, et al. Visit-to-visit variability of blood pressure and 
cardiovascular disease and all-cause mortality: a systematic review and meta-analysis. 
Hypertension 2014;64:965-82. 
146 
 
47. Palatini P, Reboldi G, Beilin LJ, et al. Added predictive value of night-time blood 
pressure variability for cardiovascular events and mortality: the Ambulatory Blood Pressure-
International Study. Hypertension 2014;64:487-93. 
48. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability 
in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of 
antihypertensive treatment. J Hypertens 2012;30:1241-51. 
49. Johansson JK, Niiranen TJ, Puukka PJ, Jula AM. Prognostic value of the variability in 
home-measured blood pressure and heart rate: the Finn-Home Study. Hypertension 
2012;59:212-8. 
50. Asayama K, Schutte R, Li Y, Hansen TW, Staessen JA. Blood pressure variability in 
risk stratification: What does it add? Clin Exp Pharmacol Physiol 2014;41:1-8. 
51. Parati G, Ochoa J, Bilo G. Blood Pressure Variability: Methodological Aspects, 
Physiology, and Clinical Implications. In: Parati G, Ochoa J, Bilo G, eds. Manual of 
Hypertension of the European Society of Hypertension. 2nd ed2014:73-91. 
52. Bliziotis IA, Destounis A, Stergiou GS. Home versus ambulatory and office blood 
pressure in predicting target organ damage in hypertension: a systematic review and meta-
analysis. J Hypertens 2012;30:1289-99. 
53. Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk 
factors for cardiovascular disease other than hypertension: a systematic review. Hypertension 
2009;54:1328-36. 
54. Sharman JE, Marwick TH, Abhayaratna WP, Stowasser M. Rationale and design of a 
randomized study to determine the value of central Blood Pressure for GUIDing 
managEment of hypertension: the BP GUIDE study. Am Heart J 2012;163:761-7. 
147 
 
55. Jenkins C, Bricknell K, Hanekom L, Marwick TH. Reproducibility and accuracy of 
echocardiographic measurements of left ventricular parameters using real-time three-
dimensional echocardiography. J Am Coll Cardiol 2004;44:878-86. 
56. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber 
quantification: a report from the American Society of Echocardiography's Guidelines and 
Standards Committee and the Chamber Quantification Writing Group, developed in 
conjunction with the European Association of Echocardiography, a branch of the European 
Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63. 
57. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial 
stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588-605. 
58. Nikolic SB, Abhayaratna WP, Leano R, Stowasser M, Sharman JE. Waiting a few 
extra minutes before measuring blood pressure has potentially important clinical and research 
ramifications. J Hum Hypertens 2014;28:56-61. 
59. El Assaad MA, Topouchian JA, Darne BM, Asmar RG. Validation of the Omron 
HEM-907 device for blood pressure measurement. Blood Press Monit 2002;7:237-41. 
60. Rogoza AN, Pavlova TS, Sergeeva MV. Validation of A&D UA-767 device for the 
self-measurement of blood pressure. Blood Press Monit 2000;5:227-31. 
61. Palatini P, Frigo G, Bertolo O, Roman E, Da Corta R, Winnicki M. Validation of the 
A&D TM-2430 device for ambulatory blood pressure monitoring and evaluation of 
performance according to subjects' characteristics. Blood Press Monit 1998;3:255-60. 
62. Boley E, Pickering TG, James GD, de Simone G, Roman MJ, Devereux RB. 
Relations of ambulatory blood pressure level and variability to left ventricular and arterial 
function and to left ventricular mass in normotensive and hypertensive adults. Blood Press 
Monit 1997;2:323-31. 
148 
 
63. Schillaci G, Verdecchia P, Borgioni C, Ciucci A, Porcellati C. Lack of association 
between blood pressure variability and left ventricular mass in essential hypertension. Am J 
Hypertens 1998;11:515-22. 
64. Kristensen KS, Hoegholm A, Bang LE, Gustavsen PH, Poulsen CB. No impact of 
blood pressure variability on microalbuminuria and left ventricular geometry: analysis of 
daytime variation, diurnal variation and 'white coat' effect. Blood Press Monit 2001;6:125-31. 
65. Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Relation of blood 
pressure variability to carotid atherosclerosis and carotid artery and left ventricular 
hypertrophy. Arterioscler Thromb Vasc Biol 2001;21:1507-11. 
66. Wei FF, Li Y, Zhang L, et al. Beat-to-beat, reading-to-reading, and day-to-day blood 
pressure variability in relation to organ damage in untreated Chinese. Hypertension 
2014;63:790-6. 
67. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour 
blood pressure variability. J Hypertens 1993;11:1133-7. 
68. Vishram JK, Dahlof B, Devereux RB, et al. Blood pressure variability predicts 
cardiovascular events independently of traditional cardiovascular risk factors and target organ 
damage: a LIFE substudy. J Hypertens 2015. 
69. Veerman DP, de Blok K, van Montfrans GA. Relationship of steady state and 
ambulatory blood pressure variability to left ventricular mass and urinary albumin excretion 
in essential hypertension. Am J Hypertens 1996;9:455-60. 
70. Ozawa M, Tamura K, Okano Y, et al. Blood pressure variability as well as blood 
pressure level is important for left ventricular hypertrophy and brachial-ankle pulse wave 
velocity in hypertensives. Clin Exp Hypertens 2009;31:669-79. 
149 
 
71. Tatasciore A, Zimarino M, Tommasi R, et al. Increased short-term blood pressure 
variability is associated with early left ventricular systolic dysfunction in newly diagnosed 
untreated hypertensive patients. J Hypertens 2013;31:1653-61. 
72. Tatasciore A, Renda G, Zimarino M, et al. Awake systolic blood pressure variability 
correlates with target-organ damage in hypertensive subjects. Hypertension 2007;50:325-32. 
73. Sega R, Corrao G, Bombelli M, et al. Blood pressure variability and organ damage in 
a general population - Results from the PAMELA study. Hypertension 2002;39:710-4. 
74. Schillaci G, Bilo G, Pucci G, et al. Relationship between short-term blood pressure 
variability and large-artery stiffness in human hypertension: findings from 2 large databases. 
Hypertension 2012;60:369-77. 
75. Webb AJS, Rothwell PM. Physiological Correlates of Beat-to-Beat, Ambulatory, and 
Day-to-Day Home Blood Pressure Variability After Transient Ischemic Attack or Minor 
Stroke. Stroke 2014;45:533-8. 
76. Song H, Wei F, Liu Z, et al. Visit-to-visit variability in systolic blood pressure: 
correlated with the changes of arterial stiffness and myocardial perfusion in on-treated 
hypertensive patients. Clinical and Experinmental Hypertension 2015;37:63-9. 
77. Martinka P, Patzak A, Stauss HM, Persson PB. Enhanced blood pressure variability 
activates mechanical stress pathways in the left ventricles of normotensive mice. FASEB J 
2004;18:A1303-A. 
78. Martinka P, Fielitz J, Patzak A, Regitz-Zagrosek V, Persson PB, Stauss HM. 
Mechanisms of blood pressure variability-induced cardiac hypertrophy and dysfunction in 
mice with impaired baroreflex. Am J Physiol Regul Integr Comp Physiol 2005;288:R767-76. 
79. Webb AJ, Rothwell PM. Blood pressure variability and risk of new-onset atrial 
fibrillation: a systematic review of randomized trials of antihypertensive drugs. Stroke 
2010;41:2091-3. 
150 
 
80. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the 
management of arterial hypertension: the Task Force for the management of arterial 
hypertension of the European Society of Hypertension (ESH) and of the European Society of 
Cardiology (ESC). J Hypertens 2013;31:1281-357. 
81. Hodgkinson J, Mant J, Martin U, et al. Relative effectiveness of clinic and home 
blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis 
of hypertension: systematic review. Brit Med J 2011;342:d3621. 
82. Jones D, Appel LJ, Sheps SG, Roccella EJ, Lenfant C. Measuring Blood Pressure 
Accurately. New and Persistent Challenges. JAMA 2003;289:1027-9. 
83. Jones D, Lenfant C, Appel LJ, et al. National Heart, Lung, and Blood 
Institute/American Heart Association.  Working Meeting on Blood Pressure Measurement: 
Summary Report. Natcher Conference Center National Institutes of Health (NIH) Bethesda, 
Maryland2002. 
84. Hackam DG, Quinn RR, Ravani P, et al. The 2013 Canadian Hypertension Education 
Program recommendations for blood pressure measurement, diagnosis, assessment of risk, 
prevention, and treatment of hypertension. Can J Cardiol 2013;29:528-42. 
85. Daskalopoulou SS, Rabi DM, Zarnke KB, et al. The 2015 Canadian Hypertension 
Education Program recommendations for blood pressure measurement, diagnosis, assessment 
of risk, prevention, and treatment of hypertension. Can J Cardiol 2015;31:549-68. 
86. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 
Hypertension 2003;42:1206-52. 
87. Gabb GM, Mangoni AA, Anderson CS, et al. Guideline for the diagnosis and 
management of hypertension in adults - 2016. Med J Aust 2016;205:85-9. 
151 
 
88. Parati G, Ochoa JE, Lombardi C, Bilo G. Blood pressure variability: assessment, 
predictive value, and potential as a therapeutic target. Curr Hypertens Rep 2015;17:537. 
89. Charkoudian N, Rabbitts AJ. Sympathetic Neural Mechanisms in Human 
Cardiovascular Health and Disease. Mayo Clin Proc 2009;84:822-30. 
90. Schulze BM, Kroke A, Bergmann MM, Boeing H. Differences of blood pressure 
estimates between consecutive measurements on one occasion: Implications for inter-study 
comparability of epedimiological studies. Eur J Epidemiol 2000;16:891-8. 
91. Shin JH, Shin J, Kim BK, et al. Within-visit blood pressure variability: relevant 
factors in the general population - age - TITLE CHANGED! J Hum Hypertens 2013;27:328-
34. 
92. Grassi G, Seravalle G, Maloberti A, et al. Within-visit BP variability, cardiovascular 
risk factors, and BP control in central and eastern Europe: findings from the BP-CARE study. 
J Hypertens 2015;33:2250-6. 
93. Marshall T. Misleading measurements: modeling the effects of blood pressure 
misclassification in a United States population. Med Decis Making 2006;26:624-32. 
94. Marshall T. When measurements are misleading: modelling the effects of blood 
pressure misclassification in the English population. Brit Med J 2004:328-933. 
95. Australian Health Survey: Users' Guide, 2011-13. Australian Bureau of Statistics, 
2013. (Accessed 14/08/2015, at 
http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4363.0.55.001Chapter1102011-13.) 
96. Australian Health Survey: Updated Results, 2011-2012. Australian Bureau of 
Statistics, 2013. (Accessed 14/08/2015, at 
http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/4364.0.55.003Explanatory%20Notes1
2011-2012?OpenDocument.) 
152 
 
97. Franklin SS, Gustin Wt, Wong ND, et al. Hemodynamic patterns of age-related 
changes in blood pressure. The Framingham Heart Study. Circulation 1997;96:308-15. 
98. Bonso E, Ragazzo F, Palatini P. Validation of A&D UA-85X device for blood 
pressure measurement. Blood Press Monit 2008;13:339-41. 
99. Australian Health Survey: Users' Guide, 2011-13. Blood Pressure. Australian Bureau 
of Statistics, 2013. (Accessed 14/08/2015, at 
http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4363.0.55.001Chapter4202011-13.) 
100.  Australian Health Survey: Users' Guide, 2011-13. Health Conditions. Australian 
Bureau of Statistics, 2013. (Accessed 14/08/2015, at 
http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4363.0.55.001Chapter3002011-13.) 
101. International Statistical Classification of Diseases and Related Health Problems 10th 
Revision. World Health Organisation, 2010. (Accessed 14/08/2015, at 
http://apps.who.int/classifications/icd10/browse/2010/en.) 
102. Australian Health Survey: Users' Guide, 2011-13. Use of Medications. Australian 
Bureau of Statistics, 2013. (Accessed 12/10/2015, 2015, at 
http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4363.0.55.001Chapter5302011-13.) 
103. O'Brien E. Why Is It That We Continue to Deny Patients Ambulatory Blood Pressure 
Monitoring? Hypertension 2016;67:484-7. 
104. Sharman JE, Howes FS, Head GA, et al. Home blood pressure monitoring: Australian 
Expert Consensus Statement. J Hypertens 2015;33:1721-8. 
105. van der Wel MC, Buunk IE, van Weel C, Thien TA, Bakx JC. A novel approach to 
office blood pressure measurement: 30-minute office blood pressure vs daytime ambulatory 
blood pressure. Ann Fam Med 2011;9:128-35. 
153 
 
106. Scherpbier-de Haan N, van der Wel M, Schoenmakers G, et al. Thirty-minute 
compared to standardised office blood pressure measurement in general practice. Brit J Gen 
Pract 2011;61:e590-7. 
107. Charkoudian N, Joyner MJ, Johnson CP, Eisenach JH, Dietz NM, Wallin BG. 
Balance between cardiac output and sympathetic nerve activity in resting humans: role in 
arterial pressure regulation. J Physiol 2005;568:315-21. 
108. Shi X, Huang G, Smith SA, Zhang R, Formes KJ. Aging and Arterial Blood Pressure 
Variability during Orthostatic Challenge. Gerontology 2003;49:279-86. 
109. Vianna CL, Hart CE, Fairfax TS, Charkoudian N, Joyner JM, Paul. FJ. Influence of 
age and sex on the pressor response following a spontaneous burst of muscle sympathetic 
nerve activity. Am J Physiol Heart Circ Physiol 2012;302:H2419–H27. 
110. Laitinen T, Niskanen L, Geelen C, Lansimies E, Hartikainen J. Age dependency of 
cardiovascular autonomic responses to head-up tilt in healthy subjects. J Appl Physiol 
2004;96:2333-40. 
111. Pandian JD, Dalton K, Scott J, Read SJ, Henderson RD. Cardiovascular autonomic 
function tests to provide normative data from a healthy older population. J Clin Neurosci 
2010;17:731-5. 
112. Taylor JA, Tan CO. BP regulation VI: elevated sympathetic outflow with human 
aging: hypertensive or homeostatic? Eur J Appl Physiol 2014;114:511-9. 
113. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Kaczorowski J. Measurement 
of blood pressure in the office: recognizing the problem and proposing the solution. 
Hypertension 2009;55:195-200. 
114. Mancia G, Parati G, Pomidossi G, Grassi G, Casadei R, Zanchetti A. Alerting 
Reaction and Rise in Blood Pressure During Measurement by Physician and Nurse. 
Hypertension 1987;9:209-15. 
154 
 
115. Clark CE, Taylor RS, Shore AC, Ukoumunne OC, Campbell JL. Association of a 
difference in systolic blood pressure between arms with vascular disease and mortality: a 
systematic review and meta-analysis. The Lancet 2012;379:905-14. 
116. Munter P, He J, Cutler JA, Wildman RP, Whelton PK. Trend in Blood Pressure 
Among Children and Adolescents. JAMA 2004;291:2133. 
117. Falkner B, Gidding SS, Portman R, Rosner B. Blood pressure variability and 
classification of prehypertension and hypertension in adolescence. Pediatrics 2008;122:238-
42. 
118. Aatola H, Hutri-Kahonen N, Juonala M, et al. Lifetime risk factors and arterial pulse 
wave velocity in adulthood: the cardiovascular risk in young Finns study. Hypertension 
2010;55:806-11. 
119. Hanevold C, Waller J, Daniels S, Portman R, Sorof J, International Pediatric 
Hypertension A. The effects of obesity, gender, and ethnic group on left ventricular 
hypertrophy and geometry in hypertensive children: a collaborative study of the International 
Pediatric Hypertension Association. Pediatrics 2004;113:328-33. 
120. McNiece KL, Gupta-Malhotra M, Samuels J, et al. Left ventricular hypertrophy in 
hypertensive adolescents: analysis of risk by 2004 National High Blood Pressure Education 
Program Working Group staging criteria. Hypertension 2007;50:392-5. 
121. Sorof JM, Alexandrov AV, Cardwell G, Portman RJ. Carotid artery intimal-medial 
thickness and left ventricular hypertrophy in children with elevated blood pressure. Pediatrics 
2003;111:61-6. 
122. Berenson GS, Wattigney WA, Tracy RE, et al. Atherosclerosis of the aorta and 
coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at 
necropsy (The Bogalusa Heart Study). Am J Cardiol 1992;70:851-8. 
155 
 
123. McGill HC, Jr., McMahan CA, Malcom GT, Oalmann MC, Strong JP. Relation of 
glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological Determinants of 
Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 
1995;15:431-40. 
124. Mitchell P, Cheung N, de Haseth K, et al. Blood pressure and retinal arteriolar 
narrowing in children. Hypertension 2007;49:1156-62. 
125. Chiolero A, Bovet P, Paradis G. Screening for elevated blood pressure in children and 
adolescents: a critical appraisal. JAMA Pediatr 2013;167:266-73. 
126. Rosner B, Cook NR, Evans DA, et al. Reproducibility and predicitve values of routine 
blood pressure measurements in children. Am J Epidemiol 1987;126:1115-25. 
127. Moyer VA. Screening for Primary Hypertension in Children and Adolescents: U.S. 
Preventive Services Task Force Recommendation Statement. An Intern Med 2013;159:613-9. 
128. Eliasdottir SB, Steinthorsdottir SD, Indridason OS, Palsson R, Edvardsson VO. 
Comparison of aneroid and oscillometric blood pressure measurements in children. J Clin 
Hypertens (Greenwich) 2013;15:776-83. 
129. Flynn JT. Assessment of blood pressure in children: it's all in the details. J Clin 
Hypertens (Greenwich) 2013;15:772-3. 
130. Falkner B, Daniels SR. Summary of the Fourth Report on the Diagnosis, Evaluation, 
and Treatment of High Blood Pressure in Children and Adolescents. Hypertension 
2004;44:387-8. 
131. Veloudi P, Blizzard CL, Srikanth V, Breslin M, Sharman JE. Age-dependent changes 
in blood pressure over consecutive office measurements: impact on hypertension diagnosis 
and implications for international guidelines. J Hypertens 2017;35:753-60. 
156 
 
132. Australian Health Survey: Users' Guide, 2011-13. Australian Bureau of Statistics, 
2013. (Accessed 14/08/2015, at 
http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4363.0.55.001Chapter1102011-13.) 
133. Australian Health Survey: Users' Guide, 2011-13. Australian Bureau of Statistics, 
2013. (Accessed 14/08/2015, at 
http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4363.0.55.001Chapter4302011-13.) 
134. Waist Circumference  and Waist-Hip Ratio. World Health Organisation, 2008. 
(Accessed 14/08/2015, at 
http://apps.who.int/iris/bitstream/10665/44583/1/9789241501491_eng.pdf?ua=1.) 
135. Clinical Growth Charts. 2000. (Accessed 12 Dec, 2015, at 
http://www.cdc.gov/growthcharts/clinical_charts.htm.) 
136. National High Blood Pressure Education Program Working Group on High Blood 
Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and 
Treatment of High Blood Pressure in Children and Adolescents. 2004;114:555. 
137. Negroni-Balasquide X, Bell CS, Samuel J, Samuels JA. Is one measurement enough 
to evaluate blood pressure among adolescents? A blood pressure screening experience in 
more than 9000 children with a subset comparison of auscultatory to mercury measurements. 
J Am Soc Hypertens 2016;10:95-100. 
138. Kawabe H, Saito I, Saruta T. Influence of repeated measurement on one occasion, on 
successive days, and on workdays on home blood pressure values. Clin Exp Hypertens 
2005;27:215-22. 
139. Woroniecki RP, Flynn JT. How are hypertensive children evaluated and managed? A 
survey of North American pediatric nephrologists. Pediatric nephrology 2005;20:791-7. 
157 
 
140. Jafar TH, Islam M, Poulter N, et al. Children in South Asia have higher body mass-
adjusted blood pressure levels than white children in the United States: a comparative study. 
Circulation 2005;111:1291-7. 
141. Papandreou D, Stamou M, Malindretos P, Rousso I, Mavromichalis I. Prevalence of 
hypertension and association of dietary mineral intake with blood pressure in healthy 
schoolchildren from northern Greece aged 7-15 years. Ann Nutr Metab 2007;51:471-6. 
142. de Moraes AC, Carvalho HB, Siani A, et al. Incidence of high blood pressure in 
children - effects of physical activity and sedentary behaviors: the IDEFICS study: High 
blood pressure, lifestyle and children. Int J Cardiol 2015;180:165-70. 
143. Dong B, Wang Z, Song Y, Wang HJ, Ma J. Understanding trends in blood pressure 
and their associations with body mass index in Chinese children, from 1985 to 2010: a cross-
sectional observational study. BMJ open 2015;5:e009050. 
144. Monyeki KD, Kemper HC, Makgae PJ. Relationship between fat patterns, physical 
fitness and blood pressure of rural South African children: Ellisras Longitudinal Growth and 
Health Study. J Hum Hypertens 2008;22:311-9. 
145. Chiolero A, Cachat F, Burnier M, Paccaud F, Bovet P. Prevalence of hypertension in 
schoolchildren based on repeated measurements and association with overweight. J 
Hypertens 2007;25:2209-17. 
146. Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and 
the prevalence of hypertension in school-aged children. Pediatrics 2004;113:475-82. 
147. McNiece KL, Poffenbarger TS, Turner JL, Franco KD, Sorof JM, Portman RJ. 
Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr 2007;150:640-
4, 4 e1. 
158 
 
148. Kagura J, Adair SL, Pisa TP, Griffiths LP, Pettitor MJ, Norris AS. Assocation of 
socioeconomic status change between infacny and adolescense, and blood pressure, in South 
African young adults: Birth to Twenty Cohort. BMJ open 2016;6:e008805. 
149. Wirix AJ, NAuta J, Groothoff JW, et al. Is the prevalence of hypertension in 
overweight children overestimated? Arch Dis Child 2016; Published Online First: 
doi:10.1136/archdischild-2015-309969. 
150. Myers MG, Valdivieso M, Kiss A. Use of automated office blood pressure 
measurement to reduce the white coat response. J Hypertens 2009;27:280-6. 
151. Pandit JA, Batlle D. Snapshot Hemodynamics and Clinical Outcomes in 
Hypertension: Precision in the Measurements Is Key. Hypertension 2015;67:270-1. 
152. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events 
and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. Journal 
of the American College of Cardiology 2010;55:1318-27. 
153. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk 
Assessment Collaborating G. Selected major risk factors and global and regional burden of 
disease. Lancet 2002;360:1347-60. 
154. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C. 
Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a 
systematic review and meta-analysis. Eur Heart J 2010;31:1865-71. 
155. Rothwell PM. Does blood pressure variability modulate cardiovascular risk? Curr 
Hypertens Rep 2011;13:177-86. 
156. Mayer O, Filipovsky J, Seidlerova J, et al. The association between low 25-
hydroxyvitamin D and increased aortic stiffness. J Hum Hypertens 2012;26:650-5. 
157. Judd SE, Nanes MS, Ziegler TR, Wilson PW, Tangpricha V. Optimal vitamin D 
status attenuates the age-associated increase in systolic blood pressure in white Americans: 
159 
 
results from the third National Health and Nutrition Examination Survey. American Journal 
of Clinical Nutrition 2008;87:136-41. 
158. Alvarez JA, Gower BA, Calhoun DA, et al. Serum 25-hydroxyvitamin D and Ethnic 
Differences in Arterial Stiffness and Endothelial Function. Journal of clinical medicine 
research 2012;4:197-205. 
159. Wu-Wong JR, Nakane M, Ma J. Vitamin D analogs modulate the expression of 
plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic 
smooth muscle cells. Journal of vascular research 2007;44:11-8. 
160. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a 
negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110:229-38. 
161. Dong Y, Stallmann-Jorgensen IS, Pollock NK, et al. A 16-week randomized clinical 
trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-
hydroxyvitamin D, adiposity, and arterial stiffness. The Journal of clinical endocrinology and 
metabolism 2010;95:4584-91. 
162. Gepner AD, Ramamurthy R, Krueger DC, Korcarz CE, Binkley N, Stein JH. A 
Prospective Randomized Controlled Trial of the Effects of Vitamin D Supplementation on 
Cardiovascular Disease Risk. PloS one 2012;7:e36617. 
163. Martins DM, Y-X.; Tareen, N.; Artaza, J.; Lee, JE.; Farodolu, C.; Gibbons, G.; 
Norris, K.;. The Effect of Short Term Vitamin D Supplementation on the Inflammatory and 
Oxidative Mediators of Arterial Stiffness. Health 2014;6:1503 - 11. 
164. Chitalia N, Ismail T, Tooth L, et al. Impact of vitamin D supplementation on arterial 
vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients. PloS one 
2014;9:e91363. 
160 
 
165. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term 
vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels 
in elderly women. The Journal of clinical endocrinology and metabolism 2001;86:1633-7. 
166. Forman JP, Scott JB, Ng K, et al. Effect of vitamin D supplementation on blood 
pressure in blacks. Hypertension 2013;61:779-85. 
167. Witham MD, Ireland S, Houston JG, et al. Vitamin D Therapy to Reduce Blood 
Pressure and Left Ventricular Hypertrophy in Resistant Hypertension Randomized, 
Controlled Trial. Hypertension 2014;63:706-12. 
168. Scragg R, Khaw KT, Murphy S. Effect of winter oral vitamin D3 supplementation on 
cardiovascular risk factors in elderly adults. European journal of clinical nutrition 
1995;49:640-6. 
169. Margolis KL, Ray RM, Van Horn L, et al. Effect of calcium and vitamin D 
supplementation on blood pressure: the Women's Health Initiative Randomized Trial. 
Hypertension 2008;52:847-55. 
170. Pan WH, Wang CY, Li LA, Kao LS, Yeh SH. No significant effect of calcium and 
vitamin D supplementation on blood pressure and calcium metabolism in elderly Chinese. 
The Chinese journal of physiology 1993;36:85-94. 
171. Nasri H, Behradmanesh S, Ahmadi A, Rafieian-Kopaei M. Impact of oral vitamin D 
(cholecalciferol) replacement therapy on blood pressure in type 2 diabetes patients; a 
randomized, double-blind, placebo controlled clinical trial. Journal of nephropathology 
2014;3:29-33. 
172. Lind L, Wengle B, Ljunghall S. Blood-Pressure Is Lowered by Vitamin-D 
(Alphacalcidol) during Long-Term Treatment of Patients with Intermittent Hypercalcemia - a 
Double-Blind, Placebo-Controlled Study. Acta medica Scandinavica 1987;222:423-7. 
161 
 
173. Lind L, Lithell H, Skarfors E, Wide L, Ljunghall S. Reduction of blood pressure by 
treatment with alphacalcidol. A double-blind, placebo-controlled study in subjects with 
impaired glucose tolerance. Acta Medica Scandinavica 1988;223:211-7. 
174. Scragg R, Slow S, Stewart AW, et al. Long-term high-dose vitamin D3 
supplementation and blood pressure in healthy adults: a randomized controlled trial. 
Hypertension 2014;64:725-30. 
175. Witham MD, Price RJG, Struthers AD, et al. Cholecalciferol Treatment to Reduce 
Blood Pressure in Older Patients With Isolated Systolic Hypertension The VitDISH 
Randomized Controlled Trial. Jama Intern Med 2013;173:1672-9. 
176. Stricker H, Bianda FT, Guidicelli-Nicolosi S, Limoni C, Colucci G. Effect of a 
Single, Oral, High-dose Vitamin D Supplementation on Endothelial Function in Patients with 
Peripheral Arterial Disease: A Randomised Controlled Pilot Study. European journal of 
vascular and endovascular surgery : the official journal of the European Society for Vascular 
Surgery 2012;44:307-12. 
177. Heidari B, Heidari P, Hajian-Tilaki K. Association between serum vitamin D 
deficiency and knee osteoarthritis. Int Orthop 2011;35:1627-31. 
178. Zhang FF, Driban JB, Lo GH, et al. Vitamin D deficiency is associated with 
progression of knee osteoarthritis. J Nutr 2014;144:2002-8. 
179. Hoeven TA, Kavousi M, Clockaerts S, et al. Association of atherosclerosis with 
presence and progression of osteoarthritis: the Rotterdam Study. Ann Rheum Dis 
2013;72:646-51. 
180. Jonsson H, Helgadottir GP, Aspelund T, et al. Hand osteoarthritis in older women is 
associated with carotid and coronary atherosclerosis: the AGES Reykjavik study. Ann Rheum 
Dis 2009;68:1696-700. 
162 
 
181. Kornaat PR, Sharma R, van der Geest RJ, et al. Positive association between 
increased popliteal artery vessel wall thickness and generalized osteoarthritis: is OA also part 
of the metabolic syndrome? Skeletal Radiol 2009;38:1147-51. 
182. Yoshimura N, Muraki S, Oka H, et al. Accumulation of metabolic risk factors such as 
overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of 
occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD study. 
Osteoarthritis Cartilage 2012;20:1217-26. 
183. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular 
disease enterprises: Part I: aging arteries: a "set up" for vascular disease. Circulation 
2003;107:139-46. 
184. Whelton A, White WB, Bello AE, Puma JA, Fort JG. Effects of celecoxib and 
rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic 
hypertension and osteoarthritis. Am J Cardiol 2002;90:959-63. 
185. Singh G, Miller JD, Huse DM, Pettitt D, D'Agostino RB, Russell MW. Consequences 
of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. J 
Rheumatol 2003;30:714-9. 
186. Cao YL, Jones G, Cicuttini F, et al. Vitamin D supplementation in the management of 
knee osteoarthritis: study protocol for a randomized controlled trial. Trials 2012;13. 
187. Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-
pressure variability. Nature reviews Cardiology 2013;10:143-55. 
188. Lau KK, Wong YK, Chan YH, et al. Visit-to-visit blood pressure variability as a 
prognostic marker in patients with cardiovascular and cerebrovascular diseases--relationships 
and comparisons with vascular markers of atherosclerosis. Atherosclerosis 2014;235:230-5. 
189. Sharman JE, Lim R, Qasem AM, et al. Validation of a generalized transfer function to 
noninvasively derive central blood pressure during exercise. Hypertension 2006;47:1203-8. 
163 
 
190. Kolade OO, O'Moore-Sullivan TM, Stowasser M, et al. Arterial stiffness, central 
blood pressure and body size in health and disease. Int J Obes (Lond) 2012;36:93-9. 
191. Holland DJ, Sacre JW, McFarlane SJ, Coombes JS, Sharman JE. Pulse wave analysis 
is a reproducible technique for measuring central blood pressure during hemodynamic 
perturbations induced by exercise. Am J Hypertens 2008;21:1100-6. 
192. Miettinen ME, Kinnunen L, Leiviska J, et al. Association of serum 25-
hydroxyvitamin D with lifestyle factors and metabolic and cardiovascular disease markers: 
population-based cross-sectional study (FIN-D2D). PloS one 2014;9:e100235. 
193. Mai XM, Chen Y, Camargo CA, Jr., Langhammer A. Cross-sectional and prospective 
cohort study of serum 25-hydroxyvitamin D level and obesity in adults: the HUNT study. Am 
J Epidemiol 2012;175:1029-36. 
194. Rahman MM, Kopec JA, Anis AH, Cibere J, Goldsmith CH. Risk of cardiovascular 
disease in patients with osteoarthritis: a prospective longitudinal study. Arthritis care & 
research 2013;65:1951-8. 
195. Singh G, Miller JD, Lee FH, Pettitt D, Russell MW. Prevalence of cardiovascular 
disease risk factors among US adults with self-reported osteoarthritis: data from the Third 
National Health and Nutrition Examination Survey. The American journal of managed care 
2002;8:S383-91. 
196. Rizzoni D, Agabiti-Rosei C. Relationships between blood pressure variability and 
indices of large artery stiffness: does the microvasculature play a role? Hypertens Res 
2017;40:348-50. 
197. Webb AJ, Rothwell PM. Physiological correlates of beat-to-beat, ambulatory, and 
day-to-day home blood pressure variability after transient ischemic attack or minor stroke. 
Stroke 2014;45:533-8. 
164 
 
198. Veloudi P, Blizzard CL, Head GA, Abhayaratna WP, Stowasser M, Sharman JE. 
Blood Pressure Variability and Prediction of Target Organ Damage in Patients With 
Uncomplicated Hypertension. American Journal of Hypertension 2016;29:1046-54. 
199. Myers MG, Cloutier L, Gelfer M, Padwal RS, Kaczorowski J. Blood Pressure 
Measurement in the Post-SPRINT Era: A Canadian Perspective. Hypertension 2016;68:251-
3. 
200. Weber MA, Poulter NR, Schutte AE, et al. Is It Time to Reappraise Blood Pressure 
Thresholds and Targets? A Statement From the International Society of Hypertension - A 
Global Perspective. Hypertension 2016;68:266-8. 
201. The Sprint Research Group. A Randomized Trial of Intensive versus Standard Blood-
Pressure Control. N Engl J Med 2015;373:2103-16. 
202. Falkner B, Gidding SS. Is the SPRINT Blood Pressure Treatment Target of 120/80 
mm Hg Relevant for Children? Hypertension 2016;67:826-8. 
203. Scragg R, Stewart AW, Waayer D, et al. Effect of Monthly High-Dose Vitamin D 
Supplementation on Cardiovascular Disease in the Vitamin D Assessment Study : A 
Randomized Clinical Trial. JAMA Cardiol 2017. 
204. Manson JE, Bassuk SS. Vitamin D Research and Clinical Practice: At a Crossroads. 
JAMA 2015. 
205. Saito Y, Kitahara H, Nakayama T, Fujimoto Y, Kobayashi Y. Night-time blood 
pressure variability negatively correlated with reactive hyperemia index. Int J Cardiol 
2016;Epub ahead of print:10.1016/j.ijcard.2016.12.110. 
206. Ruan Y, Wanlin W, Janhua Y, et al. Time rate of blood pressure variation is 
associated with endothelial fucntion in patients with metabolic syndrome. Int Heart J 
2016;57:226-33. 
165 
 
207. McDonald C, Pearce MS, Wincenciak J, Kerr SR, Newton JL. Ambulatory Blood 
Pressure Variability Increases Over a 10-Year Follow-Up in Community-Dwelling Older 
People. Am J Hypertens 2016;29:560-7. 
208. Juhanoja EP, Niiranen TJ, Johansson JK, Puukka PJ, Jula AM. Agreement between 
ambulatory, home, and office blood pressure variability. J Hypertens 2016;34:61-7. 
209. Boardman H, Lewandowski AJ, Lazdam M, et al. Aortic stiffness and blood pressure 
variability in young people: a multimodality investigation of central and peripheral 
vasculature. J Hypertens 2016;Epub ahead of print:10.1097/HJH.0000000000001192. 
210. Wu D, Li C, Chen Y, et al. Influence of blood pressure variability on early carotid 
atherosclerosis in hypertension with and without diabetes. Medicine 2016;95:e3864. 
211. Kang IS, Pyun WB, Shin J, et al. Higher Blood Pressure Variability in White Coat 
Hypertension; from the Korean Ambulatory Blood Pressure Monitoring Registry. Korean 
Circ J 2016;46:365-73. 
212. Miroslawska A, Solbu M, Skjolsvik E, Toft I, Steigen TK. Renal sympathetic 
denervation: effect on ambulatory blood pressure and blood pressure variability in patients 
with treatment-resistant hypertension. The ReShape CV-risk study. J Hum Hypertens 
2016;30:153-7. 
213. Madden JM, O'Flynn AM, Dolan E, Fitzgerald AP, Kearney PM. Short-term blood 
pressure variability over 24 h and target organ damage in middle-aged men and women. 
Journal of Human Hypertension 2015;29:719-25. 
214. Karpov YA, Gorbunov VM, Deev AD. Effectiveness of Fixed-Dose 
Perindopril/Amlodipine on Clinic, Ambulatory and Self-Monitored Blood Pressure and 
Blood Pressure Variability: An Open-Label, Non Comparative Study in the General Practice. 
High Blood Press Cardiovasc Prev 2015;22:417-25. 
166 
 
215. Johansson JK, Puukka PJ, Virtanen R, Jula AM. Beat-to-beat, ambulatory hour-to-
hour, and home day-to-day variabilities in blood pressure, pulse pressure, and heart rate in 
comparison with each other and with target-organ damage. Blood Press Monit 2015;20:113-
20. 
216. Symonides B, Holas P, Schram M, Sleszycka J, Bogaczewicz A, Gaciong Z. Does the 
control of negative emotions influence blood pressure control and its variability? Blood Press 
2014;23:323-9. 
217. Stabouli S, Papakatsika S, Kotronis G, Papadopoulou-Legbelou K, Rizos Z, Kotsis V. 
Arterial stiffness and SBP variability in children and adolescents. J Hypertens 2015;33:88-95. 
218. Tatasciore A, Zimarino M, Tommasi R, et al. Increased short-term blood pressure 
variability is associated with early left ventricular systolic dysfunction in newly diagnosed 
untreated hypertensive patients. J Hypertens 2013;31:1653-61. 
219. Leoncini G, Viazzi F, Storace G, Deferrari G, Pontremoli R. Blood pressure 
variability and multiple organ damage in primary hypertension. J Hum Hypertens 
2013;27:663-70. 
220. Ciobanu AO, Gherghinescu CL, Dulgheru ER, et al. The impact of blood pressure 
variability on subclinical ventricular, renal, and vascular function in patients with 
hypertension and diabetes. Eur J Heart Fail 2013;12:S304-S. 
221. Zuern CS, Rizas KD, Eick C, et al. Effects of Renal Sympathetic Denervation on 24-
hour Blood Pressure Variability. Front Physiol 2012;3:134. 
222. Cahan A, Ben-Dov IZ, Bursztyn M. Association of heart rate with blood pressure 
variability: implications for blood pressure measurement. Am J Hypertens 2012;25:313-8. 
223. Kotsis V, Stabouli S, Karafillis I, et al. Arterial stiffness and 24 h ambulatory blood 
pressure monitoring in young healthy volunteers: the early vascular ageing Aristotle 
University Thessaloniki Study (EVA-ARIS Study). Atherosclerosis 2011;219:194-9. 
167 
 
224. Eguchi K, Ishikawa J, Hoshide S, et al. Night time blood pressure variability is a 
strong predictor for cardiovascular events in patients with type 2 diabetes. Am J Hypertens 
2009;22:46-51. 
225. Masuda S, Tamura K, Wakui H, et al. Effects of angiotensin II type 1 receptor blocker 
on ambulatory blood pressure variability in hypertensive patients with overt diabetic 
nephropathy. Hypertens Res 2009;32:950-5. 
226. Verdecchia P, Angeli F, Gattobigio R, Rapicetta C, Reboldi G. Impact of blood 
pressure variability on cardiac and cerebrovascular complications in hypertension. American 
Journal of Hypertension 2007;20:154-61. 
227. Shintani Y, Kikuya M, Hara A, et al. Ambulatory blood pressure, blood pressure 
variability and the prevalence of carotid artery alteration: the Ohasama study. J Hypertens 
2007;25:1704-10. 
228. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Hayashi M. Ambulatory blood 
pressure variability and brachial-ankle pulse wave velocity in untreated hypertensive patients. 
J Hum Hypertens 2006;20:529-36. 
229. Abramson JL, Lewis C, Murrah NV, Anderson GT, Vaccarino V. Relation of C-
reactive protein and tumor necrosis factor-alpha to ambulatory blood pressure variability in 
healthy adults. Am J Cardiol 2006;98:649-52. 
230. Okada T, Wada T, Nagaoka Y, Kanno Y. Association between visit-to-visit clinic 
blood pressure variability and home blood pressure variability in patients with chronic kidney 
disease. Ren Fail 2014;0:1-6. 
231. Liu Z, Zhao Y, Zhang H, et al. Excessive variability in systolic blood pressure that is 
self-measured at home exacerbates the progression of brain white matter lesions and 
cognitive impairment in the oldest old. Hypertens Res 2016;39:245-53. 
168 
 
232. Hashimoto T, Kikuya M, Ohkubo T, et al. Home blood pressure level, blood pressure 
variability, smoking, and stroke risk in Japanese men: the Ohasama study. Am J Hypertens 
2012;25:883-91. 
233. Hoshide S, Yano Y, Shimizu M, Eguchi K, Ishikawa J, Kario K. Is home blood 
pressure variability itself an interventional target beyond lowering mean home blood pressure 
during anti-hypertensive treatment? Hypertens Res 2012;35:862-6. 
234. Okada T, Matsumoto H, Nagaoka Y, Nakao T. Association of home blood pressure 
variability with progression of chronic kidney disease. Blood Press Monit 2012;17:1-7. 
235. Kikuya M, Ohkubo T, Metoki H, et al. Day-by-day variability of blood pressure and 
heart rate at home as a novel predictor of prognosis: the Ohasama study. Hypertension 
2008;52:1045-50. 
236. Ishikura K, Obara T, Kato T, et al. Associations Between Day-by-Day Variability in 
Blood Pressure Measured at Home and Antihypertensive Drugs: The J-HOME-Morning 
Study. Clin Exp Hypertens 2012;34:297-304. 
237. Kato T, Kikuya M, Ohkubo T, et al. Factors associated with day-by-day variability of 
self-measured blood pressure at home: the Ohasama study. Am J Hypertens 2010;23:980-6. 
238. Shin MS, Kang DR, Kim C, et al. Fimasartan for independent reduction of blood 
pressure variability in mild-to-moderate hypertension. Drug Des Devel Ther 2016;10:1573-
80. 
239. Johansson JK, Niiranen TJ, Puukka PJ, Jula AM. Factors affecting the variability of 
home-measured blood pressure and heart rate: the Finn-home study. J Hypertens 
2010;28:1836-45. 
240. Tedla YG, Yano Y, Carnethon M, Greenland P. Association Between Long-Term 
Blood Pressure Variability and 10-Year Progression in Arterial Stiffness: The Multiethnic 
169 
 
Study of Atherosclerosis. Hypertension 2016;Epub ehad of 
print:10.1161/HYPERTENSIONAHA.116.08427. 
241. Wang A, Li Z, Yang Y, et al. Impact of baseline systolic blood pressure on visit-to-
visit blood pressure variability: the Kailuan study. Ther Clin Risk Manag 2016;12:1191-6. 
242. Faramawi MF, Delongchamp R, Said Q, et al. High-normal blood pressure is 
associated with visit-to-visit blood pressure variability in the US adults. Blood Press 2016:1-
6. 
243. Wang Y, Yang Y, Wang A, et al. Association of long-term blood pressure variability 
and brachial-ankle pulse wave velocity: a retrospective study from the APAC cohort. Sci Rep 
2016;6:21303. 
244. Nagai M, Dote K, Kato M, et al. Visit-to-visit blood pressure variability, average BP 
level and carotid arterial stiffness in the elderly: a prospective study. J Hum Hypertens 
2016;31:292-8. 
245. Ogliari G, Smit AJR, Westendorp RG, Jukema JW, de Graen JMA, Sabayan B. Visit-
to-visitblood pressure variability and future functional decline in old age. J Hypertens 
2016;34:1544-50. 
246. Yano Y, Vongpatanasin W, Ayers C, et al. Regional Fat Distribution and Blood 
Pressure Level and Variability: The Dallas Heart Study. Hypertension 2016;Epub ahead of 
print:10.1161/HYPERTENSIONAHA.116.07876. 
247. Takao T, Kimura K, Suka M, et al. Relationships between the risk of cardiovascular 
disease in type 2 diabetes patients and both visit-to-visit variability and time-to-effect 
differences in blood pressure. J Diabetes Complications 2015;29:699-706. 
248. Parati G, Ochoa JE, Bilo G, et al. Hypertension in Chronic Kidney Disease Part 2: 
Role of Ambulatory and Home Blood Pressure Monitoring for Assessing Alterations in 
Blood Pressure Variability and Blood Pressure Profiles. Hypertension 2016;67:1102-10. 
170 
 
249. Gondo K, Miura S-i, Suematsu Y, et al. Association Between Visit-to-Visit 
Variability in Blood Pressure and Cardiovascular Events in Hypertensive Patients After 
Successful Percutaneous Coronary Intervention. J Clin Med Res 2015;7:545-50. 
250. Darabont R. Visit-to-Visit Blood Pressure Variability and Arterial Stiffness 
Independently Predict Cardiovascular Risk Category in a General Population: Results from 
the SEPHAR II Study. Hellenic J Cardiol 2015; 56:208-16. 
251. Jo AH, An NJ, Lee PJ, Oh K-H, Lim CS, Oh KY. Visit-to-visit variability in systolic 
blood pressure is a risk factor for rapid loss of residual renal function in peritoneal dialysis 
patients. Tohoku J Exp Med 2015;235:295-304. 
252. Nakano C, Morimoto S, Nakahigashi M, et al. The relationships between visit-to-visit 
blood pressure variability and renal and endothelial function in chronic kidney disease. 
Hypertens Res 2015;38:193-8. 
253. Chang TI, Tabada GH, Yang J, Tan TC, Go AS. Visit-to-visit variability of blood 
pressure and death, end-stage renal disease, and cardiovascular events in patients with 
chronic kidney disease. J Hypertens 2016;34:244-52. 
254. Lau KK, Wong YK, Chang RSK, et al. Visit-to-visit systolic blood pressure 
variability predicts all-cause and cardiovascular mortality after lacunar infarct. Eur J Neurol 
2014;21:319-25. 
255. Yokota K, Fukuda M, Matsui Y, Kario K, Kimura K. Visit-to-visit variability of 
blood pressure and renal function decline in patients with diabetic chronic kidney disease. 
Journal of clinical hypertension 2014;16:362-6. 
256. Lau KK, Wong YK, Chan YH, et al. Visit-to-visit blood pressure variability as a 
prognostic marker in patients with cardiovascular and cerebrovascular diseases - 
Relationships and comparisons with vascular markers of atherosclerosis. Atherosclerosis 
2014;235:230-5. 
171 
 
257. Faramawi MF, Delongchamp R, Said Q, Jadhav S, Abouelenien S. Metabolic 
syndrome is associated with visit-to-visit systolic blood pressure variability in the US adults. 
Hypertension Research 2014;37:875-9. 
258. Faramawi MF, Delongchamp R, Lin YS, et al. Environmental lead exposure is 
associated with visit-to-visit systolic blood pressure variability in the US adults. Int Arch 
Occup Environ Health 2015;88:381-8. 
259. Cao HJ, Wu SL, Li SQ, et al. Characterization and influencing factors of visit-to-visit 
blood pressure variability of the population in a northern Chinese industrial city. Chin Med J 
2014;127:1022-6. 
260. Noshad S, Mousavizadeh M, Mozafari M, Nakhjavani M, Esteghamati A. Visit-to-
visit blood pressure variability is related to albuminuria variability and progression in patients 
with type 2 diabetes. J Hum Hypertens 2014;28:37-43. 
261. McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw 
D. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in 
patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study 
and the Irbesartan Diabetic Nephropathy Trial. American Journal of Kidney Diseases 
2014;64:714-22. 
262. Song HB, Liu ZD, Zhao YX, et al. Reducing Visit-To-Visit Variability in Systolic 
Blood Pressure for Improving the Progression of Carotid Atherosclerosis and Endothelial 
Dysfunction in Patients with Hypertension Management. Iranian J Publ Health 2014;43:722-
35. 
263. Yano Y, Ning H, Allen N, et al. Long-Term Blood Pressure Variability Throughout 
Young Adulthood and Cognitive Function in Midlife: The Coronary Artery Risk 
Development in Young Adults (CARDIA) Study. Hypertension 2014;64:983-8. 
172 
 
264. Yu JM, Kong QY, Schoenhagen P, et al. The prognostic value of long-term visit-to-
visit blood pressure variability on stroke in real-world practice: a dynamic cohort study in a 
large representative sample of Chinese hypertensive population. Int J Cardiol 2014;177:995-
1000. 
265. Masugata H, Sendai S, Inukai M, et al. Analysis of association between brain 
natriuretic peptide levels and blood pressure variability. Exp Ther Med 2014;8:21-4. 
266. Lattanzi S, Luzzi S, Provinciali L, Silvestrini M. Blood pressure variability predicts 
cognitive decline in Alzheimer's disease patients. Neurobiol Aging 2014;35:2282-7. 
267. Selvarajah V, Pasea L, Ojha S, Wilkinson IB, Tomlinson LA. Pre-dialysis systolic 
blood pressure-variability is independently associated with all-cause mortality in incident 
haemodialysis patients. PloS one 2014;9:e86514. 
268. Lau KK, Wong YK, Chan YH, et al. Mediterranean-style diet is associated with 
reduced blood pressure variability and subsequent stroke risk in patients with coronary artery 
disease. American Journal of Hypertension 2015;28:501-7. 
269. Chowdhury EK, Owen A, Krum H, et al. Systolic blood pressure variability is an 
important predictor of cardiovascular outcomes in elderly hypertensive patients. J Hypertens 
2014;32:525-33. 
270. Poortvliet RK, Lloyd SM, Ford I, et al. Biological correlates of blood pressure 
variability in elderly at high risk of cardiovascular disease. American Journal of Hypertension 
2015;28:469-79. 
271. Sabayan B, Wijsman LW, Foster-Dingley JC, et al. Association of visit-to-visit 
variability in blood pressure with cognitive function in old age: prospective cohort study. Brit 
Med J 2013;347:f4600. 
173 
272. Obara T, Kikuya M, Kobayashi Y, et al. Associations Between Visit-to-visit
Variability in Blood Pressure Measured in the Office and Antihypertensive Drugs: The J-
HOME-Morning Study. Clin Exp Hypertens 2013;35:285-90. 
273. Mallamaci F, Minutolo R, Leonardis D, et al. Long-term visit-to-visit office blood
pressure variability increases the risk of adverse cardiovascular outcomes in patients with 
chronic kidney disease. Kidney Int 2013;84:381-9. 
274. Muntner P, Shimbo D, Diaz KM, Newman J, Sloan RP, Schwartz JE. Low correlation
between visit-to-visit variability and 24-h variability of blood pressure. Hypertens Res 
2013;36:940-6. 
275. Hata J, Arima H, Rothwell PM, et al. Effects of Visit-to-Visit Variability in Systolic
Blood Pressure on Macrovascular and Microvascular Complications in Patients With Type 2 
Diabetes Mellitus The ADVANCE Trial. Circulation 2013;128:1325-34. 
276. Kawai T, Ohishi M, Ito N, et al. Alteration of vascular function is an important factor
in the correlation between visit-to-visit blood pressure variability and cardiovascular disease. 
J Hypertens 2013;31:1387-95. 
277. Epstein NU, Lane KA, Farlow MR, et al. Cognitive Dysfunction and Greater Visit-to-
Visit Systolic Blood Pressure Variability. J Am Geriatr Soc 2013;61:2168-73. 
278. Suchy-Dicey AM, Wallace ER, Mitchell SV, et al. Blood pressure variability and the
risk of all-cause mortality, incident myocardial infarction, and incident stroke in the 
cardiovascular health study. Am J Hypertens 2013;26:1210-7. 
279. Rossignol P, Cridlig J, Lehert P, Kessler M, Zannad F. Visit-to-visit blood pressure
variability is a strong predictor of cardiovascular events in hemodialysis: insights from 
FOSIDIAL. Hypertension 2012;60:339-46. 
174 
 
280. Eguchi K, Hoshide S, Schwartz JE, Shimada K, Kario K. Visit-to-visit and 
ambulatory blood pressure variability as predictors of incident cardiovascular events in 
patients with hypertension. Am J Hypertens 2012;25:962-8. 
281. Poortvliet RK, Ford I, Lloyd SM, et al. Blood pressure variability and cardiovascular 
risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). PloS one 
2012;7:e52438. 
282. Shimbo D, Newman JD, Aragaki AK, et al. Association between annual visit-to-visit 
blood pressure variability and stroke in postmenopausal women: data from the Women's 
Health Initiative. Hypertension 2012;60:625-30. 
283. Muntner P, Joyce C, Levitan EB, et al. Reproducibility of visit-to-visit variability of 
blood pressure measured as part of routine clinical care. J Hypertens 2011;29:2332-8. 
284. Nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K. Visit-to-visit blood pressure 
variations: new independent determinants for carotid artery measures in the elderly at high 
risk of cardiovascular disease. J Am Soc Hypertens 2011;5:184-92. 
285. Masugata H, Senda S, Murao K, et al. Visit-to-visit variability in blood pressure over 
a 1-year period is a marker of left ventricular diastolic dysfunction in treated hypertensive 
patients. Hypertens Res 2011;34:846-50. 
286. Muntner P, Shimbo D, Tonelli M, Reynolds K, Arnett DK, Oparil S. The relationship 
between visit-to-visit variability in systolic blood pressure and all-cause mortality in the 
general population: findings from NHANES III, 1988 to 1994. Hypertension 2011;57:160-6. 
287. Yeh CH, Yu HC, Huang TY, et al. High Systolic and Diastolic Blood Pressure 
Variability Is Correlated with the Occurrence of Peripheral Arterial Disease in the First 
Decade following a Diagnosis of Type 2 Diabetes Mellitus: A New Biomarker from Old 
Measurement. Biomed Res Int 2016;2016:9872945. 
175 
 
288. About CURF Microdata. Australian Bureau of Statistics, 2011. (Accessed 
14/08/2015, at 
http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/4364.0.55.003Explanatory%20Notes1
2011-2012?OpenDocument ) 
289.  Australian Health Survey: Biomedical Results for Chronic Diseases, 2011-12  
Australian Bureau of Statistics, 2013. (Accessed 14/08/2015, at 
http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4364.0.55.005main+features12011-12 ) 
290. Australian Health Survey: Users' Guide, 2011-13. Australian Bureau of Statistics, 
2013. (Accessed 14/08/2015, at 
http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/53E501320131C7F7CA257C3D000D879
B?opendocument.) 
291. Gunton JE, Girgis CM, Baldock PA, Lips P. Bone muscle interactions and vitamin D. 
Bone 2015;80:89-94. 
292. Tetlow LC, Woolley DE. Expression of vitamin D receptors and matrix 
metalloproteinases in osteoarthritic cartilage and human articular chondrocytes in vitro. 
Osteoarthritis Cartilage 2001;9:423-31. 
293. Norman PE, Powell JT. Vitamin D and cardiovascular disease. Circulation Research 
2014;114:379-93. 
294. Rahman A, Hershey S, Ahmed S, Nibbelink K, Simpson RU. Heart extracellular 
matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem 
Mol Biol 2007;103:416-9. 
295. Eelen G, Verlinden L, Laureys J, et al. Antiproliferative and calcemic actions of trans-
decalin CD-ring analogs of 1,25-dihydroxyvitamin D3. Anticancer research 2009;29:3579-
84. 
176 
 
296. Yuan W, Pan W, Kong J, et al. 1,25-dihydroxyvitamin D3 suppresses renin gene 
transcription by blocking the activity of the cyclic AMP response element in the renin gene 
promoter. The Journal of biological chemistry 2007;282:29821-30. 
297. Kestenbaum B, Katz R, de Boer I, et al. Vitamin D, parathyroid hormone, and 
cardiovascular events among older adults. Journal of the American College of Cardiology 
2011;58:1433-41. 
298. Drechsler C, Pilz S, Obermayer-Pietsch B, et al. Vitamin D deficiency is associated 
with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis 
patients. Eur Heart J 2010;31:2253-61. 
299. Correia LC, Sodre F, Garcia G, et al. Relation of severe deficiency of vitamin D to 
cardiovascular mortality during acute coronary syndromes. Am J Cardiol 2013;111:324-7. 
300. Anderson JL, May HT, Horne BD, et al. Relation of vitamin D deficiency to 
cardiovascular risk factors, disease status, and incident events in a general healthcare 
population. Am J Cardiol 2010;106:963-8. 
301. Fiscella K, Franks P. Vitamin D, race, and cardiovascular mortality: findings from a 
national US sample. Ann Fam Med 2010;8:11-8. 
302. Schierbeck LL, Jensen TS, Bang U, Jensen G, Kober L, Jensen JE. Parathyroid 
hormone and vitamin D--markers for cardiovascular and all cause mortality in heart failure. 
European Journal of Heart Failure 2011;13:626-32. 
303. Thomas GN, o Hartaigh B, Bosch JA, et al. Vitamin D levels predict all-cause and 
cardiovascular disease mortality in subjects with the metabolic syndrome: the Ludwigshafen 
Risk and Cardiovascular Health (LURIC) Study. Diabetes Care 2012;35:1158-64. 
304. Lee HM, Liu M, Lee K, Luo Y, Wong ND. Does low vitamin D amplify the 
association of COPD with total and cardiovascular disease mortality? Clin Cardiol 
2014;37:473-8. 
177 
 
305. Lishmanov A, Dorairajan S, Pak Y, Chaudhary K, Chockalingam A. Treatment of 25-
OH vitamin D deficiency in older men with chronic kidney disease stages 3 and 4 is 
associated with reduction in cardiovascular events. American journal of therapeutics 
2013;20:480-6. 
306. Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 
1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrology, dialysis, 
transplantation : official publication of the European Dialysis and Transplant Association - 
European Renal Association 2004;19:179-84. 
307. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood 
pressure in the Third National Health and Nutrition Examination Survey. American Journal 
of Hypertension 2007;20:713-9. 
308. Zhao G, Ford ES, Li C, Kris-Etherton PM, Etherton TD, Balluz LS. Independent 
associations of serum concentrations of 25-hydroxyvitamin D and parathyroid hormone with 
blood pressure among US adults. J Hypertens 2010;28:1821-8. 
309. Tomaino K, Romero KM, Robinson CL, et al. Association Between Serum 25-
Hydroxy Vitamin D Levels and Blood Pressure Among Adolescents in Two Resource-
Limited Settings in Peru. American Journal of Hypertension 2015;28(8):1017-23. 
310. Lind L, Hanni A, Lithell H, Hvarfner A, Sorensen OH, Ljunghall S. Vitamin-D Is 
Related to Blood-Pressure and Other Cardiovascular Risk-Factors in Middle-Aged Men. Am 
J Hypertens 1995;8:894-901. 
311. Park HY, Kim JH, Bae S, Choi YY, Park JY, Hong YC. Interaction effect of serum 
25-hydroxyvitamin D levels and CYP1A1, CYP1B1 polymorphisms on blood pressure in an 
elderly population. J Hypertens 2014. 
312. Almirall J, Vaqueiro M, Bare ML, Anton E. Association of low serum 25-
hydroxyvitamin D levels and high arterial blood pressure in the elderly. Nephrology, dialysis, 
178 
 
transplantation : official publication of the European Dialysis and Transplant Association - 
European Renal Association 2010;25:503-9. 
313. Weinert LS, Reichelt AJ, Schmitt LR, et al. Serum vitamin d insufficiency is related 
to blood pressure in diabetic pregnancy. American Journal of Hypertension 2014;27:1316-20. 
314. Sowers MFR, Wallace RB, Hollis BW, Lemke JH. Relationship between 1,25-
Dihydroxyvitamin-D and Blood-Pressure in a Geographically Defined Population. American 
Journal of Clinical Nutrition 1988;48:1053-6. 
315. Seker T, Gur M, Kuloglu O, et al. Serum 25-hydroxyvitamin D is associated with 
both arterial and ventricular stiffness in healthy subjects. Journal of Cardiology 2013;62:361-
5. 
316. Giallauria F, Milaneschi Y, Tanaka T, et al. Arterial Stiffness and Vitamin D Levels: 
the Baltimore Longitudinal Study of Aging. Journal of Clinical Endocrinology & Metabolism 
2012;97:3717-23. 
317. Rezai MR, Anderson SG, Sattar N, Finn J, Wu F, Cruickshank JK. Ethnic differences 
in aortic pulse wave velocity occur in the descending aorta independent of blood pressure and 
may be related to vitamin D. Hypertension 2011;25:632-3. 
318. Chang J, Ye XG, Hou YP, Wu JL, Li SL, Sun QM. Vitamin D Level is Associated 
with Increased Left Ventricular Mass and Arterial Stiffness in Older Patients with Impaired 
Renal Function. Medical science monitor : international medical journal of experimental and 
clinical research 2015;21:3993-9. 
319. Kutlay S, Atli T, Aydogan I, Tutkak H, Nergizoglu G. The association of serum 
vitamin D levels with several cardiometabolic risk and aortic pulse wave velocity in elderly 
persons. European Geriatric Medicine 2014;5:238-41. 
179 
 
320. van Dijk SC, Sohl E, Oudshoorn C, et al. Non-linear associations between serum 25-
OH vitamin D and indices of arterial stiffness and arteriosclerosis in an older population. Age 
and ageing 2014. 
321. Lee JI, Oh SJ, Ha WC, et al. Serum 25-hydroxyvitamin D concentration and arterial 
stiffness among type 2 diabetes. Diabetes Research and Clinical Practice 2012;95:42-7. 
322. Jha P, Dolan LM, Khoury PR, Urbina EM, Kimball TR, Shah AS. Low Serum 
Vitamin D Levels Are Associated With Increased Arterial Stiffness in Youth With Type 2 
Diabetes. Diabetes Care 2015;38:1551-7. 
323. Zagami RM, Di Pino A, Urbano F, Piro S, Purrello F, Rabuazzo AM. Low circulating 
vitamin D levels are associated with increased arterial stiffness in prediabetic subjects 
identified according to HbA1c. Atherosclerosis 2015;243:395-401. 
324. Andrade J, Er L, Ignaszewski A, Levin A. Exploration of association of 1,25-OH2D3 
with augmentation index, a composite measure of arterial stiffness. Clinical journal of the 
American Society of Nephrology : CJASN 2008;3:1800-6. 
325. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common Carotid 
Intima-Media Thickness and Risk of Stroke and Myocardial Infarction: The Rotterdam 
Study. Circulation 1997;96:1432-7. 
326. Reis JP, von Muhlen D, Michos ED, et al. Serum vitamin D, parathyroid hormone 
levels, and carotid atherosclerosis. Atherosclerosis 2009;207:585-90. 
327. Hao Y, Ma X, Luo Y, et al. Inverse association of serum vitamin D in relation to 
carotid intima-media thickness in Chinese postmenopausal women. PloS one 
2015;10:e0122803. 
328. van de Luijtgaarden KM, Voute MT, Hoeks SE, et al. Vitamin D deficiency may be 
an independent risk factor for arterial disease. European journal of vascular and endovascular 
surgery : the official journal of the European Society for Vascular Surgery 2012;44:301-6. 
180 
 
329. Yiu YF, Chan YH, Yiu KH, et al. Vitamin D Deficiency Is Associated with Depletion 
of Circulating Endothelial Progenitor Cells and Endothelial Dysfunction in Patients with 
Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism 2011;96:E830-E5. 
330. London GM, Guerin AP, Verbeke FH, et al. Mineral metabolism and arterial 
functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. 
Journal of the American Society of Nephrology 2007;18:613-20. 
331. Chitalia N, Recio-Mayoral A, Kaski JC, Banerjee D. Vitamin D deficiency and 
endothelial dysfunction in non-dialysis chronic kidney disease patients. Atherosclerosis 
2012;220:265-8. 
332. Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular 
events. Circulation 2007;115:846-54. 
333. Wallis DE, Penckofer S. Letter by Wallis and Penckofer regarding article, 
"Calcium/vitamin D supplementation and cardiovascular events". Circulation 2007;116:e86; 
author reply e7. 
334. Zittermann A, Schleithoff SS, Koerfer R. Letter by Zitterman et al regarding article, 
"Calcium/vitamin D supplementation and cardiovascular events". Circulation 2007;116:e85; 
author reply e7. 
335. Lind L, Wengle B, Ljunghall S. Blood pressure is lowered by vitamin D 
(alphacalcidol) during long-term treatment of patients with intermittent hypercalcaemia. A 
double-blind, placebo-controlled study. Acta Medica Scandinavica 1987;222:423-7. 
336. Lind L, Wengle B, Wide L, Sorensen OH, Ljunghall S. Hypertension in primary 
hyperparathyroidism--reduction of blood pressure by long-term treatment with vitamin D 
(alphacalcidol). A double-blind, placebo-controlled study. American Journal of Hypertension 
1988;1:397-402. 
181 
337. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves
endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. 
Diabet Med 2008;25:320-5. 
338. Witham MD, Dove FJ, Dryburgh M, Sugden JA, Morris AD, Struthers AD. The
effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 
diabetes: a randomised controlled trial. Diabetologia 2010;53:2112-9. 
339. Mozaffari-Khosravi H, Loloei S, Mirjalili MR, Barzegar K. The effect of vitamin D
supplementation on blood pressure in patients with elevated blood pressure and vitamin D 
deficiency: a randomized, double-blind, placebo-controlled trial. Blood Press Monit 2014. 
340. Gepner AD, Haller IV, Krueger DC, Korcarz CE, Binkley N, Stein JH. A randomized
controlled trial of the effects of vitamin D supplementation on arterial stiffness and aortic 
blood pressure in Native American women. Atherosclerosis 2015;240:526-8. 
341. Dalan R, Liew H, Assam PN, et al. A randomised controlled trial evaluating the
impact of targeted vitamin D supplementation on endothelial function in type 2 diabetes 
mellitus: The DIMENSION trial. Diabetes & vascular disease research : official journal of 
the International Society of Diabetes and Vascular Disease 2016:pii: 1479164115621667. 
[Epub ahead of print]. 
342. Ryu OH, Chung W, Lee S, Hong KS, Choi MG, Yoo HJ. The effect of high-dose
vitamin D supplementation on insulin resistance and arterial stiffness in patients with type 2 
diabetes. Korean Journal of Internal Medicine 2014;29:620-9. 
343. Yiu YF, Yiu KH, Siu CW, et al. Randomized controlled trial of vitamin D supplement
on endothelial function in patients with type 2 diabetes. Atherosclerosis 2013;227:140-6. 
344. Breslavsky A, Frand J, Matas Z, Boaz M, Barnea Z, Shargorodsky M. Effect of high
doses of vitamin D on arterial properties, adiponectin, leptin and glucose homeostasis in type 
2 diabetic patients. Clinical nutrition (Edinburgh, Scotland) 2013;32:970-5. 
182 
345. Witham MD, Dove FJ, Sugden JA, Doney AS, Struthers AD. The effect of vitamin D
replacement on markers of vascular health in stroke patients - a randomised controlled trial. 
Nutrition, metabolism, and cardiovascular diseases : NMCD 2012;22:864-70. 
346. Dreyer G, Tucker AT, Harwood SM, Pearse RM, Raftery MJ, Yaqoob MM.
Ergocalciferol and Microcirculatory Function in Chronic Kidney Disease and Concomitant 
Vitamin D Deficiency: An Exploratory, Double Blind, Randomised Controlled Trial. PloS 
one 2014;9. 
347. Marckmann P, Agerskov H, Thineshkumar S, et al. Randomized controlled trial of
cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. 
Nephrology, dialysis, transplantation : official publication of the European Dialysis and 
Transplant Association - European Renal Association 2012;27:3523-31. 
348. Witham MD, Dove FJ, Khan F, Lang CC, Belch JJ, Struthers AD. Effects of vitamin
D supplementation on markers of vascular function after myocardial infarction--a randomised 
controlled trial. Int J Cardiol 2013;167:745-9. 
349. Jorde R, Sneve M, Torjesen P, Figenschau Y. No improvement in cardiovascular risk
factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. 
Journal of internal medicine 2010;267:462-72. 
350. Veloudi P, Blizzard CL, Ding CH, et al. Effect of Vitamin D Supplementation on
Aortic Stiffness and Arterial Hemodynamics in People With Osteoarthritis and Vitamin D 
Deficiency. Journal of the American College of Cardiology 2015;66:2679-81. 
351. Daly RM, Nowson CA. Long-term effect of calcium-vitamin D(3) fortified milk on
blood pressure and serum lipid concentrations in healthy older men. European journal of 
clinical nutrition 2009;63:993-1000. 
183 
352. Beveridge LA, Struthers AD, Khan F, et al. Effect of Vitamin D Supplementation on
Blood Pressure: A Systematic Review and Meta-analysis Incorporating Individual Patient 
Data. JAMA Internal Medicine 2015;175:745-54. 
353. Kollias A, Lagou S, Zeniodi ME, Boubouchairopoulou N, Stergiou GS. Association
of Central Versus Brachial Blood Pressure With Target-Organ Damage: Systematic Review 
and Meta-Analysis. Hypertension 2016;67:183-90. 
354. Sharman J, Stowasser M, Fassett R, Marwick T, Franklin S. Central blood pressure
measurement may improve risk stratification. J Hum Hypertens 2008;22:838-44. 
355. Larsen T, Mose FH, Bech JN, Hansen AB, Pedersen EB. Effect of cholecalciferol
supplementation during winter months in patients with hypertension: a randomized, placebo-
controlled trial. American Journal of Hypertension 2012;25:1215-22. 
356. McGreevy C, Barry M, Davenport C, et al. The effect of vitamin D supplementation
on arterial stiffness in an elderly community-based population. J Am Soc Hypertens 
2015;9:176-83. 
357. Zaleski A, Panza G, Swales H, et al. High-Dose versus Low-Dose Vitamin D
Supplementation and Arterial Stiffness among Individuals with Prehypertension and Vitamin 
D Deficiency. Dis Markers 2015;2015:918968. 
358. Braam LA, Hoeks AP, Brouns F, Hamulyak K, Gerichhausen MJ, Vermeer C.
Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in 
postmenopausal women: a follow-up study. Thrombosis and haemostasis 2004;91:373-80. 
359. Harris RA, Pedersen-White J, Guo DH, et al. Vitamin D3 supplementation for 16
weeks improves flow-mediated dilation in overweight African-American adults. American 
Journal of Hypertension 2011;24:557-62. 
184 
360. Sokol SI, Srinivas V, Crandall JP, et al. The effects of vitamin D repletion on
endothelial function and inflammation in patients with coronary artery disease. Vasc Med 
2012;17:394-404. 
361. Longenecker CT, Hileman CO, Carman TL, et al. Vitamin D supplementation and
endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-
controlled trial. Antivir Ther 2012;17:613-21. 
362. Thethi TK, Bajwa MA, Ghanim H, et al. Effect of paricalcitol on endothelial function
and inflammation in type 2 diabetes and chronic kidney disease. J Diabetes Complications 
2015;29:433-7. 
363. Holland DJ, Sacre JW, McFarlane SJ, Coombes JS, Sharman JE. Pulse wave analysis
is a reproducible technique for measuring central blood pressure during hemodynamic 
perturbations induced by exercise. Am J Hypertens 2008;21:1100-6. 
364. Pilz S, Gaksch M, Kienreich K, et al. Effects of Vitamin D on Blood Pressure and
Cardiovascular Risk Factors: A Randomized Controlled Trial. Hypertension 2015. 
365. Arora P, Song Y, Dusek J, et al. Vitamin D therapy in individuals with
prehypertension or hypertension: the DAYLIGHT trial. Circulation 2015;131:254-62. 
366. Witham MD, Price RJG, Struthers AD, et al. Effect of vitamin D supplementation on
orthostatic hypotension: data from the Vitamin D in Isolated Systolic Hypertension 
randomized controlled trial. J Hypertens 2014;32:1693-9. 
367. Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation enhances the
beneficial effects of weight loss on cardiovascular disease risk markers. American Journal of 
Clinical Nutrition 2009;89:1321-7. 
368. Orwoll ES, Oviatt S. Relationship of mineral metabolism and long-term calcium and
cholecalciferol supplementation to blood pressure in normotensive men. American Journal of 
Clinical Nutrition 1990;52:717-21. 
185 
369. Heaney RP. Guidelines for optimizing design and analysis of clinical studies of
nutrient effects. Nutr Rev 2014;72:48-54. 
370. Kennel KA, Drake MT, Hurley DL. Vitamin D deficiency in adults: when to test and
how to treat. Mayo Clin Proc 2010;85:752-7; quiz 7-8. 
371. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin
supplement. American Journal of Clinical Nutrition 2006;84:694-7. 
372. Chao YS, Brunel L, Faris P, Veugelers PJ. The importance of dose, frequency and
duration of vitamin D supplementation for plasma 25-hydroxyvitamin D. Nutrients 
2013;5:4067-78. 
373. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and
prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. The 
Journal of clinical endocrinology and metabolism 2011;96:1911-30. 
374. Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a
systematic review and meta-analysis. J Hypertens 2009;27:1948-54. 
375. Pittas AG, Chung M, Trikalinos T, et al. Systematic review: Vitamin D and
cardiometabolic outcomes. An Intern Med 2010;152:307-14. 
376. Kunutsor SK, Burgess S, Munroe PB, Khan H. Vitamin D and high blood pressure:
causal association or epiphenomenon? European journal of epidemiology 2014;29:1-14. 
377. Wu SH, Ho SC, Zhong L. Effects of vitamin D supplementation on blood pressure.
Southern medical journal 2010;103:729-37. 
378. Lee KJ, Lee YJ. Effects of vitamin D on blood pressure in patients with type 2
diabetes mellitus. Int J Clin Pharmacol Ther 2016;54:233-42. 
379. Hussin AM, Ashor AW, Schoenmakers I, Hill T, Mathers JC, Siervo M. Effects of
vitamin D supplementation on endothelial function: a systematic review and meta-analysis of 
randomised clinical trials. Eur J Nutr 2017;56:1095-104. 
186 
380. Upala S, Sanguankeo A, Congrete S, Jaruvongvanich V. Effect of cholecalciferol
supplementation on arterial stiffness: a systematic review and meta-analysis. Scand 
Cardiovasc J 2016;50:230-5. 
381. Rodriguez AJ, Scott D, Srikanth V, Ebeling P. Effect of Vitamin D Supplementation
on Measures of Arterial Stiffness: A Systematic Review and Meta-Analysis of Randomised 
Controlled Trials. Clin Endocrinol 2016;84:645-57. 
